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Abstract
Cell migration plays a major role in processes like wound healing, including
lymphangiogenesis. It is especially influenced by the extracellular matrix. In
this thesis chemical synthesis and material science are combined to address bi-
ological questions in a biological chemistry approach. This enables the analysis
of the influence of different extracellular matrix modules on cell behaviour. On
the one hand a concentration and density dependent effect of short hyaluronan
is analysed. On the other hand a novel specific and unspecific binding model
for the extracellular matrix is developed.
Several chemical modification strategies are tested to immobilise hyaluronan
on a surface. Therefore modifications at the reducing-end are introduced us-
ing cysteamine hydrochloride, propargylamine and dibenzocyclooctyne-amine
and at the carboxy groups within the chain using again propargylamine. In
case of the end-thiolated hyaluronan a degree of thiolation of 4.0 ± 0.5 % is
achieved, and for the functionalisation within the chain a degree of alkynation
of 16% is determined. All desired molecules could be synthesised and enable
immobilisation of the hyaluronan species.
After the chemical modification, the bioactivity is verified via the analysis
of the interaction between the hyaluronan species and the hyaladherine ag-
grecan as well as LYVE-1. Especially the interaction between aggrecan and
hyaluronan proves the conservation of the bioactivity during the modification.
To determine the influence of short hyaluronan on lymphendothelial cells the
AlamarBlue® and CyQuant® assay are established. A cell density of 131 /mm2,
an incubation time of 2 h (AlamarBlue® assay) and 5min (CyQuant® assay)
are determined. Compared are the influences of an enzymatically digested
(10 kDa) and short hyaluronan (20 kDa) species which are applied to lym-
phendothelial cells in different concentrations and densities. To analyse the
density related effect, the hyaluronan is immobilised on gold nanostructured
surfaces. Between the two employed species no difference in cell behaviour is
found. In the case of the application of hyaluronan in solution no difference
in the relative metabolic activity is found. For the immobilised hyaluronan
species a reduced ability to adhere to the surface is observed for the increasing
nanoparticle density. Here, for both hyaluronan species a biphasic effect in
relative metabolic activity is detected with maxima for a particle density of
540 /µm2.
To investigate collective cell migration two novel photocleavable ligands
are developed. Synthesised are an unspecific ligand 1-(4,5-dimethoxy-2-nitro-
phenyl)ethyl 11-mercaptoundecanoate and the specific, caged antagonist of the
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integrin α5β1 1-(4,5-dimethoxy-2-nitrophenyl)-ethyl (3(S))-3-(4-(3-(6-(3-mer-
captopropanamido)-hexanamido)-propoxy)-benzamido)-4-(4-(3-((4-methoxy-
pyridin-2-yl)-amino)-propoxy)phenyl)butanoate.
1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecanoate can be syn-
thesised with a yield of 18%. In QCM-D experiments, the adsorption happens
with a specific decay time of (1899.0 ± 776.3) min at 21 ◦C, while the cleavage
after UV irradiation takes (2.52 ± 0.64) min at 21 ◦C. The absorption spec-
trum of the molecule shows a band at 345 nm, which is blue shifted to 322 nm
upon irradiation with UV light. Also, an isobestic point can be observed at 370
nm. An analysis of the toxicity of 4,5-dimethoxy-2-nitrophenyl ethanol shows
an increasing metabolic activity of the used MDCK II cells for 4,5-dimethoxy-
2-nitrophenyl ethanol, but no effect for 1-(4,5-dimethoxy-2-nitrophenyl)ethyl
11-mercaptoundecanoate is observed.
In summary, well-controlled chemical variations of surfaces enable novel ap-
proaches to study biological systems. Here a method is demonstrated to immo-
bilise HA on a surface which allows the evaluation of the influence of HA on
the basal side of lymphendothelial cells. Furthermore a novel intergrin-specific
photocleavable ligand is developed to study collective cell migration.
Zusammenfassung
Herstellung chemisch modifizierter Substrate zur
Analyse von Zellverhalten
Zellmigration ist ein wichtiger Prozess bei der Wundheilung und der Lym-
phangiogenese. Diese wird im Besonderen durch die extrazelluläre Matrix
beeinflusst. In dieser Arbeit werden chemische Synthese und Materialentwick-
lung zu einem neuen Konzept der biologischen Chemie vereint, um biologische
Fragestellungen zu untersuchen. Auf diese Weise ist es möglich, den Einfluss
verschiedener Modelle für die extrazelluläre Matrix und ihren Einfluss auf das
Zellverhalten zu analysieren. Auf der einen Seite wird ein konzentrations- und
dichteabhängiger Effekt von kurzkettiger Hyaluronsäure untersucht. Auf der
anderen Seite wird ein neuartiges Modell der extrazellularen Matrix für un-
spezifische und spezifische Zellinteraktion vorgestellt.
Verschiedene Strategien zur chemischen Modifikation werden getestet, um
die Immobilisierung von Hyaluronsäure auf Oberflächen zu ermöglichen. Dazu
werden Modifikationen am reduzierenden Ende der Hyaluronsäure mittels
Cysteaminhydrochlorid, Propargylamin und Dibenzocyclooctin-amin durchge-
führt. Außerdem wird die Carboxygruppe in der Kette mit Propargylamin
modifiziert. Im Fall der endständigen Thiolierung kann ein Thiolierungsgrad
von (4.0 ± 0.5) % und im Fall der Alkinierung innerhalb des Moleküls ein
Alkinierungsgrad von 16% erreicht werden. Alle angestrebten Modifikationen
konnten erfolgreich durchgeführt werden und ermöglichen die Immobilisierung
der Hyaluronsäurevarianten.
Nach der chemischen Modifikation, die nötig ist, um die Hyaluronsäure zu
immobilisieren, wird die biologische Aktivität der Spezien überprüft. Dazu
wird die Interaktion der immobilisierten Hyaluronsäure mit dem Hyaladherin
Aggrecan sowie dem Rezeptor LYVE-1 analysiert. Besonders die Interaktion
zwischen Aggrecan und Hyaluronsäure zeigt, dass die Bioaktivität durch die
chemische Modifikation nicht beeinträchtigt wird.
Um den Einfluss kurzkettiger Hyaluronsäure auf Lymphendothelzellen zu
untersuchen wird sowohl der AlamarBlue® als auch der CyQuant® Assay
eingesetzt. Für die Verwendung der Assays wird eine optimale Zelldichte von
131 /mm2 und eine Inkubationszeit von 2 h für den AlamarBlue® und 5min
für den CyQuant® Assay ermittelt.
Anschließend wird der konzentrations- und dichteabhängige Einfluss einer
enzymatisch verdauten (10 kDa) und einer kurzen (20 kDa) Hyaluronsäure-
spezies auf Lymphendothelzellen untersucht. Um den Einfluss der Dichte zu un-
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tersuchen, wird endthiolierte HA auf Gold-nanostrukturierten Oberflächen im-
mobilisiert. Der Vergleich der beiden verschiedenen Spezies zeigt keine Verän-
derung im Zellverhalten. Im Fall der Inkubation der Zellen mit Hyaluronsäure
in Lösung konnte ebenfalls kein Einfluss auf die metabolische Aktivität ermit-
telt werden. Für die immobilisierte Hyaluronsäure hingegen wird ein Rückgang
in der Zelladhäsion mit zunehmender Nanopartikeldichte verzeichnet. Sowohl
für die enzymatisch verdaute als auch die kurzkettige Hyaluronsäure wird
ein biphasischer Effekt für die relative metabolische Aktivität festgestellt, mit
einem Maximum bei einer Partikeldichte von 540 /µm2.
Um kollektive Zellmigration zu untersuchen werden im zweiten Teil zwei
neuartige photospaltbare Liganden vorgestellt. Zum einen ein Ligand für ein
unspezifisches Bindungsmodell (1-(4,5-Dimethoxy-2-nitrophenyl)ethyl 11-mer-
captoundecansäure) und zum anderen für ein selektives Bindungsmodell, der
spezifische, maskierte Antagonist des Integrins α5β1 1-(4,5-Dimethoxy-2-nitro-
phenyl)-ethyl-(3(S))-3-(4-(3-(6-(3-mercaptopropanamido)-hexanamido)-prop-
oxy)-benzamido)-4-(4-(3-((4-methoxypyridin-2-yl)-amino)-propoxy)-phenyl)-
butansäure. 1-(4,5-Dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecansäure
kann mit einer Ausbeute von 18% hergestellt werden. Mittels QCM-D wird die
Adsorption und Spaltung des Liganden untersucht und eine spezifische Halb-
wertszeit von (1899.0 ± 776.3) min für die Adsorption und (2.52 ± 0.64) min
für die Spaltung jeweils bei 21 ◦C ermittelt. Das Absorptionsspektrum des Lig-
anden weist eine Bande bei 345 nm auf, die eine Blauverschiebung zu 322 nm
aufgrund einer Bestrahlung mit UV-Licht aufweist. Außerdem zeigt das Spek-
trum einen isobestischen Punkt bei 370 nm. Die Analyse der Toxizität von 4,5-
Dimethoxy-2-nitrophenylethanol und 1-(4,5-Dimethoxy-2-nitrophenyl)ethyl-
11-mercapto-undecansäure zeigt einen Anstieg der metabolischen Aktivität der
genutzten MDCK II Zellen mit zunehmender Ligandenkonzentration für 4,5-
Dimethoxy-2-nitrophenylethanol, jedoch keinen Effekt für die Thiolspezies.
Kurzum, durch die kontrollierte chemische Veränderung von Oberflächen
ist es möglich, neue Strategien zur Untersuchung biologischer Fragestellun-
gen zu entwickeln. In dieser Arbeit werden chemische Methoden vorgestellt,
um Hyaluronsäure zu immobilisieren und so deren Auswirkung auf Lymphen-
dothelzellen zu untersuchen. Dabei erfolgt die Wechselwirkung von Zellen und
Hyaluronsäure an der basalen Seite. Darüberhinaus wird ein neuer photospalt-
bar maskierter Ligand vorgestellt, der zur Untersuchung kollegtiver Migration
verwendet werden kann.
Part I.
Introduction and Aim
1

Chapter 1.
Introduction
The migration of cells is of great importance in many processes like morphogen-
esis, wound healing and metastatic spreading of cancer. During wound healing
cells migrate in a coordinated sheet-like structure to close wounds and reform
blood and lymph vessels. The migration of the cells is triggered by extraneous
influences like an increased level of several growth factors and the composition
of the extracellular matrix.[1–3]
1.1. Structure of the Human Skin
Figure 1.1.: Scheme of a healthy skin tissue with the epidermis consisting of
keratinocytes and the dermis formed by the ECM with fibroblasts and the
embedded blood and lymph capillaries (adapted from [4]). Epidermis and
dermis are separated by the basement membran (green).[4, 5]
The largest organ in the human body is the skin. The two outer layers are
formed by the dermis and the epidermis (fig. 1.1). In the epidermis, layers
of keratinocytes protect the body against the environment and mechanical
force. The dermis, which is separated from the epidermis by the basement
membrane, consists of the extracellular matrix (ECM) with fibroblasts and
endothelial cells. Here the fibroblasts produce and organise the ECM, whereas
the endothelial cells form blood and lymph capillaries in the dermis.[4, 6, 7] The
ECM itself is formed by three major groups of macromolecules which are also
3
4 The Lymphatic System and Lymphangiogenesis
responsible for the water binding in the tissue due to their large hygroscopic
properties. The macromolecules include structural proteins like collagen, fi-
bronectin and laminin, which are embedded in the so-called ground substance
made of gycosaminoglycans and proteoglycans, and the connective tissue gly-
coproteins. In a healthy tissue, the basement membrane consists mainly of
the structural proteins collagen and laminin.[3, 8] Glycosaminoglycans (GAG)
are unbranched polysaccharide chains like heparan sulfate, chondroitin sulfate,
keratan sulfate and hyaluronan (hyaluronic acid, HA). Hyaluronan is a special
case of these macromolecules, because it is the only polysaccharide without
any sulfate groups, whereas the other members of this group are found with
different sulfate densities within the chains.
Figure 1.2.: Scheme of a wounded skin tissue with migrating keratinocytes,
which start closing the epidermis and the dermis with the provisional matrix
(dark red) and damaged capillaries (adapted from [4]).
After an injury fibroblasts synthesise the provisional matrix (fig. 1.2). To
assist the re-epithelialisation, lymph- and angiogenesis, the composition of the
ECM changes. In the healthy skin the ECM is mainly formed by laminin and
collagen (type IV and VII).[7] During wound healing more collagen type I,
fibronectin and vitronectin are present.[7] Because of the change in the ECM,
different integrins are addressed to promote wound healing and angiogenisis.
During re-epithelisation the fibrin clot is formed within minutes and several
cytokines and chemokines are released. In the following 1 to 3 days migration
of the keratinocytes is promoted to close the wound. In the upcoming weeks
and month the fibroblasts within the dermis start to remodel the ECM.[6, 7]
1.2. The Lymphatic System and Lymphangiogenesis
The mechanism of formation of new blood vessels (angiogenesis) during wound
healing is a well studied phenomenon, while not much is known about lym-
phangiogenesis.[9–11] The objective of the lymph system is the uptake of the
interstitial fluid, which contains immune cells and various macromolecules,
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Figure 1.3.: The lymph capillaries are formed by partly-overlapping endothe-
lial cells. They are connected via button-like junctions which enable the up-
take of macromolecules like HA into the lumen. Cell migration during wound
healing is promoted by the interaction of HA with LYVE-1, the growth fac-
tors VEGF-C and -D with their receptor VEGFR-2 and the integrins with
the ECM. Podoplanin enable the interaction of immune cells or platelets
with lymphatic cells via CLEC-2.[4, 5, 12,13]
and its transport to the lymph nodes, were the fluid is cleaned and drained
back in the blood circulation.[12] The lymph vessels end in the dermis in small
blind ended capillaries. Compared to the blood capillaries found in the dermis,
these lymph capillaries are much larger (diameter of 50 to 100 µm) to en-
able the transport function.[5] The lymph capillaries are formed by endothelial
cells which are partly-overlapping connected by button-like junctions (fig. 1.3).
These junctions work as microvalves and enable the uptake of the interstitial
fluid.[5, 14,15] The microvalves have a size of 500 to 800 nm in diameter.[15] Dur-
ing inflammation, infection and tissue injury the flux in the vessels is increased
dramatically to remove degraded ECM and other compounds in the wound
which need to be removed.[15] Thus, an intact lymph system is very important
for wound healing. In case of an injury of lymph capillaries, a highly organised
migration of the cells through the ECM starts. During this process the button-
like junctions change into zipper-like junctions, so that the vessel stays intact
during the migration. A key player in the regulation of this permeability of the
lymphatic vessels is podoplanin.[9] Podoplanin binds to galactin-8 and CLEC-2
(C-type lectin-like receptor), which is expressed on platelets and immune cells.
The binding to immune cells increases their motility and protrusion, whereas
the binding to platelets promotes their aggregation and activation. On the
intracellular side, it binds to ezrin, which is known to promote cell migration
and interacts with CD44, a receptor for HA.[13, 16–18] The migration itself is in-
fluenced by the growth factors VEGF-C and -D and their receptor VEGFR-3,
which is important in the regulation of lymphangiogenesis, and the HA recep-
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tor LYVE-1, which is the main HA receptor in lymphendothelial cells.[9, 15]
Because the composition of the ECM changes during wounding and due to
the signaling of growth factors and short hyaluronan the expression of inte-
grins, which promote the migration, is increased.[5, 12,15] Signaling of HA and
its fragments occur here in different ways. So the HA can interact with the
HA receptors on the ECM side of the capillary and on its luminal side. The
role in signaling of the uptake of the HA through the microvalves is not clear
yet.[19]
1.3. Interaction Between Extracellular Matrix and Cells
To enable the migration of cells in wound healing or lymphangiogenesis the
cells interact with the ECM via integrins. Integrins are heterodimeric trans-
membrane proteins which are formed by an α and a β subunit. Both units are
non-covalently connected to each other. There are 18 different α and 8 differ-
ent β subunits known which can form 24 different integrins. The combination
of both subunits enable the adhesion to different structural proteins in the
ECM. Thus, the α5β1 integrin binds to fibronectin whereas the αvβ1 intergrin
typically binds to vitronectin and the α2β1 integrin to collagen.[6, 7, 20]
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Figure 1.4.: The artificial peptide cyclic RGD mimics a binding domain of
fibronectin. It consists of arginine (R, green), glycine (G, brown) and as-
partic acid (D, blue). To enable the cyclisation phenylalanine (orange) and
a modified glycine (grey) with a functional group (R’), which enables the
immobilisation on a substrate, is added.
One common binding sequence in fibronectin and vitronectin is the amino
acid sequence arginine-glycine-aspartic acid (RGD, fig. 1.4). Thus, it is possible
to use only a small peptide with this sequence in cell experiments instead of the
whole protein. New developments are directing the specific adhesion of chosen
integrins to a surface. Published are for example antagonists to the α5β1 or
the αvβ3 integrin (fig. 1.5).[21–23] This enables the analysis of migration and
adhesion depending on the addressed integrins. Due to the usage of small
peptides instead of whole proteins it is possible to analyse the influence of the
density of adhesive molecules on a surface. Therefore surfaces decorated with
gold nanoparticles can be used (fig. 1.6). To create a defined particle pattern on
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Figure 1.5.: These peptides are artificial, highly selective antagonists to the
a) α5β1 and b) αvβ3 integrins.[21]
the surface the block copolymer nanolithography (BCML) technique is used.
Via thiol functions the peptides can be immobilised on the gold nanoparticles
in a well-controlled manner. To ensure that cells only adhere to the peptides,
the glass surface itself is functionalised with a silane bearing polyethylenglycol
(PEG) to passivate the surface against any unspecific interactions.[24–27] To
Figure 1.6.: Via block copolymer nanolithography (BCML) glass surfaces are
decorated with gold nanoparticles. Afterwards the surface is passivated with
PEG2000 silane and the nanoparticles functionalised with cRGD to enable
the use in cell experiments.
form the adhesion, two different ways are possible. On the one hand, anchor
proteins like talin, paxillin and vinculin bind to the intracellular part of the
integrin. This leads to a conformational change of the integrin. Due to this
the binding affinity of the extracellular domain to the binding sequence is
increased (inside-out signaling). On the other hand the ECM protein binds to
the integrin first. This induces clustering of the integrins and the binding of
intracellular anchor proteins (outside-in signaling).[28] Via the anchor proteins
like talin the cytoskeleton is connected to the focal complexes which form the
focal adhesions (fig. 1.7). During migration the focal adhesions are important
to transfer the force of the moving cell to the substrate. The formation of the
focal adhesions is regulated during the process via different kinases like focal
adhesion kinase (FAK) and tyrosine-protein kinase (Src), which co-localise
with the focal complex. These proteins are also important for signaling in cell
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Figure 1.7.: Cells interact via integrins with the ECM. The anchor protein
talin associated with vinculin connects the cytoskeleton (actin) to integrins.
Proteins like paxillin and the kinases Src and FAK (P: phoshporylated),
which are important for the signaling in cell migration, actin organisation,
survival and proliferation are members of the focal complex.[8, 12, 20,28]
migration, actin organisation, survival of the cell and proliferation.[8, 20]
To promote the ability of cells to migrate during wound healing the expres-
sion level of different integrins is changed during injury. Additionally, the com-
position of the ECM changes and thus the integrins which enable migration
can be addressed. During wound healing an up regulation of α5β1 intergrins
are found in the first days.[12] After day three also the number of integrins
with the subunit αv are increased, especially the integrins αvβ5 and αvβ6.[6, 7]
In contrast, the key player in lymphangiogenesis is the integrin α9β1 which
promotes the cell migration.[12]
1.4. Hyaluronan - A Polysaccharide
In the skin the HA is synthesised by fibroblasts which are located in the
dermis. The dermis contains about 200 to 500 µg/g and the epidermis 100µg/g
of hyaluronan. Overall, the human body (70 kg) contains about 15 g HA, of
which about one third is renewed every day.[15, 29] The half-live of HA within
the dermis is below 24 h and within the epidermis even in the range of 2 to
3 h.[30, 31]
HA consist of repeating disaccharide units of N -acetyl-d-glucosamine and
d-glucuronic acid, which are linked via β-(1→4) and β-(1→3) glycosidic bonds
(fig. 1.8). Native HA has a weight of 103 - 104 kDa corresponding to 2000 to
25 000 disaccharide units and a total contour length of 2 to 25 mm.[15, 34,35]
In literature a secondary and tertiary structure of HA in aqueous solutions
is reported comparable to the structure of proteins.[32, 34,35] Depending on
the counter ion, helical structures of 2 to 4 HA chains are found. In case of
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Figure 1.8.: Hyaluronan consists of repeating disaccharide units of d-glu-
curonic acid (orange) and N -acetyl-d-glucosamine (green). For each unit a
rotation of about 90° (α) is found due to the hydrogen bonds (blue).[32, 33]
CaII for example, three HA chains form with additional six water molecules
per CaII one large complex. In this complex each cation complexes only two
HA chains. In the crystallised species a length of 0.94 nm/unit is discovered.
Due to hydrogen bonds within each chain a rotation of 90° per unit is deter-
mined. As tertiary structure a coiling of the HA chain is found with a radius
of gyration of 150 to 500 nm.[32] In the ECM tissue specific proteoglycans
Figure 1.9.: HA is synthesised by hyaluronan synthase (HAS) at the non-
reducing end, while the HA is released in the extracellular space. Aggrecan
(grey) binds with the link protein (red dot) to the HA chain, which binds
to its receptor in the membrane. Additionally other GAGs like chondroitin
bind to the aggrecan.[30, 36]
like aggrecan, versican and the link protein bind to HA (fig. 1.9). Aggrecan
itself binds other GAGs like chondroitin for example.[37] The HA is synthe-
sised via the transmembrane proteins hyaluronan synthase (HAS 1-3) in the
inner leaflet of the plasma membrane of fibroblasts. They synthesise the HA
from the non-reducing end on, while the chain is released in the extracellu-
lar space.[15, 36,38] The cells can interact with HA via different receptors. The
main receptors are RHAMM, CD44 and its analogous LYVE-1.[39, 40] CD44 is
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expressed in fibroblasts, keratinocytes, lymphocytes and endothelial cells.[30]
RHAMM is also expressed in fibroblasts and endothelial cells with a limited
level in healthy skin but increases in cancer.[30, 39,41] LYVE-1 is expressed in
lymphatic endothelial cells. The interaction between HA and the different re-
ceptors enables the stimulation of different processes. So it is shown that small
fragments of HA (10 kDa) interacting with endothelial cells promote prolifer-
ation, migration and tube formation.[2, 10,41,42] Thus, short HA also influences
the angiogenesis which is important in tumor progression. In case of the recep-
tor LYVE-1 the lymphangiogenesis is promoted.[39] To recognise the HA and
to enable different processes a minimal number of repeating disaccharide units
is necessary. In case of LYVE-1 8 to 10 repeating units are required, whereas
for its analogous CD44 6 to 8 repeating units are sufficient.[15, 39]
1.4.1. Hyaluronan in Wound Healing and Lymphangiogenesis
During wound healing, HA with a high molecular weight is found to inhibit
proliferation, migration and has an anti-angiogenic and anti-inflammatory ef-
fect on blood vessel cells.[2, 30,41,43] HA with a medium molecular weight (100
to 300 kDa) promotes wound closure in experiments with human keratinocytes,
whereas low molecular weight HA stimulates proliferation, motility and tube
formation in endothelial cells and promotes inflammation and angiogenesis.
[2, 41] Besides the different length depending effect, also a concentration de-
pending effect is described. The application of an oligo HA (4 to 20 repeating
units) on blood vessel cells stimulate proliferation in a concentration range of
3 to 20 µg/mL showing a maximum response at 10µg/mL.[41] This biphasic
effect is also found for the application of a low molecular weight HA species
on mouse lymphendothelial cells. Here a maximal effect on proliferation for a
concentration of 3.13µg/mL is found.[44]
1.4.2. Chemical Modification of Hyaluronan
Scheme 1.1.: Functional groups of hyaluronan: carboxy group in blue, primary
hydroxy group in green and carbonyl group in orange. The carbonyl-function
appears only during the anomerisation between the α- and β-species of the
N -acetyl-d-glucosamine-motif at the reducing-end of hyaluronan. The equi-
librium is on the side of the closed ring-form.
To enable a well-controlled method to analyse the interaction of HA with
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cells or receptors at the basal side (bottom side of cells) in different ECM
models, it is necessary to modify HA in a chemical fashion to immobilise the
HA. The modification of HA is straight-forward due to its various, accessible
functional groups as shown in scheme 1.1. Via the primary and secondary hy-
droxy groups as well as the carboxy function the short HA can be statistically
modified within the chain. To create only a single modification per chain, the
carbonyl group at the reducing end is used, which occurs during anomerisation.
One possibility to immobilise HA on a surface is to use a host/guest in-
teraction between ferrocen and cyclodextrine. The cyclodextrine is randomly
attached to the hyaluronan chain using the carboxy groups. The cyclodextrine
can interact with immobilised ferrocen and bind so the HA.[45–47] Disadvantage
of this approach is the large construct which is needed to immobilise the HA
on the surface which might also interfere with the bioactivity of the HA. Other
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Figure 1.10.: Overview of chemical modifications of HA which can be easily
transferred to immobilise HA on a surface.[48–51]
chemical modifications of the HA are mainly used to form hydrogels.[48, 51,52]
Here also the carboxy group within the chain is functionalised to enable the
cross linking between several HA molecules (fig. 1.10). On the one hand thiol
groups are introduced which lead to a cross linking via dithiol bonds or more
complex systems.[51, 52] This allows also the direct immobilisation of the HA
to a gold surface or a gold nanostructured surface. On the other hand, the
functionalisation with azide and alkyne groups within the HA chain is found.
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[48] Here the copper catalysed azide alkyne cycloaddition (CuAAC) is used to
form the gels.
To immobilise HA via CuAAC on a surface, the approach used in the
host/guest approach can be used. In this case different thiol terminated oli-
goethylenglycol (OEG) molecules are added to a gold coated surface. They
form a dense SAM on a gold surface, which passivates the surface against un-
specific interactions. A second functionality allows the immobilisation of the
HA to the SAM.[45, 53,54] Alternatively the cooper-free strain-promoted azide-
alkyne cycloaddition (SPAAC) can be performed to immobilise the HA. In this
case a strained cyclooctenyl-ring is used instead of the smaller alkyne function.
Because the driving force is the strained ring no copper is necessary, which is
better in a biological context.[50, 55–57]
1.5. Photolabile Protecting Groups
Since the 1960’s photolabile protecting groups are found in organic chemistry.
They are used especially in cases where many different functional groups are
available like in peptide, nucleotide and carbohydrate synthesis, among other
things.[58, 59] Photolabile groups which are successfully used are derivatives
of benzoin esters (a),[58–61] o nitrobenzyl (b),[58–61] coumarin (c)[60, 61] and
indol derivatives (d),[60, 61] ruthenium complexes (e)[60, 61] or dinitrobenzene-
sulphenyl (f),[58] antraquinon (g)[58, 60] and phenacyl derivatives (h, fig. 1.11).
[58–61] These groups are stable against most chemicals and can be cleaved off
with a good yield. Because no strong acids or bases are necessary for deprotec-
tion, it is a rather mild method in synthesis, even though irradiation with UV
light is necessary. The applied wavelength for the cleavage ranges from 245 to
420 nm depending on the functionality (fig. 1.11). Besides their application in
synthesis, photolabile groups are also used in a more technical context like for
example for creating matrices in MALDI MS,[63] in single molecule force mi-
croscopy,[64] to facilitate a controlled polymerisation[65] and to create defined
patterns or films on a surface.[66] More and more the approach of photolabile
protection is found as approach in biological chemistry to prepare surfaces for
cell experiments.[62] Here, photocleavable systems are used to release amino
acids,[67–69] proteins[70] or growth factors to study their influence as a drug
delivery system especially in cancer therapy.[71] This approach is also used to
create well-controlled patterns on a surface with for example proteins[72, 73] or
to tune the adhesion of cells to a surface.[74, 75] A further development is to
use a photocleavable molecule not only to create a pattern on the surface but
to use the system as a chemical barrier to investigate cell migration.
1.5.1. Development in Wound Healing Assays
To observe collective cell migration as a wound healing model several tech-
niques are established (fig. 1.12). Therefore methods are used where a cell
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Figure 1.11.: Overview of photolabile protecting groups and their cleavage
wavelength: a) benzoin ester (245 nm), b) o-nitrobenzyl derivatives (250 to
360 nm), c) coumarin derivatives (360 to 420 nm), d) indol derivatives (350
to 370 nm), e) ruthenium complexes (800 nm), f) dinitrobenzenesulphenyl
derivatives (245 nm), g) anthraquinon derivatives (245 nm) and h) phenacyl
derivatives (245 nm).[58–62]
sheet is damaged using a sharp object like a tip or scalpel, a laser beam or
electricity.[76–78,81] The removed cells leave a gap in which the remaining cells
can start to migrate into. Disadvantage of all these methods is, that during the
process cells get damaged and so all intracellular components are released and
can induce a uncontrolled signaling, which influences the migration process in
an unknown manner. Additionally, the surface coating used in the assay can be
removed so that the cell-surfaces interaction remains unclear. Much more de-
fined systems can be created using a physical barrier like custom made PDMS
masks[79, 80,82] or commercially available masks.[83] Advantage of this system
is, that the migration is started by removing the barrier and thus no cells get
damaged and no unknown signaling occurs. Also the surfaces stay intact and
the influence of the coating can be analysed. Disadvantage of this method is,
that it is difficult to use on surfaces with a rough structure or a high water
content like PEG- or HA-hydrogels, or even PEG-passivated, nanostructured
surfaces. Here, it is very difficult to form a defined cell sheet, because the
physical barrier does not stick to the surface or due to the roughness gaps are
found between the surface and the barrier so that cells can crawl underneath
it (fig. 1.13). To overcome this problem a chemical barrier can be used (fig.
1.12 e).
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Figure 1.12.: Several methods to study cell migration in a wound healing
assay are reported in literature. The wound can be created with a scratch
assay where the cells are removed with a sharp object (a), with a laser beam
(b) or with electricity (c). Alternatively a physical barrier out of PDMS can
be used to create a gap between two collectives (d).[76–80] An alternative is
the use of a chemical barrier where a photocleavable protection layer is used
on the surface (e).[60]
Figure 1.13.: It proves to be difficult to use a PDMS mask to create a cell
sheet on a rough surfaces, because the cells crawl underneath the barrier if
there is a gap. The pictures shows a physical barrier with a circular (a) and
rectangular shape (b). The edges of the barriers are markt with an arrow
(scale bar: 300µm).
1.5.2. Triggering Cell Adhesion and Migration with
Photoactivatable Surfaces
To create a chemically modified biointerface two approaches are available. On
the one hand, it is possible to functionalise the surface with a photocleav-
able protected (caged) ligand which allows an unspecific adhesion of the cells
on the substrate.[84–86] On the other hand, it is possible to functionalise the
surface with a caged ligand which enables a specific adhesion of the cells.
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A possible candidate for the specific interaction is the amino acid sequence
arginine-glycine-aspartic acid (RGD).[87–89] This RGD sequence matches to
the binding domain of many proteins of the extracellular matrix (ECM) and
enables so a wide application. The commonly used protecting group used in
this method are derivatives of o nitrobenzyl. To use this approach a surface
is functionalised with the photocleavable ligand (fig. 1.14). The formed layer
Figure 1.14.: Scheme of the pattering of a surface decorated with a caged ad-
hesion molecule to analyse cell migration. In a) the surface is covered with the
o nitrobenzyl-caged ligand, which prevents cell adhesion. After irradiation
of the surface through a mask with defined pattering (b), the photolabile
protecting groups are removed in this areas. This enables the adhesion of
cells in defined regions on the surface (c). After a second irradiation the cells
can start to migrate (d).
passivates the surface against unspecific interactions between cells and the
surface (a). In a second step the surface is irradiated through a photomask
to create a defined pattern on the surface (b). The irradiated areas, the o-
nitrobenyl-protecting group is cleaved off. Thus this area is now adhesive and
controlled cell sheets can only form here (c), because the passivation in the
non-irradiated area stays intact. In a second irradiation step of the surface the
remaining protecting groups are removed and the cells can begin to migrate
into the open space (d).
The wavelength which is necessary to cleave different o nitrobenzyl deriva-
tives depends strongly on the substitution of the aromatic ring of the protect-
ing group (tab. 1.1). To use photocleavable layers in this biological chemistry
approach the applied wavelength is very important as well as the yield of the
cleavage in a preferably short irradiation time, because the UV light itself
can damage cells.[90] In general, higher wavelengths are (as close to the visible
range of light as possible, 390 to 700 nm) better suitable in cell experiments.
So substituents are chosen which lead to a high cleavage wavelength. To reduce
the irradiation time a substitution pattern is applied with a high attenuation
coefficient (ǫ) so that the irradiation time can be kept low. The overview of
different substituents shows the highest attenuation coefficient for the case of
o-nitrobenzyl (tab. 1.1 # 2) with the specific wavelength of 260 nm. Because
of this a compromise between attenuation coefficient and wavelength needs to
be found. A very common applied version is the dimethoxy-substitution (#5).
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Table 1.1.: Overview of different pattern in substituents and their specific
cleavage wavelength and molar attenuation coefficient. X represents the
molecule which is protected with the o-nitrobenzyl derivativ.[60]
NO2R'
R' X
R
NO2R'
R' O
R
NR'
R'
O
R
OH
X
hν
# substitution λmax [nm] ελmax [1/(mol cm)]
1 R’ = R = H 346 7159
2 R’ = H; R = Me 260 19600
3 R’ = H; R = COOH 266 5200
4 R’ = OMe; R = H 360 5000
5 R’ = OMe; R = Me 355 5340
1.6. Aim of the Study
The overview of the migration processes in epidermis and dermis after an
injury raises four major questions which will be addressed in this study:
1. Which role do different ECM compounds and especially short HA species
play during lymphangiogenesis and wound healing?
2. Which strategies can be employed to immobilise HA on a surface in a
well-controlled manner to probe cell behaviour in a lymphangiogenesis
model?
3. What is needed to develop a migration assay on structurally advanced
surfaces?
4. How is wound healing influenced by the density of a specific or unspecific
binding model of the ECM?
In the first part of this thesis, human primary lymphendothelial cells are
chosen as a minimal model for this process to analyse the influence of short HA
on lymphangiogenesis. The cells are incubated with different concentrations
of HA in the absence and presence of cRGD. Two different molecular weights
of HA are compared (10 kDa, 20 kDa), to study the effect of chain length on
cell behaviour. The determined parameters are toxicity of the HA species and
concentration as well as metabolic activity of the cells.
Because cells can interact with HA both at the basal (outside of lumen) and
apical side (inside the lumen) a method needs to be developed to immobilise
HA on a surface to mimic the ECM. Therefore several strategies are tested.
Possible methods to immobilise HA are via thiol-groups to gold surfaces like
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nanostructured surfaces or gold coated quartz crystals, or via alkyne groups to
azide bearing surfaces via CuAAC or SPAAC. Before using the modified HA
species their bioactivity is verified. Afterwards, the HA can be immobilised on
a gold nanostructured surface whose HA density can be tuned in presence of
cRGD by chaning the particle density.
In the second part the strategy of using a chemical barrier method to analyse
cell migration is established. Here two novel, photocleavable ligands with a 4,5-
dimethoxy-2-nitrophenyl ethanol protecting group are applied to analyse cell
migration. The ligands can be immobilised on gold nanostructured surfaces
which enables variation of the density of the adhesive background. Chosen
are an unspecific (11-mercaptoundecanoic acid) and specific antagonist to in-
tegrin α5β1 (((S))-3-(4-(3-(6-(3-mercaptopropanamido)hexanamido)propoxy)-
benzamido)-4-(4-(3-((4-methoxypyridin-2-yl)amino)propoxy)phenyl)butanoic
acid).

Part II.
Materials, Methods and
Synthesis
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Chapter 2.
Materials and Methods
2.1. Materials
Table 2.1.: Overview of the used consumables
Compound Supplier
12-well plate Greiner-bio-one
96-microwell plate µClear Greiner-bio-one
96-well plate Greiner-bio-one
dialysis membrane (3.5 kDa) Carl Roth
glass surface 20 x 20mm Carl Roth
glass surface 24 x 24mm Carl Roth
glass surface d = 22mm Menzel Glaeser
gold coated quartz crystal (QSX301) QSense AB
petridish (6 cm) Greiner-bio-one
TLC plate Merck
TwinSil 22 picodent
Table 2.2.: Overview of the used chemicals. All chemicals were used as received
from the suppliers unless stated otherwise. All reactions were carried out
under atmospheric conditions unless stated otherwise.
Chemical Compound Supplier
acetone Carl Roth
upalpha-amino-ω-alkyne PEG3000 Rapp Polymere
ascorbic acid Sigma Aldrich
5-(3-Carboxy-4-nitrophenyl)disulfanyl-2-nitro-
benzoic acid
Sigma Aldrich
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Chemical Compound Supplier
chloroform Carl Roth
copper sulfate Sigma Aldrich
cRGD-azide PSL
cysteamine hydrochloride Sigma Aldrich
d-chloroform Sigma Aldrich
d6-DMSO Carl Roth
DBCO-amine Sigma Aldrich
DCC Sigma Aldrich
DCM Carl Roth
deuterium oxide Sigma Aldrich
3,4-dimethoxyacetophenone Sigma Aldrich
4-dimethylaminopyridine Sigma Aldrich
DIPEA Sigma Aldrich
ethanol Carl Roth
ethyl acetate Merck
glacial acetic acid Fluka
hyaluronan (20 kDa, batch: 024505) lifecore
hydrochloric acid Sigma Aldrich
hydrogen peroxide AppliChem
magnesium sulfate Gruessing
11-mercaptoundecanoic acid Sigma Aldrich
methanol Carl Roth
α-methoxy-ω-amino PEG2000 Rapp Polymere
moleculare sieve (4 Å) Carl Roth
nitric acid Sigma Aldrich
2-propanol Carl Roth
propargylamine Sigma Aldrich
SDS Carl Roth
silica gel Carl Roth
sodium acetate Sigma Aldrich
sodium borhydrid Sigma Aldrich
sodium chloride Sigma Aldrich
sodium cyanoborhydrid Sigma Aldrich
sodium tetraborate Sigma Aldrich
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Chemical Compound Supplier
sulfuric acid Sigma Aldrich
THF Carl Roth
toluen Merck
triethylamine Sigma Aldrich
trifluoroacetic acid Sigma Aldrich
triisopropylsilyl ether Sigma Aldrich
tris(hydroxymethyl)-aminomethane Carl Roth
tris(3-hydroxypropyltriazolylmethyl)amine Sigma Aldrich
Tritylchloride Sigma Aldrich
Table 2.3.: Overview of the used cell culture consumables.
Compound Supplier
AlamarBlue® kit ThermoFischer
cellculture flask (75 cm2) Greiner-bio-one
cellculture flask (25 cm2) Greiner-bio-one
CyQuant® kit ThermoFischer
EGM-2 MV Lonza
FBS Gibco, Life Technology
fibronectin (bovine) Sigma Aldrich
Ibidi-chamber ibidi
L-glutamine Gibco, Life Technology
LEC (Batch 3061003.3) Promocell
MEM Sigma Aldrich
MDCK II Sigma Aldrich
PBS tablets Gibco, Life Technology
Penicillin/Strepomycin Gibco, Life Technology
Pluronic F-127 Sigma Aldrich
Trypsin-EDTA Gibco, Life Technology
Table 2.4.: Overview of the used antibodies for cell stainings.
Compound Supplier
primary antibodies
DAPI Sigma Aldrich
mouse anti-Paxillin (IgG) BD (610620)
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Compound Supplier
mouse anti-Talin (monoclonal) Sigma Aldrich
mouse anti-Vinculin (monoclonal) Sigma Aldrich
Phalloidin/FITC Sigma Aldrich (P1951)
Phalloidin-647 Lifetechnologies
rabbit anti-LYVE-1 (polyclonal) abcam
rabbit anti-human LYVE-1 (polyclonal) Reliatech (102-PA50S)
rabbit anti-Paxillin (monoclonal) abcam
secondary antibodies
goat anti-mouse Alexa 488 (2mg/mL) Invitrogen
goat anti-rabbit Alexa 594 (2mg/mL) Invitrogen
goat anti-rabbit Alexa 647 (2mg/mL) Invitrogen
2.2. Analytical Methods
2.2.1. NMR-Spectroscopy
All NMR-analyses were performed at the NMR-department of the inorganic-
chemical institute at Heidelberg University. The spectra were all measured at
room temperature using the "Avance III 400" (1H: 400MHz; 13C: 100MHz) or
"Avance III 600" (1H: 600MHz; 13C: 150MHz) NMR of the company Bruker.
The chemical shift (δ) was specified in part per million (ppm) and the J-
coupling accordingly in Hertz (Hz). The spectra were calibrated to the solvent
residual signal of the used solvent (1H: D2O = 4.79 ppm, CDCl3 = 7.26 ppm,
(CD3)2SO = 2.50 ppm;
13C: CDCl3 = 77.16 ppm, (CD3)2SO = 39.52 ppm)
[91]
To analyse the NMR-spectra the software "Topspin" (version 3.5pl4; Bruker)
was utilised and following abbreviations were used: s = singlet, d = doublet,
t = triplet, q = quartet, m = multiplet, b = broad.
To identify the signals the 2D-spectra COSY (1H1H) and HSQC (1H13C)
were performed as well.
2.2.2. Mass-Spectrometry
The MS-analyses were performed at the mass spectrometry facility of the
organic-chemical institute at Heidelberg University. The measurements are
performed with the ionisation methods ESI and DART using the "ICR Apex-
Qe" from Bruker.
2.2.3. Absorption Spectroscopy
Experiments Using a UVVIS Spectrometer
For analysing the interaction of light with the photocleavable molecules the
UVVIS-spectrometer "Cary 500 Scan" (Varian/ Agilent Technologies) from the
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group of Prof. Herten (institute of physical chemistry at Heidelberg University)
was used. The measurement was performed in quartz cuvettes from Hellman
Analytics against air and corrected to the absorption of the cuvette containing
the pure solvent (acetonitril) and to the offset coming from the change of
the ligth source at 350 nm. For irradiation of the compounds a pulsed diode
laser source ("pdl375", PicoQuant) with a wavelength of 375 nm and 800µW is
applied. 100µL of a 100µm solution of DMNPE-thiol (1) respectively DMNPE
(2) are irradiated. The measurement is started before the irradiation up to
70min between 250 to 500 nm. To prevent evaporation of the solvent the
cuvette is closed with a Teflon stopper and parafilm. The resulting spectra are
corrected and plotted using "OriginPro 2016G" (version b9.3.226; OriginLab
Corporation).
Experiments Using a Plate Reader
For the performance of the Ellman’s, AlamarBlue® and CyQuant®assay the
plate reader "Infinite 200 Pro" from Tecan was used with a 96- or 12-well
plate from greiner-bio-one respectively 96-well microplate "µClear" (greiner-
bio-one). The measurements are corrected to the well plate containing the
utilised media. The different used wavelength are summerised in table 2.5.
The evaluation of the data is performed using "Excel for Mac" (2011, version
14.7.1, Microsoft). The results for the AlamarBlue® and CyQuant®assay are
plotted and the Kruskal-Wallis test followed by Dunn’s multiple comparison
test was performed using "GraphPad Prism6" (for Mac, version 6.0e,GraphPad
Software Inc., USA).
Table 2.5.: Summary of the used wavelength in the Ellmans’s, AlamarBlue®
and CyQuant®assay.
# assay fluorescence [nm] absorption [nm]
λex λem
1 Ellman 420
2 AlamarBlue® 540 585 570 and 600
3 CyQuant® 480 520
2.3. Microscopy
2.3.1. Zeiss Oberserver Z1
To perform the migration assay the inverted, partially motorised "Observer Z1"
(Zeiss) is used. It is equipped with an "Orca ER" camera (Hamamatsu), a "def-
inite focus" module as well as a small incubation chamber for 12-well plates
(Peacon), which enabled the control of temperature, CO2 ("TempModulS",
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"CO2ModulS", all Zeiss) and humidity. For imaging the software Zen2pro
(Zeiss) was applied. For illumination in phase contrast images a "HAL 100"
halogen lamp was used. For the irradiation of the surfaces functionalised with
a photocleavable linker the UV-lamp "X-cite" (Series 120 PC, EXFO) and the
BFP-filter set (Excitation 377 ± 28 nm; Beamsplitter 403 nm; Emission 464 ±
100 nm, Zeiss) are used. Before phase contrast images were taken the light path
was always adjusted according to the Koehler method.[92, 93] For imaging a 20x
objective ("EC-Plan Neofluar", num0.5 NA, PH2, Zeiss) was used. Irradiation
was performed via a 5x objective ("Plan Apochrom", 0.16 NA, Zeiss).
2.3.2. Zeiss Axiovert
For imaging the glass surfaces within a well-plate and the overview images a
"Axiovert 40 C" (Zeiss) using a 10x objective ("A-Plan", 0.25, PH1, Zeiss) was
used. The microscope was equipped with a "DS-2Mν" camera system (Nikon).
2.3.3. Leica DM 6000B
To analyse the fluorescence staining an upright microscope from Leica Mi-
crosystems CMS GmbH ("DM6000B"; "CT3 HS controller") equipped with a
motorised stage is used. The microscope is equipped with a 1.4 MPixel CCD
camera ("DFC 365 FX", Leica) and the external light source "EL 6000" (Leica).
For taking images a 10x mgnification objective ("HCX PL APO", 0.4, Leica)
and the software "LAS AF" (Version 3.2.0.9652; Leica) is used.
2.4. QCM-D
The quartz crystal microbalance (QCM) is a nanogram sensitive technique
based on the inverse piezoelectric effect.[94] Therefore a silicon single crystal
is cut using the AT-cut. This cut enables a standing transversal wave in the
crystal and shows a low influence of temperature to the resonance frequency.
The crystal is sandwiched between two electrodes. An external electric poten-
tial is applied to the crystal, which leads to an internal mechanical stress and
thus to an oscillation. Because the oscillation is induced through an electric
field, which leads to a charge separation at the crystal edge with the electrodes
attached, only odd harmonics can be excited. The resonance frequency of the
oscillation of the crystal depends on the thickness of the wafer, its chemical
structure, its shape as well as its mass. Because of this correlation any ad-
sorption on top of the crystal leads to a change of the resonance frequency
and its harmonics.[94–96] Sauerbrey describes the direct correlation between
the absorbed mass (∆ m), the density of the crystal (cQ) and the change in
frequency (equation 2.1 and 2.2).
∆m =
cQ
n
·∆f (2.1)
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cQ =
tQ · ρQ
f0
(2.2)
Often crystals with a thickness tQ of 330µm and thus a fundamental fre-
quency f0 of about 5MHz are used. This leads to a density cQ of approxi-
mately −17.7Hz ng/cm. This equation is only valid, if the adsorbed mass is
small relative to the mass of the crystal, the mass is evenly distributed and a
rigid film is formed on the surface.[94, 96] To increase the response of adsorbed
mass on the crystal, which enables QCM as analysis method, a ring electrode
is placed on top of the crystal around the adsorption area, which achieves the
function of an acoustic lens. In a QCM-D experiment the resonance frequency
with harmonics are determined in air. Afterwards, the crystal is equilibrated
in buffer (B) used in the experiment. This equilibrium is set to zero before
adding the compounds of interest (fig. 2.1 a, step 1). The adsorption leads
to a decrease in frequency. After the system is equilibrated again the pure
buffer (B) is added on top of the crystal to remove unbound compounds. To
determine the change in frequency (∆∆ fn, fig. 2.1 a grey) due to the ad-
sorbed mass the plateau values in buffer are compared. This is repeated for
every compound respectively layer on the surface. Additional to the change
in frequency the adsorbed substances influence the damping of the sinusoidal
frequency (equation 2.3).
A(t) = A0 · exp[t/τ ] · sin(2πft+ α) (2.3)
This is observed in the dissipation, which is described with D = 1/(πft). If a
rigid film is adsorbed on top of the crystal only a small decay of the oscillation
is determined and thus a small change in dissipation (fig. 2.1 a, step 1). If a
large molecule with many numbers of degrees of freedom is adsorbed, a high
loss of energy occurs and thus a large change in dissipation is observed (fig. 2.1
a, step 2). In the case shown in figure 2.1 a) the adsorption of the compound
in step 2 is reversible and it can be washed away again.
The QCM-D technique is applied to analyse the adsorption and bioactivity
of various functionalsied HA and to analyse the adsorption and cleavage prop-
erties of 1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecanoate. The
experiments are either performed in the fully automated "Omega Auto" (bioac-
tivity assays) or the manual "E4 modul" (both Q-Sense AB) with the so called
"open modul" (machine workshop at Heidelberg University; fig. 2.1 b; photo-
cleavable assay, adsorption of HA). For the experiment gold coated quartz crys-
tals ("QSX301", Q-Sense AB) are used, which were activated using a UV-ozone
cleaner ("OzoneProCleaner™", BioForce Nanoscience) with an irradiation time
of 10min. After installing the sensor in the instrument the fundamental fre-
quency and its overtones (n = 3, 5, 7, 9, 11 and 13) are determined in air. Then
the system is equilibrated in the applied buffer and the change in frequency as
well as the dissipation are observed. The equilibrium is indicated by a plateau
in ∆fn/n. Then the different compounds are added in the buffer, the system
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Figure 2.1.: Overview of a QCM-D experiment. An exemplary change in
frequency (∆f, green) and dissipation (∆D, orange) progress of a QCM-D
experiment is shown in a) (adapted from Dixon[94]). After equilibrating the
crystal in buffer (B), a rigid layer is formed at the surface (step 1), followed
by the reversible adsorption of a molecule, which forms a viscoelastic layer
(step 2). In b) a QCM-D sensor with gold coating in top and bottom view is
shown and and a scheme of the open module c).
is equilibrated in, followed by a washing step with buffer each time. To analyse
the data the average of the last 5min of each buffer plateau were calculated
including the standard deviation using "Excel for Mac2011" (Version 14.7.1,
Microsoft) or "Open Office" (version 4.1.2, Appache). The change in frequency
and dissipation for n = 7 is plotted using "Origin" (OriginPro2016G, version
b9.3.226, Origin Lab Corporation).
Cleaning Procedure
To clean the system the sensors as well as the chamber itself is rinsed with
2wt% SDS in water in the ultrasonic bath for 10min. Afterwards the sensors
were rinsed with ddH2O and dried under a stream of nitrogen before adding
them to a mixture of ddH2O:NH3 (23%): H2O2 (30%) 5:1:1 at 80
◦C for 5min
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Table 2.6.: Summary of all compounds used in the QCM-D experiments with
their concentrations.
# compound amount
1 HA 0.4 g/L
2 HA-end-thiol (3) 0.4 g/L
3 HA-end-alkyne (4) 0.4 g/L
4 HA-end-DBCO (5) 1.0 g/L
6 HA-side-alkyne (6) 1.0 g/L
7 DMNPE thiol (1) 100µm
8 11-mercaptoundecanoic acid (7) 100µm
9 DMNPE (2) 100µm
10 BSA 0.4%
11 EDTA 1mm
12 THPTA 500µm
13 aggrecan 100µg/mL
14 LYVE-1a 20µg/mL
a) recombinant humna LYVE-1 with a C-terminal 6-His tag (R&D Systems)
Table 2.7.: Overview of the used buffers with their concentrations and pH
values used in the QCM-D experiments.
# buffer concentration pH
1 PBS 7.5
2 TRIS 100mm 8.5
according to the cleaning protocol form Q-Sense. Afterwards the crystal is
rinsed with ddH2O and dried under a stream of nitrogen.
E4-Module
In the QCM-D experiment 200µL solution are added to the middle of the
crystal. To change the solution the complete 200µL are removed at the edge of
the chamber. For experiments with the photocleavable linker the open moduls
were covered with a quartz glass slide and the sensor irradiated with UV light
(365 nm, "VL-6L", Vilbert Lourmat) until a plateau is reached.
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Omega Auto1
The gold-coated sensors were activated by a O2-plasma treatment for 45min
with 150W and 0.4mbar ("360M", PVA Tepla). The Omega Auto is used
with a flow rate of 20.0µL/min. Each channel was running independently
with a seperate Hamilton syringe pumpe. The crystals were cleaned with a
2% hellmanex solution (Hellmanex), rinsed with ddH2O and dried under a
nitrogen stream.
2.5. Water Contact Angle
Surfaces show different properties respective their surface energy, which can
be changed by functionalisation for example with a SAM. This change can be
used to characterise the surface and its surface energy via its wetting behaviour.
To analyse this, the so called contact angle (Θ) is measured. For this a solvent-
droplet is introduced to the sample and its geometric properties are determined.
[97, 98] The change of geometry of the drop is due to the difference in surface
tension between the liquid and the surface. The liquid molecules interact with
their neighbours within the droplet resulting in a balance net force of zero. The
molecules at the interfaces have no direct neighbour (or of a different kind),
which leads to an inward-looking force, manifesting in the drop shape with
the lowest surface free energy (fig. 2.2). These unbalanced forces contract the
droplet and correlate with the surface tension. Additional external forces like
gravity, influence the droplet as well, so due to that only amounts of liquid of
1 to 5 µL were used.[98]
Figure 2.2.: The surface tension is due to unbalanced forces between liquid
molecules and their environment, which is manifested in the shape of the
droplet.(adapted from [98])
In the case where the substrate surface energy is higher than the liquid sur-
face tension, the resulting contact angle will be in the range of 0◦ < ΘY < 90◦.
This corresponds to a high wetting ability (fig. 2.3), which means for using
water a very hydrophilic surface (for example HA coated surfaces). Contrarily,
for a lower surface tension in compared to the substrate surface tension the
1The experiments with the Omega Auto were performed by Dr. Burcu B. Minsky and were
published in Scientific Reports.[54]
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liquid undergoes poorly wetting (90◦ < ΘY < 150◦), which relates for water
to a hydrophobic surface. This culminates in the case of a so called superhy-
drophobic surface, which corresponds to a contact angle ΘY larger than 150°
with almost no wetting (lotus effect).[97–99]
Figure 2.3.: Scheme of different water contact angles on an homogeneous,
solid surface with ΘY < 90◦ for hydrophilic surfaces up to ΘY > 150◦ for
superhydrophobic surfaces (lotus effect).(adapted from [98])
The correlation between the surface tension and the measurable contact
angle in an equilibrated system is described by the three interfacial tensions,
describing the three different interfaces of the system: surface and liquid inter-
face (γsl), surface and vapour interface (γsv) and liquid and vapour interface
(γlv).[98–100] This is expressed through the Young-Dupre equation (2.4) with
ΘY as Young’s contact angle:
cos(ΘY ) =
γsv − γsl
γlv
(2.4)
The Young-Dupre equation is only valid for ideal surfaces. This implies
homogeneous, inert and smooth surfaces, which can be produced with the fol-
lowing techniques accoring to Lamour et al. and Kwok et al.: heat pressing,
solvent castig, SAM formation, dip coating, vapour deposition and surface
polishing.[99, 100] Cassie and Baxter postulated a possibility to analyse the con-
tact angle of rough and porous surfaces as well in 1944. They expanded the
Young-Dupre equation with a geometrical model to describe the rough surface.
[101]
Measurement of the Contact Angle
The contact angle measurements were performed with the "OCAH 230" devices
(DataPhysics Instruments GmbH ) applying the sessile drop method. Therefore
1.0µL water is pipetted to the surface and an image was captured by a CCD
camera. The contact angles of the left and the right side of the drop were
evaluated by the software "SCA20" (DataPhysics Instruments GmbH ). Five
spots were measured per surface and multiple measurements were done.
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Surface Preparation for Contact Angle of HA Functionalised Surfaces2
The used silicon wafer (Silicon Materials, 2" wafer, Typ P/ Boron <100>,
R = 5 - 10Ω, d = 256 to 306 µm) is cleaned with freshly prepared Caro’s
acid (H2SO4 : H2O2 (30%) 3:1) for 1 h and is coated with gold (100 nm) using
a thermal evaporation method (1 Å/s; p = 10-6 millibar, Pfeiffer "Vacuum
Classic 500"). The surfaces are incubated with either a 0.004% solution of
the end-thiolated HA species or a 100mm solution of HS (CH2)11 EG3 OH
and HS (CH2)11 EG6 HA in a ratio of 2:1. Here the HA is clicked to the
azid with the CuAAC before the adsorption on the surface. The solutions are
incubated for 1 h, the surfaces rinsed with water and dried under a stream of
nitrogen.
Surface Preparation for Contact Angles of Photocleavable Functionalised
Surfaces
The used glass slide (Carl Roth, 24 x 24 mm) is coated with titanium (3 nm)
and gold (30 nm) using the sputter coater from Bal-Tec (tab. 2.8; Bal-Tec Med
020 Coating System with Bal-Tec MCS 010 Multi Control System). Before
using the surface, they were rinsed with EtOH and then incubated with a
100µm solution of DMNPE-thiol (1) (1% EtOH in PBS) over night using a
humidifying chamber. After incubation the surfaces were again rinsed with
ddH2O and dried under a stream of nitrogen. The surfaces were irradiated
with a UV hand lamp ("VL-6 L", Vilber) at 365 nm for 60min and washed with
ddH2O before measuring the contact angle again. The measured contact angles
are plotted and a Kruskal-Wallis test followed by Dunn’s multiple comparison
test are performed using "GraphPad Prism6" (for Mac, version 7.0c, GraphPad
Software Inc., USA).
Table 2.8.: Parameter used for sputtering of glass slides and silicon wafers.
metal thickness [nm] I [mA] t [s] p [mbar]
Ti 3 60 40 1.3 · 10−2
Au 30 60 35 5.0 · 10−2
2.6. BCML
2.6.1. Preparation of Micellar Solution
Poly(styrene(x)-block-(2-vinylpyridine)(y))(PS(x)-b -P2VP(y)) was dissolved
in toluene to a final concentration of 2-8 mg/mL in a pre-cleaned glass tube.
2The contact angles were measured by Dr. Burcu B. Minsky and were published in Scientific
Reports.[54]
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Figure 2.4.: Scheme of the preparation of micellular solution. a) A coblock-
polymer consisting of polystyrene (PS, grey) and polyvinylpyridine (P2VP,
white) is suspended in toluene or xylene (b). After the formation of the
micells HAuCl4 is added to load the micells with gold.
The utilised ratio between PS- and P2VP-units depends on the target inter-
particle spacing (tab. 2.9). The solution was stirred for 24 h to obtain the
formation of micelles. The tetrachloroaureate(III)trihydrate (HAuCl4· 3H2O)
was added and the solution stirred for another 24 h while being protected from
light (fig. 2.4). The amount of required salt is calulated applying equation 2.5
and should be in a range of 0.2 to 0.5 depending on the used polymer.
mHAuCl4· 3 H2O =
mpolymer
Mpolymer
· (2− V Punits · L) ·MHAuCl4· 3 H2O (2.5)
Table 2.9.: Overview of the ratio of styrene- (PS) to vinylpyridine-units
(P2VP) and the possible resulting interparticle spacing.
# PS units (x) P2VP units (y) particle spacing [nm]
1 154 33 18 to 32
2 227 99 24 to 30
3 451 228 42 to 83
4 1057 495 55 to 110
5 1776 694 46 to 102
6 3120 875 53 to 112
7 5348 713 180 to 300
2.6.2. Nanostructuring of Glass Slides by Dip-coating
Before using, the glass surfaces were cleaned with freshly prepared Caro’s
acid (H2SO4 : H2O2 (30%) 3:1) over night. Afterwards they were rinsed with
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ddH2O and dried under a nitrogen stream. The glass slides were dipped into
the prepared micellular solution with a defined immersion and retraction speed
(table 2.10) at a Θ = 90° angle towards the solution surface using a home-
build dipping-machine (machine shop University of Heidelberg, fig. 2.5, tab.
2.10).The surfaces were dried on a lint free paper. The metal salt (AuIII →
Au0) was reduced and the polymer shell removed by using hydrogen plasma
(W10, 350W, 0.4mbar, 45min, "Plasma System 100-E", TePLa).
Figure 2.5.: Overview of the preparation of nanostructured glass surfaces. The
micellular solutions is either distributed on the surface via a) dipping or b)
spin coating. The resulting SAM of gold loaded micells c) is plasma treated
to remove the polymer coat and to reduce the AuIII to Au0.
Table 2.10.: Overview of used loading of the micelles in o xylen and ap-
plied speed/ voltage for creating nanostructured surfaces and the resulting
interparticle spacing.
# spacing [nm] c [mg/mL] loading voltage [V]
1 40 5 0.5 7 to 12
2 60 5 0.3 12 to 15
3 100 3 0.3 12 to 15
2.6.3. Nanostructuring of Glass Slides by Spin-coating
Before the modification, the glass surfaces were cleaned with freshly prepared
Caro’s acid (H2SO4 : H2O2 (30%) 3:1) over night. Afterwards they were rinsed
with ddH2O and dried under a nitrogen stream. The slides were fixed in the
spin-coater applying a slight vacuum. 20.0µL of the micellular solution were
quickly added on top of the rotating glass slide in the spin coater (fig. 2.5 b).
Each surface was spin coated for 30 s and a speed between 5000 and 12 000 rpm
(tab. 2.11). The metal salt (AuIII → Au0) was reduced and the polymer shell
removed by using hydrogen plasma (W10, 350W, 0.4mbar, 45min, "Plasma
System 100-E", TePLa).
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Table 2.11.: Overview of used loading of the micelles in o xylen and applied
speed for creating nanostructured surfaces and the resulting interparticle
spacing.
# spacing [nm] c [mg/mL] loading speed [rpm]
1 35 5 0.5 12 000
2 61 8 0.3 4000
3 102 3 0.4 3000
2.7. General Protocol for the Passivation of Surfaces
Protocol for the passivation of 10 cover glasses, which were labelled with num-
bers using a diamond writer:
component m [mg] V
PEG 5.0
Toluene (dry) 20 mL
Triethyl amine 3 drop
The surfaces were treated with oxygen-plasma (10min, 0.4mbar, 150W,
either "Plasma System 100-E", TePLa or "360M", PVA Tepla) to activate the
surface. A Schlenk flask was flushed with nitrogen. then the toluene, NEt3 and
PEG (section 3.2) were filled in the flask. The surfaces were inserted into a
glass holder and added to the flask. If the humidity is very low (≤ 20%) 1µL
ddH2O per 10.0mL toluene were added. The reaction solution was heated up
to 80 ◦C over night. After the reaction the glass slides were rinsed twice with
ethyl acetate and sonicated for 1min in ethyl acetate. then they were rinsed
with methanol, ddH2O and dried under a nitrogen stream.
2.7.1. Passivation of Pure Glass Surfaces with PEG
The glass cover slides were pre-cleaned with freshly prepared Caro’s acid
(H2SO4 : H2O2 (30%) 3:1) over night. The glass slides were rinsed with ddH2O
and dried under a nitrogen stream. For this passivation PEG2000 silane (8,
(EtO)3Si (CH2)3 NH C(O) NH PEG2000) was used following the general
protocol.
2.7.2. Passivation of Nanostructured Surfaces with PEG
For the passivation of nanostructured surfaces PEG2000 silane (8) was utilised
following the general protocol.
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2.7.3. Passivation of Pure Glass Surfaces with Click-PEG
The glasses were pre-cleaned with freshly prepared Caro’s acid (H2SO4 : H2O2
(30%) 3:1) over night. The glass slides were rinsed with ddH2O and dried
under a nitrogen stream. The further procedure follows the general protocol
using a mixture of PEG2000 silane (8) and PEG3000 alkyne (9, (EtO)3Si-
(CH2)3 NH C(O) NH PEG3000 NH C(O) (CH2)2 C≡CH) in a ratio of
100:1.
2.7.4. Passivation of Nanostructured Surfaces with Click-PEG
The cover glasses were treated according to the passivation protocol using a
mixture of PEG3000 alkyne (9) and PEG2000 silane (8) in a ratio of 1:100.
2.8. MDCK II migration experiments
MDCK II (Madine-Darby Canine Kidney Strain II, Sigma Aldrich) cells were
grown in 75 cm2 cellculture flasks in 10mL Minimum Essential Medium Eagle
with phenolred (MEM) containing 5.0% Fetal Bovine Serum (FBS), 1.0% L-
glutamine, and 0.1% Penicillin/Streptomycin (PenStrep) at 37 ◦C with 5.0%
CO2. The cells were splitted at 80% confluence. The cells were washed 3
times with 10.0mL warm PBS (37 ◦C), once with 2.5mL trypsin-EDTA and
incubated with 2.5mL trypsin-EDTA at 37 ◦C for 8 to 10min. The cells were
re-suspended in 7.5mL pre-warmed MEM complete to deactivate the trypsin
enzyme. 10.0µL were taken to count the cells using a Neubauer counting
chamber. The cells were centrifuged at 1200 rpm (220 g) for 3min in a 15.0mL
falcon. The cells were diluted as desired for the experiment or splitting (tab.
2.12).
Table 2.12.: Number of cells seeded to different used surfaces
type # seeded cells
splitting 1.0 to 1.5 ·106
photocleavable surface 2 · 105
96 well plate 5000
Functionalisation of Nanostructured Surfaces with
1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-(tritylthio)undecanoate (1)
The 24 x 24mm PEG-passivated, nanostructured surface was incubated with
70.0µL of a 100µm solution of 1 in 1.0% EtOH and PBS over night using
a humidifying chamber. The surface was washed with ddH2O three times for
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10min and glued to a custom-made Teflon-ring using "PicoDent Twinsil" (Pi-
coDent). Before irradiating the surface with UV light, the surfaces are washed
with PBS. For irradiating for the first time the microscope "Observer Z1" with
a 5x magnification and the UV-lamp "X-cite" (Series 120 PC, EXFO) are uti-
lized. The used pattern is created with a rectangular aperture in an imaging
plan conjugated to the sample surface. The surface is irradiated under PBS
and after washing with PBS the surfaces are prepared for the cell experiment.
For the second irradiation step the surfaces with the Teflon-rings are added
to a 12 well incubation chamber (Peacon) at the microscope (37 ◦C, 5% CO2).
Several positions along the edge of the collective are chosen, the positions
saved with the software Zen (Zeiss) and irradiated with UV light for 60 s. Af-
terwards the same positions are observed for 2 h and a phase contrast image
is taken every 20min.
2.9. Influence of sHA on Lymphatic Endothelial Cells
The "human dermal lymphatic endothelial cells" (LEC, PromoCell) used in
the following experiments were always taken from Batch 3 061 003.3 (order no.
C12 216) unless stated otherwise.
The LECs were thawed and 10 000 to 20 000 cells were seeded in a 25 cm2
flask in 5.0mL "EGM-2 MV" medium (endothelial basal medium-2, Lonza).
The media contains 0.1% epidermal growth factor ("hEGF"), 0.1% vascu-
lar endothelial growth factor ("VEGF"), 0.1% R3-Insulin like growth fac-
tor ("R3-IGF-1"), 0.1% ascorbic acid, 0.04% hydrocortisone, 0.4% human
fibroblast growth factor-beta ("hFGF-β") 5.0% fetal bovine serum ("FBS")
and 0.1% Gentamicin/ Amphotericin-B ("GA", all Lonza). After one day the
medium was changed completely. When the cells reached 80% confluence, they
were washed twice with 5.0mL warm PBS (37 ◦C) and incubated with 2.0mL
trypsin-EDTA for approximately 3min. 8.0mL medium were added to the
flask to deactivate the trypsin enzyme. The cells were centrifuged for 5min
at 1200 rpm (0.2 g). The cells were re-suspended and after counting the cells
10 000 to 20 000 were seeded in a 25 cm2 flask in 5.0mL medium. When the
cells reached again 80% confluence, they were used for further experiments.
2.9.1. Functionalised and Unfunctionalised HA in Solution on Cell
Culture Plastic
Stock solutions of the utilised HA-species of 40µg/mL in media were prepared
and further diluted in the ratios of 1:20, 1:8; 1:4 and 1:2. 100µL of these
dilutions were added to each well before 4210 cells were seeded per surface
suspended in 100µL medium. This results in a final concentration of the HA-
species of 0.0, 1.0, 2.5, 5.0 and 20.0 µg/mL. After 46 h the AlamarBlue® assay
was performed according to the protocol in section 2.10.1 followed by the
CyQuant® assay (section 2.10.2).
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2.9.2. Functionalised and Unfunctionalised HA in Solution on
Click-PEG Surfaces
Round glass cover slide (d = 22mm) were passivated with click-PEG according
to the protocol for the passivation of glass slides with click-PEG (section 2.7).
Afterwards the surfaces were incubated with 75µL of the click-reaction-buffer
(table 2.13) on parafilm in a humidifying chamber for 1.5 h at room tempera-
ture. The surfaces were washed three times with ddH2O for 10min each and
dried under a stream of nitrogen. then the surfaces were added under sterile
conditions to a 12-well plate and washed with sterile PBS. A stock solution
of the HA-species of 40µg/mL was diluted in the ratios of 1:20, 1:8; 1:4 and
1:2. 500µL medium containing the different dilutions were added to each well
before 50 000 cells per surfaces were seeded in additional 500µL medium. This
results in the final concentrations of HA of 1.0, 2.5, 5.0 and 20.0 µg/mL. Af-
ter 46 h the AlamarBlue® assay was performed according to the protocol in
section 2.10.1 followed by the CyQuant® assay (section 2.10.2).
2.9.3. Immobilised, End-thiolated HA on Nanostructured Surfaces
Round, nanostructured glass cover slides (d = 22mm) were passivated with
click-PEG according to the protocol for nanostructured glass slides (section
2.7). Afterwards the surfaces were incubated with 75µL of the click-reaction-
buffer (table 2.13) on parafilm in a humidifying chamber for 1.5 h at room
temperature. The surfaces were washed three times with ddH2O for 10min
and dried under a stream of nitrogen. To functionalise the Au-nanoparticles
the surfaces were incubated with 75µL of a solution of HA or end-thiolated HA
(1wt%/v% in PBS [pH = 7.4]) on parafilm in a humidifying chamber for 1 h
at room temperature. The surfaces were washed twice with PBS and added
to a 12-well plate under sterile conditions. The surfaces were again washed
with sterile PBS before 50 000 cells per surface were seeded in 1.0mL medium.
After 46 h the AlamarBlue® assay was performed according to the protocol in
section 2.10.1 followed by the CyQuant® assay (section 2.10.2).
Table 2.13.: Composition of click-reaction buffer to create an adhesive back-
ground on nanostructured, passivated glass surfaces with HA in ddH2O.
# substance concentration [mm]
1 TRIS (pH 8.5) 100.00
2 ascorbic acid 100.00
3 R3-Azide 0.15
4 CuSO4 1.00
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2.9.4. Influence of Immobilised Hyaluronan on the Clustering and
Adhesion of LECs
To analyse the clustering of LECs, glass surfaces as well as nanostructured sur-
faces are prepared as described above. In a first step the surfaces are passivated
with click-PEG (section 2.7), followed by the functionalisation with cRGD via
CuAAC. The nanostructured surfaces were incubated with 75µL of a solution
of HA or end-thiolated HA (1wt%/v% in PBS, pH = 7.4) on parafilm in a
humidifying chamber for 1 h at room temperature. After the functionalisation
with cRGD and end-thiolated HA the surfaces are glued to a Teflon ring using
Twinsil and washed sterile with PBS. Then 50 000 cells are seeded per surface
and the cells incubated for 48 h at 37 ◦C and 5% CO2. Afterwards the cells
are fixed with a solution of 4% PFA in PBS and an ICC staining is performed
(section 2.11).
2.10. Assays
2.10.1. AlamarBlue® Assay
To analyse the influence of environmental factors like the surface, the pro-
liferation and metabolic activity of the cells are measured. This is possible
because stressed cells will show a different metabolism and proliferation rate
than resting cells. One well established method for testing the metabolic activ-
ity of organisms is the MTT-assay.[102] This is a colorimetric assay based on
the cleavage of the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide to (E,Z)-5-(4,5-dimethylthiazol-2-yl)-1,3-diphenylformazan.
The transformation through Mitochondrial Reductase leads to a colorimetric
change from yellow to purple, which can be spectroscopically observed.[102–104]
An alternative to the MTT-assay is the AlamarBlue® assay. In comparison
to the MTT-assay, the AlamarBlue® assay is more sensitive to smaller numbers
of cells, which is important especially for studies of cell toxicity of chemicals.
[105] Since components of the AlamarBlue® kit are not toxic for cells, they can
be used for further analysis (no end-point assay), which is a huge advantage of
this assay.[106–108] Disadvantage of this assay is the missing linear correlation
between reduced dye and cell number. This is due to the interaction of BSA
or FBS with resazurin, which leads to a reduced uptake of the chromophore
by the cell and also quenches the fluorescence of resorufin. To overcome this,
the assay can be combined with an assay like the CyQuant® assay.[107–109]
The AlamarBlue® assay is as well based on a colorimetric change of a dye by
reduction induced through a product of the metabolic pathway, for example
ROS, NAD(P)H or FADH.[105–107,110]
The AlamarBlue® assay was developed in the 1940’s to measure the con-
tamination of fresh milk. This assay is based on the pH and oxidative state
depending properties of resazurin (fig. 2.1).[110] During metabolism, products
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Scheme 2.1.: Active species of the AlamarBlue®kit: a) Resazurin (blue in
alkali, pink acid, non-fluorescent), b) Resorufin (pink, fluorescent, colourless
in acid) and c) Dihydroresorufin (colourless, nonfluorescent)
appear, which can reduce resazurin (blue) to resorufin (pink) and to dihy-
droresorufin (colourless), which leads to a detectable change in colour. Later,
an additional change in the fluorescence was observed, making it easy to anal-
yse the metabolic activity of different species.[106,111]
Although it is not fully understood where the reduction of the resazurin
takes place, it is known, that the cells need to take up the chromophore. It
was shown that resazurin is very stable in cell culture media (t1/2 = 10 d)
and the analysis based on confocal microscopy did not show any reduction of
resazurin on the cell surface as on the mitochondrial surface.[106,108] Analysing
the redox-potential of AlamarBlue® (E0 = +380 mV, pH 7.0, 25 ◦C) NAD(P),
FADH, FMNH and Cytochrome could be identified as key players.[107] Proof
for this is, that blocking Cytochrome C, which is correlated to the production
of reactive oxygen species needed for the reduction, with NaN3 inhibits the
AlamarBlue® assay.[112]
To analyse the metabolic activity either the change in fluorescence of re-
sorufin (λex = 540 nm; λem = 585 nm) or the change in adsorption at the two
different wavelength 570 and 600 nm are measured. Using equation 2.6 the
relative metabolic activity can be calculated.
%reduction =
ǫox,600nm ·A570nm − ǫox,570nm ·A600nm
ǫred,570nm ·AC,600nm − ǫred,600nm ·AC,570nm
· 100 (2.6)
Table 2.14.: Molar attenuation coefficient ǫ of reduced and oxidised resazurin
at 570 and 600 nm used for the calculation of the relative amount of reduced
resazurin.[113]
# λ [nm] state ǫ [L/(mol cm)]
1 570 oxidised 80586
2 reduced 155677
3 600 oxidised 117216
4 reduced 14652
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The measurement at two different wavelength helps to reduce systematic
errors. Therefore the molar attenuation coefficient ǫ for the oxidised form
of AlamarBlue® (table 2.14) is multiplied with the value for the absorption
(A). The result is normalised to the absorption of the negative controls (AC)
multiplied with the according molar attenuation coefficient of the reduced
AlamarBlue®. The adsorption of the used media with AlamarBlue® and with-
out cells is used as negative control in this case.
Toxicity Assay
The assay is performed in a "µ-Clear" 96 well plate (greiner-bio-one). The
cells are incubated for 18 h with the substance of interest in different concen-
trations in 200µL media. Afterwards 100µL media are removed and 10µL of
the AlamarBlue® kit are added. The cells are incubated for either 1 h or in
case of the UV toxicity 1, 2 and 3 h. Then the adsorption at 570 and 600 nm
is measured. For each condition three surfaces are prepared. The data are
evaluated using "Excel for Mac 2011" (version 14.7.1, Microsoft), plotted and
a Kruskal-Wallis test followed by Dunn’s multiple comparison test was per-
formed using "GraphPad Prism6" (for Mac, version 6.0e, GraphPad Software
Inc., USA).
Metabolic Activity Assay
The cells are incubated with HA either in solution or immobilised on the sur-
face for 46 h. Afterwards 100µL (96 well plate) respectively 450µL (12 well
plate) are removed and 10µL/ 55µL of the AlamarBlue® kit are added. After
2 h incubation the fluorescence is measured (table 2.5). For each condition in
each experiment three surfaces are prepared and normalised to the mean value
of the background. The data is evaluated using "Excel for Mac 2011" (version
14.7.1, Microsoft), plotted and a Kruskal-Wallis test followed by Dunn’s mul-
tiple comparison test performed using "GraphPad Prism6" (for Mac, version
6.0e, GraphPad Software Inc., USA).
2.10.2. CyQuant® Assay
The CyQuant® assay is based on an unsymmetrical cyanine dye, which is more
sensitive to low cell numbers compared to "Neutral Red" or "Methylene Blue"
even below 1000 cells per sample.[114] Unlike the MTT assay, this assay is not
based on the conversion of a dye via cellular metabolic activity, thus it is a
rapid method. The fluorescence of the used dye increases when it is bound to
cellular nucleic acids.[114,115] Even though the dye binds to DNA and RNA,
no high fluorescence signal for the binding to RNA is found. The assay can
only be used for non-synchronised cell lines to eliminate the error due to the
variation in amount of DNA during the cell cycle.[114]
42 Assays
In this study the CyQuant® assay is combined with the AlamarBlue® as-
say to determine the relative metabolic activity. Therefore, the surfaces are
washed twice with warm PBS after the AlamarBlue® assay. Then the cells
with the surfaces are frozen at −80 ◦C. For the assay the CyQuant-dye (400 x
solution) and cell-lysis buffer (20 x solution) are diluted in ddH2O to their fi-
nal concentrations. Either 600µL (12-well) or 200µL (96-well) of this solution
are added to the surfaces. After 5min the fluorescence is measured with an
excitation wavelength (λex) of 480 nm and an emission wavelength (λem) of
520 nm. The evaluation of the data is performed using "Excel for Mac 2011"
(version 14.7.1, Microsoft). For each condition in each experiment three sur-
faces are prepared and normalised to the mean value of the background. The
results are evaluated and a Kruskal-Wallis test followed by Dunn’s multiple
comparison test performed using "GraphPad Prism6" (for Mac, version 6.0e,
GraphPad Software Inc., USA).
2.10.3. Relative Metabolic Activity
To calculate the relative metabolic activity of the LECs the normalised results
of the AlamarBlue® assay are divided by the corresponding normalised results
of the CyQuant® assay (equation 2.7).
rel. metab. activity =
AlamarBluex/AlamarBlueC
CyQuantx/CyQuantC
· 100 (2.7)
The values of each surface were normalised to the mean value of the surfaces
without applied HA. The results were plotted in a box plot and a Kruskal-
Wallis test followed by Dunn’s multiple comparison test was performed using
"GraphPad Prism6" (for Mac, version 6.0e, GraphPad Software Inc., USA).
2.10.4. Ellman’s Assay
The degree of thiolation was determined with the Ellman’s assay. It is based on
the quantitative reaction of 5,5′-dithiobis-2-nitrobenzoic acid (DTNB) with a
thiol-group (scheme 2.2). The reaction releases 2-nitro-5-thiobenzoate (TNB2-),
which shows a detectable yellow colour (ε = 13 600/cm at 412 nm).[116–118]
Due to the direct correlation between the absorbance and the concentration
(equation 2.8[116]) it can be used in a wide range of applications, for example
to determine an enzymatic activity and blood testing.[118,119]
c(−SH) =
absorbance
13600
mol
L
(2.8)
To create a calibration curve, samples of 850.0µL containing different con-
centrations of cysteamine hydrochloride (0, 5, 10, 15, 20, 30, 40, 50, 60, 80 and
100 µm) were prepared by diluting a 2mm stock solution in ddH2O. To every
sample 100.0µL 1m Tris-HCl buffer (pH 8.0) and 50.0µL of a 2mm DTNB
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Scheme 2.2.: The reaction of 5,5′-dithiobis-2-nitrobenzoic acid (DTNB) with
thiol-groups causes in the release of the detectable, yellow 2-nitro-5-thioben-
zoate (TNB2-), which is used for the Ellman’s assay.
solution in ddH2O containing 50mm sodium acetate were added. Three differ-
ent dilutions (1: 41.5; 1:16; 1:9.6) of a stock solution with 1.0mg/mL of the
end-thiolated HA were prepared and 100.0µL of a 1m Tris-HCl buffer (pH
8.0) and 50.0µL of a 2mm DTNB solution were added. The absorbance at
λ = 420 nm of 300.0µL of each sample were measured using a plate reader.
amount of thiols =
cf
cHA
=
A420 ·M · VStock · Vend
a ·m
=
A420
a · cStock · Vend
(2.9)
The data of the concentration range is plotted for creating the calibration
curve and a linear fit obtained using "GraphPad Prism6" (for Mac, version
6.0e, GraphPad Software Inc., USA). The linear equation A420 = a · cf (A420:
absorbance at 420 nm; a: gradient; cf concentration of thiols), the concentra-
tion of HA (cHA) and the volume of the measured sample (Vend) is used to
calculate the amount of thiols for each sample via equation 2.9. The concentra-
tion of the HA can be calculated via the mass of HA (m), the molecular weight
of HA (M) and the volume of the used stock solution (Vstock). The degree of
thiolation is the mean of the three samples with different concentrations.
2.11. Protocol for ICC Staining
2.11.1. ICC Staining
To label compounds of the cells with a fluorescent dye the media is removed
from the cells and the cells washed with warm PBS. Afterwards, the cells are
incubated with a solution of 4% PFA in PBS for 10min to fix the cells to
the surface. The cells are washed again with PBS for 2min. To permeabilise
the cell membrane, the cells are incubated with a solution of 0.1% Triton
X-100 in PBS for 3min, followed by washing with PBS for 2min twice. To
block unspecific labelling, the cells are incubated with a 5% solution of goat-
serum in PBS for 60min. To incubate the cells with the primary antibody a
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solution of 5% goat-serum, 0.1% Triton X-100 and the primary antibody in
the appropriate dilution (tab. 2.15) in PBS is prepared and the surface placed
up side down on a drop of this solution on parafilm for 60min. If only the nuclei
are labelled the cells are incubated with DAPI instead of an antibody and can
be evaluated after washing for two times 10min with PBS. If a secondary
antibody is necessary the cells are washed with PBS and again incubated with
a solution of 0.1% Triton X-100 in PBS for 5min. After two times washing
with PBS for 10min and 10min incubation with a 5% solution of goat-serum
in PBS, the cells are incubated with a solution of 5% goat-serum, 0.1% Triton
X-100 and the secondary antibody in the appropriate dilution (tab. 2.15). The
surfaces are washed twice for 10min with PBS and stored in PBS at 4 ◦C.
Table 2.15.: Summary of the dilution of primary and secondary antibodies
used for the ICC staining.
# antibody dilution
primary antibodies
1 DAPIa 1:1000
2 mouse anti-Paxillin 1:100; 1:200
3 mouse anti-Talin 1:500; 1:1000
4 mouse anti-Vinculin 1:100; 1:200
5 Phalloidin/FITCa 1:100
6 Phalloidin-647a 1:100
7 rabbit anti-LYVE-1 1:140; 1:300; 1:500
8 rabbit anti-human LYVE-1 1:200; 1:50
9 rabbit anti-Paxillin 1:100; 1:200; 1:500
secondary antibodies
10 goat anti-mouse Alexa 488 1:1000
11 goat anti-rabbit Alexa 594 1:1000
12 goat anti-rabbit Alexa 647 1:1000
a) incubated with the secondary antibody
2.11.2. Evaluation of MDCK II Cells on Surfaces
To determine the number of cells on a PEG-passivated surface with and with-
out UV irradiation the staining of the nuclei with DAPI is used. Therefore,
five positions arranged like on a die are measured using the "Observer Z1". To
determine the number of cells on a surface Fiji (ImageJ 1.51h) is used. Each
picture is set to a saturation of 0.35. Via "Find Maxima" with a noise of 125
and the output "count" the number of nuclei is determined. The results are
plotted in a result frame. The data is plotted using "GraphPad Prism7" (for
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Mac, version 7.0c, GraphPad Software Inc., USA).
2.11.3. Evaluation of LECs on Surfaces
To determine the number of cells on a surface with immobilised HA and with-
out HA the staining of the nuclei with DAPI is used. In the middle of each
surface an area of 8.5 x 6.2mm is measured. To determine the number of cells
on a surface Fiji (ImageJ 1.51h) is used. Each picture is set to a saturation
of 0.35. Via "Find Maxima" with a noise of 125 and the output "count" the
number of nuclei is determined. The results are plotted in a result frame. The
data is plotted using "Excel for Mac 2011" (version 14.7.1, Microsoft).

Chapter 3.
Synthesis
3.1. Functionalisation of Short Hyaluronan
3.1.1. General Procedure of the Functionalisation at the Reducing
End
component M n c m ρ V
[g/mol] [mmol] [mm] [mg] [g/mL] [mL]
short HA n·361.31 100.0
sodium chlorideb 58.44 8.0 400.0 468.0
NaBH3CN 62.84 4.0 200.0 251.0
borate buffer 100.0 20.0
DMSOc 10.0
cysteamine · HCl 113.61 1.1 52.8 120.0
propargylamine 55.08 1.0 52.3 57.6 0.86 0.067
DBCO-aminea 276.33 0.04 4.0 10.0
BCN-aminea 207.27 0.02 25.0 40.0
a) only 50.0mg HA are used
b) not added if the solvent is DMSO
c) solvent amount for half approach
To functionalise the N -acetyl-d-glucosamine unit at the reducing end of HA
a protocol by Lee et al. is adapted.[49] Therefore, HA is diluted in borate
buffer (100mm, pH 8.5) containing 4.7wt% NaCl and then the amine species
is added. The solution is stirred for 2 h at room temperature. 2.5wt% sodium
cyanoborohydrid is added and the reaction solution stirred for 5 d at 40 ◦C.
Afterwards the solution is dialysed (MWCO: 2000 Da) against 4.5L ddH2O
containing 10mL 2m HCl and 5 g NaCl for 2 h followed by the dialysis against
4.5L ddH2O containing 10mL 2m HCl for 2 d, while the water is exchanged six
times. The functionalised HA is recovered by freeze-drying ("Benchtop Freeze
Dry System", Latconco, USA) and stored at −80 ◦C.
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3.1.2. End-thiolated Hyaluronan (3)[49]
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b) 5 d, 40°C
NaBH3CN
NaCl
borate buffer
a) 2 h, rt
3
The reaction is performed according to the general protocol 3.1 using cys-
teamine hydrochloride as the amine species. Before the dialysis, an excess of
DTT is added and the solution stirred for 2 h at 40 ◦C.
3.1.3. End-alkynated Hyaluronan (4)
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4
The reaction is performed according to the general protocol 3.1 applying
propargylamine as amine species.
3.1.4. sHA-end DBCO-amine (5)
OHO
HO OH
OH
O O
O
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O
O
HO OH
OH
O O
O
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NH
O
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HO
HO
n-1
HA
OH
OH
NH
O
HOOHA
b) 5 d, 40°C
NaBH3CN
NaCl
borate buffer
a) 2 h, rt
DBCO-amine HN
O
N
5
The reaction is performed according to the general protocol 3.1 to function-
alise HA at the reducing end applying DBCO amine as amine species and
DMSO as a solvent. The sodium cyanoborohydride is added in 5mL borate
buffer.
3.1.5. Internal Alkynation of Hyaluronan (6)[48]
To functionalise the HA within the chain, HA was dissolved in MES buffer.
1.4 wt/wt EDC/HCl, 1.4 wt/wt NHS and 1.1 wt/wt propargylamine were
added to the solution. The reaction mixture was stirred at room temperature
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for 24 h before it was dialysed (MWCO: 3500 Da) against ddH2O containing 5 g
NaCl solution for 1 d and against ddH2O for 5 d. The solution was lyophilised
and the product stored at −80 ◦C.
1H-NMR (600MHz, D2O): δ (ppm) = 4.68 to 4.29 (m, 2H, H2, H3, H14),
4.00 to 3.14 (m, 11H, H1, H4, H5, H7, H10, H11, H12, H13, H15), 2.69 to 2.53
(m, 0.4H, H9), 1.99 (s, 3H, H17).
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3.2. Synthesis of PEG-derivative for Surface
Functionalisation
3.2.1. Synthesis of PEG2000 silane (8)
[25]
O O NH2
2000 O
SiNC
O
3
+
O O
H
N
2000
H
N
O
Si O
3
8
component m [mg] ρ [g/mL] V [µL] eq
H2N PEG2000 500.0 1.0
DMF 5000.0
3-(triethoxysilyl)propyl isocyanate 43.0 0.999 43.0 1.1
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α-Methoxy-ω-amino PEG (H2N PEG2000) was washed three times with
toluene in a brown glass flask and dried in vacuum. Afterwards, dry DMF
and 1.1 eq 3-(triethoxysilyl)propyl isocyanate were added under nitrogen at-
mosphere. The reaction mixture was stirred for 24 h at room temperature. The
solution was cooled to 0 ◦C and 10.0mL cold diethyl ether were added. The
mixture was gently stirred for 1.5 h. The white precipitate was filtered off by
using a ceramic frit and washed with cold diethyl ether. The product was dried
over night under reduced pressure.
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1H-NMR (600MHz, CDCl3): δ (ppm) = 3.75 (t,
3J(H) = 4.7Hz, 2H, H5),
3.71 (q, 3J(H) = 7.0Hz, 5H, H2), 3.69 to 3.59 (m, 182H, H9,H10), 3.56 to 3.53
(m, 2H, H7), 3.53 to 3.50 (m, 1H, H8), 3.37 (s, 3H, H11), 1.40 to 1.36 (m, 1H,
H4), 1.24 (t,
3J(H) = 7.0Hz, 5H, H1), 0.7 (bs, 2H, H3).
3.2.2. Synthesis of Silane PEG3000 alkyne (9)
[120]
H
N O NH2
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9
component m [mg] ρ [g/mL] V [µL] eq
H2N PEG3000-alkyne 500.0 1.0
DMF 5000.0
3-(triethoxysilyl)propyl isocyanate 43.0 0.999 43.0 1.1
After α-amino-ω-alkyne PEG (H2N PEG3000 alkyne) was washed three
times with toluene in a brown glass flask, dry DMF and 1.1 eq 3-(triethoxysi-
lyl)propyl isocyanate were added. The reaction mixture was stirred for 24 h
at room temperature under nitrogen atmosphere. To precipitate the product,
the solution was cooled to 0 ◦C and 10.0mL diethyl ether were added. The
mixture was gently stirred for 1.5 h, the white solid was filtered off by using a
suction filter and washed with cold diethyl ether. The product was dried over
night under reduced pressure.
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1H-NMR (600MHz, CDCl3): δ (ppm) = 5.97 (s, 1H, HNH), 3.76 to 3.73
(m, 7H, H8), 3.73 to 3.56 (m, 874H, H2, H9, H10), 3.55 to 3.45 (m, 6H, H5,
H7), 2.96 (s, 2H, H13), 2.88 (s, 2H, H12), 1.37 (t,
3J(H) = 7.2Hz, 1H, H4),
1.23 (t, 3J(H) = 7.0Hz, 9H, H1).
3.3. Synthesis of 1-(4,5-dimethoxy-2-nitrophenyl)ethyl
11-mercaptoundecanoate (1)
3.3.1. Nitration of 3,4-Dimethoxyacetophenone
O
O
O
O
O
O
O2NHNO3
HOAc
rt
over night
[180.2] [225.2]
10
component M n m ρ V eq
[g/mol] [mmol] [g] [g/mL] [mL]
3,4-dimethoxy- 180.20 11.1 2.0 - - 1.0
acetophenone
nitric acid 63.01 83.25 5.2 1.51 3.5 7.5
acetic acid 60.05 832.50 49.9 1.05 47.6 75.0
3,4-Dimethoxyacetophenone was dissolved in acetic acid. While stirring the
solution at 0 ◦C, 7.5 eq nitric acid was added dropwise. Afterwards, the reaction
solution was stirred for 24 h at room temperature. The yellowish solution was
poured onto ice, the yellowish solid was filtered off using a ceramic frit (# 4)
and washed with cold ddH2O. The filtrate was stored at 4
◦C over night and
filtered again. The combined solid fractions were dried under vacuum. The
raw product was dissolved in acetone and filtered over silica gel (h = 0.5 cm)
using a ceramic frit (# 4). The acetone was removed under reduced pressure.
The yellowish product was obtained with a yield of 67% (7.4mmol, 1.67 g).
Rf (n-hexane : acetone 2:1) = 0.23.
HR-MS (EI+): for C10H11NO5 calcd 225.0632, found 225.0645.
1H-NMR (600MHz, CDCl3): δ (ppm) = 7.62 (s, 1H, H5), 6.76 (s, 1H, H8),
3.99 (s, 6H, H9,H10), 2.50 (s, 3H, H1).
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13C-NMR (150MHz, CDCl3): δ (ppm) = 200.1 (C2), 154.0 (C6, C7), 149.6
(C4), 132.9 (C3), 108.6 (C8), 106.8 (C5), 56.7 (C9, C10), 56.6 (C9, C10), 30.5
(C1).
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3.3.2. Hydration of 4,5-Dimethoxy-2-nitroacetophenone (10)
O
O
O
O2N
[225.2]
NaBH4,
THF
iPr-OH
rt
HO
O
O
O2N
[227.2]
10 2
component M n m V eq
[g/mol] [mmol] [g] [mL]
3,4-dimethoxy-2- 225.22 7.4 1.67 1.0
nitroacetophenone
NaBH4 37.83 10.4 0.39 1.4
THF 8.0
isopropanol 16.0
4,5-Dimethoxy-2-nitroacetophenone was dissolved in a mixture of THF and
isopropanol at room temperature. To the dark yellow solution 1.4 eq NaBH4
were added and the reaction solution stirred for 6 h at room temperature. The
now reddish solution was quenched with 3.3mL 2m HCl and 16.0mL ddH2O.
The product was extracted three times with CHCl3. The combined organic
layers were washed once with ddH2O and dried over MgSO4. The solvent
was removed in vacuo. The product was purified via column chromatogra-
phy (SiO2, n-hexane:acetone 2:1) and the yellow 4,5-dimethoxy-2-nitrophenyl
ethanol (DMNPE, 2) was obtained with a yield of 93% (1.56 g, 6.9mmol).
HR-MS (DART-): for C10H13NO5 calcd 227.0799, found 227.0800,
for C20H25N2O10 calcd 453.1515, found 453.1516.
1H-NMR (600MHz, CDCl3): δ (ppm) = 7.58 (s, 1H, H5), 7.31 (s, 1H, H8),
5.58 (q, 3J(H) = 6.3Hz, 1H, H2), 4.01 (s, 3H, H10), 3.95 (s, 3H, H9), 1.56 (d,
3J(H) = 6.3Hz, 3H, H1).
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13C-NMR (150MHz, CDCl3): δ (ppm) = 153.8 (C6, C7), 147.8 (C8), 108.5
(C3, C4), 107.7 (C5), 65.8 (C2), 56.4 (C9, C10), 24.3 (C1).
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3.3.3. Protection of Thiol-group of 11-mercaptoundecanoic acid
(7)
HS OH
O
S OH
O
Cl
9 9
+
[218.35] [278.78] [460.68]
NEt3
DCM
2.5 h
rt
7 11
component M n m V eq
[g/mol] [mmol] [g] [mL]
7 218.35 13.7 3.0 1.0
trityl chloride 278.78 16.5 4.6 1.2
triethylamine 0.5
DCM 10+10+5
Trityl chloride was dissolved in DCM containing a catalytic amount of NEt3.
11-mercaptoundecanoic acid was dissolved in DCM as well and added drop
wise to the reaction solution over a period of 20min. The solution was stirred
for 2.5 h at room temperature, before washing with ddH2O three times. The
combined aqueous layers were washed once with DCM. The combined organic
layers were dried over MgSO4. The solvent was removed under reduced pres-
sure. The product (white solid, NMR yield: 52%) was used without further
purification because no complete purification could be obtained.
Rf (hexane/ EtOAc 3:1) = 0.15.
HR-MS (DART-): for C30H35O2S calcd 459.2363, found 459.2364,
for C60H71O4S2 calcd 919.4799, found 919.4802.
1H-NMR (600MHz, CDCl3): δ (ppm) = 7.42 to 7.40 (m, 6H, H15, H17),
7.33 to 7.27 (m, 12H, H14, H18), 7.20 (tt,
3J(H) = 7.3Hz, 4J(H) = 1.5Hz, 3H,
H16), 2.34 (t,
3J(H) = 7.5Hz, 2H, H11), 2.13 (t,
3J(H) = 7.4Hz, 2H, H2), 1.62
(quint, 3J(H) = 7.5Hz, 3H, H10), 1.38 (quint,
3J(H) = 7.5Hz, 3H, H3), 1.33
to 1.28 (m, 5H, H9), 1.28 to 1.11 (m, 11H, H4, H8).
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13C-NMR (150MHz, CDCl3): δ (ppm) = 147.0 (C1), 145.2 (C13), 129.8 (C15,
C17), 127.9 (C14, C18), 126.6 (C16), 66.5 (C12), 33.9 (C11), 32.2 (C12), 29.5 to
29.2 (5C, C4, C5, C6, C7, C8), 29.1 (C9), 28.7 (C3), 24.8 (C10).
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3.3.4. Coupling of 4,5-dimethoxy-2-nitrophenyl ethanol (2) and
11-(tritylthio)undecanoic acid (11)
S OH
O
9Tr
HO
O
O
O2N
O
O
O
S
DCC
DMAP
DCM
0°C - rt
+
[227.22] [460.68] [669.88]
9
NO2
O
11 2 12
component M n m V eq
[g/mol] [mmol] [g] [mL]
2 227.22 4.4 1.0 1.0
11 460.68 6.7 3.1 1.5
DCC 206.33 6.7 1.36 1.5
DMAP 122.17 0.3 0.03 0.06
DCM 75
DMNPE (2) was dissolved in DCM at 0 ◦C. Then 1.5 eq DCC and a cat-
alytic amount of DMAP were added to the reaction solution as well as 1.5 eq
11-(tritylthio)undecanoic acid (11). The reaction solution was stirred for 3 h
at room temperature before the reaction was quenched with 30.0mL aque-
ous, saturated sodium carbonate solution. The organic layer was removed
and washed three times with aqueous, saturated sodium carbonate solution.
The combined aqueous phases were extracted with CHCl3 three times. The
combined organic layers were dried over MgSO4. The solvent was removed
under reduced pressure. The product was purified via column chromatog-
raphy (SiO2, n-hexane:acetone 4:1) and the yellow 1-(4,5-dimethoxy-2-nitro-
phenyl)ethyl 11-(tritylthio)undecanoate (12) was obtained with a yield of 33%
(239mg, 0.4mmol).
Rf (hexane/ acetone 4:1) = 0.2.
1H-NMR (600MHz, CDCl3): δ (ppm) = 7.58 (s, 1H, H21), 7.41 (d,
3J(H) =
7.5Hz, 6H, H2), 7.33 to 7.27 (m, 12H, H1, H3), 7.20 (t,
3J(H) = 7.3Hz, 3H,
H1), 7.00 (s, 1H, H26), 6.48 (quint,
3J(H) = 6.9Hz, 1H, H17), 3.96 (s, 3H,
H25), 3.93 (s, 3H, H23), 2.39 to 2.27 (m, 2H, H6), 2.13 (t,
3J(H) = 7.4Hz, 2H,
H15), 1.64 to 1.59 (m, 5H, H7), 1.38 (quint,
3J(H) = 7.4Hz, 2H, H14), 1.33 to
1.10 (m, 11H, H8, H9, H10, H11, H12, H13, H18).
13C-NMR (150MHz, CDCl3): δ (ppm) = 172.5 (C16), 153.7 (C22, C24), 148.2
(C20), 145.4 (C4), 129.8 (C2), 128.1 (C3), 127.9 (C1), 126.6 (C19), 108.2 (C26),
107.9 (C21), 68.2 (C17), 66.6 (C5), 56.5 (C23, C25), 34.6 (C6), 32.2 (C15), 31.7
to 29.1 (C8, C9, C10, C11, C12, C13), 28.8 (C14), 22.8 (C7), 14.2 (C18).
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3.3.5. Deprotection of Thiolgroup of 1-(4,5-dimethoxy-2-nitro-
phenyl)ethyl 11-(tritylthio)undecanoate (12)
O
O
O
S 9
NO2
O
O
O
O
HS 9
NO2
O
[669.88]  [427.56]
TFA, TIPS,
H2O
rt
3 h
12 1
component M n m ρ V eq
[g/mol] [mmol] [g] [g/mL] [mL]
12 657.87 0.6 0.40 1.0
TFA 114.02 120.0 13.68 1.48 9.24 200.0
TIPS 158.36 0.773 0.19
ddH2O 0.19
To deprotect the thiol function, TFA, TIPS and ddH2O (95.0:2.5:2.5 v%)
were mixed and 1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-(tritylthio)undecano-
ate (12) added. The reaction solution was stirred for 2 h at room temperature.
Afterwards, the reaction was quenched by adding 5mL ddH2O and the so-
lution was extracted with CHCl3 for three times and the combined organic
layers dried over MgSO4. The solvent was removed under reduced pressure.
The raw producte was dissolved in acetone and filtered over silica gel using
a ceramic frit (#4). To obtain the product the solvent was removed under
reduced pressure. with CHCl3 three times. The combined organic layers were
dried over MgSO4. The solvent was removed under reduced pressure. The prod-
uct was purified via column chromatography (SiO2, n-hexane:ethyl acetate 5:1)
and the yellow 1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecanoate
(DMNPE-thiol, 1) was obtained with a yield of 89% (228mg, 0.53mmol).
Rf (hexane/ EtOAc 5:1) = 0.09.
HR-MS (DART-): for C21H30NO6S calcd 424.1800, found 424.1799,
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for C21H32NO6S calcd 426.1956, found 426.1956.
1H-NMR (600MHz, CDCl3): δ (ppm) = 7.58 (s, 1H, H2), 7.01 (s, 1H, H7),
6.47 (quint, 3J(H) = 6.4Hz, 1H, H9), 3.97 (s, 3H, H6), 3.94 (s, 3H, H4), 2.54
to 2.49 (m, 3H, H21), 2.40 (t,
3J(H) = 7.5Hz, 1H, H12), 2.38 to 2.27 (m, 2H,
H10), 1.95 to 1.55 (m, H20), 1.43 to 1.12 (m, 27H, H13, H14, H15, H16, H17, H18,
H19).
13C-NMR (150MHz, CDCl3): δ (ppm) = 172.6 (C11), 153.7 (C3, C5), 148.0
(C3), 140.0 (C7), 133.5 (C1), 108.0 (C2), 107.8 (C7), 68.2 (C9), 56.5 (C4, C6),
34.2 (C20), 34.1 (C12), 29.5 to 28.5 (C14, C15, C16, C17, C18, C19), 25.1 (C13),
24.8 (C21), 22.2 (C10).
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3.4. Modification of α5β1-specific Antagonist
component M n m V eq
[g/mol] [mmol] [g] [mL]
13
2 227.22 6.6 1.5 2.1
DCC 206.33 4.6 1.0 1.5
DMAP cat.
DCM 0.3
(S)-3-(4-(3-(6-(3-mercaptopropanamido)hexanamido)propoxy)benzamido)-
4-(4-(3-((4-methoxypyridin-2-yl)amino)propoxy)phenyl)butanoic acid (13)
and DMNPE (2) are dissolved in DCM. Then, DCC and DMAP were added
under stirring at room temperature. The reaction solution is stirred for 3 h
at room temperature, before the reaction is quenched with 200µL of a sat-
urated sodium hydrogen carbonate solution. The organic phase is removed
and the aqueous phase extracted three times with 200µL CHCl3. The com-
bined organic phases are dried over MgSO4 and the solvent removed under
reduced pressure. The raw product is purified using an HPLC. As solvents are
used 0.1m TEAA in ddH2O (buffer A) and 0.1m TEAA in 75% acetonitrile
and 25% ddH2O (buffer B). A flow rate of 3mL/min is applied with a lin-
ear gradient of 13% buffer B in buffer A up to 100% buffer B over 30min.
The used conditions are appropriate to deprotect the thiol-function during the
purification.
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retention time (min) = 37.4 to 38.3.
1H-NMR (600MHz, CDCl3): δ (ppm) = 7.56 (s, 1H, H26), 7.43 (s, 1H, H30),
7.32 (s, 1H, H11), 7.23 (s, 1H, H6), 7.08 (s, 1H, H27), 5.57 (quint,
3J(H) =
6.2Hz, 1H, H18), 3.99 (s, 3H, H23), 3.93 (s, 3H, H25), 3.71 (q,
3J(H) = 7.1Hz,
7H, H36), 3.13 to 3.07 (m, 1H1, H41), 2.97 (s, 1H, H14), 2.72 (s, 1H, H14),
2.65 (s, 1H, H16), 2.26 (s, 1H, H16), 2.12 (s, 4H, H8), 2.08 (s, 1H1, H7), 2.05
(s, 5H, H6), 1.55 (d,
3J(H) = 6.2Hz, 3H, H19), 1.41 (t,
3J(H) = 7.2Hz, 16H,
H40), 1.23 (t,
3J(H) = 7.2Hz, 12H, H38).
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Chapter 4.
Experiments
The following section deals with the modification of HA to enable its immobil-
isation on surfaces. Nanostructured surfaces with immobilised HA can be used
to probe the influence of HA in a defined density. In this study the immobilised
(basal) and diluted (apikal) application of HA is compared. Additionally a
concentration dependency is tested. In the second part a novel photocleavable
ligand is introduced and characterised, which enables cell adhesion without
addressing specific integrins. In the end also a novel photocleavable ligand to
the integrin α5β1 is introduced.
4.1. Chemical Modification Strategies to Immobilise
Short Hyaluronan
To create an interface with a well-controlled amount of short HA, it is neces-
sary to enable the immobilisation of short HA on the surface. Two different
strategies are followed to achieve the immobilisation of the HA chain. On the
one hand an alkyne function is introduced to the HA chain. So it is possible
to attach the HA to an azide bearing surface using a [3+2]-cycloaddition. On
the other hand a thiol function is introduced to enable the immobilisation on
a gold coated surface.
Scheme 4.1.: Functional groups of hyaluronan enable different chemical mod-
ification strategies: carboxy group in blue, primary hydroxy group in green
and carbonyl group in orange. The Carbonyl-function appears only during
the anomerisation between the α- and β-species of the N -acetylglucosamine-
motif at the reducing-end of hyaluronan. The equilibrium is on the side of
the closed ring-form.
The modification of HA is straight-forward due to its various, accessible
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functional groups as shown in scheme 4.1. Via the primary and secondary hy-
droxy groups as well as the carboxy function the short HA can be statistically
modified within the chain. To create only a single modification per chain, the
carbonyl group at the reducing end is used, which occurs during anomerisa-
tion. To investigate the biocompatibility and bioactivity of the modification
strategies, the HA species are characterised using QCM-D.
4.1.1. Introducing a Terminal Thiol Function to Short Hyaluronan
For the decoration of a gold coated quartz crystal in the QCM-D with short
hyaluronan, the HA is functionalised with a thiol group at its reducing end.
Therefore the carbonyl-group, which appears during the anomerisation be-
tween α- and β-N -acetylglucosamine (scheme 4.1), is modified according to a
protocol of Lee et al..[49]
OH
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SH SH SH
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Scheme 4.2.: Reaction scheme for the coupling of HA with cysteamine. In the
first step the amine attacks the carbonyl C-atom and forms a imine which
is selectively hydrogenated with sodium cyanoborohydrid.
The amine group of cysteamine hydrochloride substitutes the carbonyl-
group at the reducing-end of the HA in a nucleophilic substitution reaction
(scheme 4.2). The formed imine is selectively hydrogenated using NaBH3CN.
Due to the statistically rare open-form of the terminal N -acetylglucosamine,
the reaction time is rather long. To prevent the development of dithiol bonds
within two HA molecules or to break already formed dithiol bonds, dithiothre-
itol is added as reducing agent after 5 days.
Purification of the reaction mixture is carried out via dialysis. Here, modi-
fied and unmodified HA cannot be separated because of the small difference
in size, so only the amine and the reducing agent could be removed. Analy-
sis of the HA derivative with NMR and MS is challenging due to the large
difference in size between the HA (10 -20 kDa) and the cysteamine linker
(M = 77.15 g/mol). A good alternative method to characterise the HA species
is QCM-D, which is very sensitive to the binding of the thiol modified HA
to a gold-coated quartz crystal.[121] This enables also further analysis of the
HA and different interactions. Figure 4.1 compares the interaction between
thiolated and non-functionalised HA with a gold surface, as well as the ad-
sorption of the cysteamine hydrochloride. For the measurement, the sensor
is equilibrated in PBS before the endthiolated short HA (3, 0.4 g/L), short
HA (0.4 g/L) and the cysteamine (100µm) are added to the different gold
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coated crystal surfaces in PBS. After reaching the equilibrium the crystals are
washed three times with PBS. The difference in frequency between the two
plateaus in PBS is correlated to the amount of immobilised substance. The
large change in frequency for 3 (∆(∆f7) = 65Hz) shows the specific adsorption
of the HA species and thus that the synthesis was performed successfully. In
comparison, the change in frequency due to uncoupled cysteamine amounts
only to ∆(∆f7) = 17Hz. Furthermore, after the dialysis almost no impurities
of the cysteamine should remain. The unfunctionalised HA does also interact
with the activated surfaces (∆(∆f7) = 22Hz, dark green), but in a reversible
manner. Using the so-called open module for the QCM-D experiments, no per-
manent flow is applied, which leads to sedimentation of the HA. While the
solution is changed on top of the crystal the sedimented HA or other unbound
compounds are removed again. This can be seen in the increase of frequency
due to the change of PBS (step 1 ∆(∆f7) = 26Hz, step 2 ∆(∆f7) = 24Hz). In
the case of the immobilised short HA the change in frequency stays constant
when the PBS is exchanged. This is also true for the change in dissipation for
the different, analysed surfaces.
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Figure 4.1.: Successful adsorption of end-thiolated HA (3) on a gold coated
quartz crystal which verifies the modification. Comparison of the adsorption
of 3 (0.4 g/L, ∆f7: green, D: orange), unfunctionalised short HA (0.4 g/L,
∆f7:dark green, D: dark brown) and cysteaminehydrochloride (100µm, ∆f7:
light green, D: light brown) for the 7th overtone on a gold surface: The system
is equilibrated in PBS, then the three compounds (step A) are added in PBS.
Afterwards, the crystal is washed three times with PBS.
Additionally the water contact angle (ΘW ) of the pure gold surface as well
as with the short HA-layer on top are measured to verify the adsorption. The
activated, pure gold surface shows an angle of 69° and for the short HA-layer
of below 20°, which indicates the presence of a highly hydrophilic surface.[54]
Another possibility to determine the presence of the thiol group is the Ell-
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man’s assay. This is performed for each batch of 3 to determine the thiolation
degree (section 2.10.4). This assay is well established in literature to analyse
the amount of thiol groups in a sample. The assay is based on the conversion
of 5,5′-dithiobis-2-nitrobenzoic acid to 2-nitro-5-thiobenzoate, which is utilised
for detection at λ = 412 nm. A thiolation degree below 5% was identified as
successful synthesis (Appendix B).
The combination of QCM-D experiment, which shows the binding of the
thiolated short HA (3), and the performance of an Ellmann’s assay, to directly
detect the chemical modification of the HA, proves the successful thiolation of
short HA at the reducing end.
4.1.2. Introducing a Terminal Alkyne Function to Short Hyaluronan
To enable the variation of the density of immobilised HA on a surface as
well as to create the possibility of the co-representation of HA with an adhe-
sive background, an alkyne-group is introduced to the reducing end of short
hyaluronan via propargylamine (fig. 4.3). As passivating background OEG
(HS (CH2)11 EG3 OH) is chosen, because it prevents unspecific interactions
of proteins and cells with the surface and can be used in QCM-D studies.
[53, 122,123] Additional, it is a simplified model for PEG, which is used in cell
culture experiments to prevent unspecific interactions. The synthesis is per-
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Scheme 4.3.: Reaction scheme for the coupling of HA with propargylamine.
In the first step the amine attacks the carbonyl C-atom and forms a imine
which is selectively hydrogenated with sodium cyanoborohydrid.
formed adapting the protocol from Lee et al. for creating end-thiolation of
HA.[49] Therefor, propargylamine is used instead of cysteamine hydrochloride.
The amine function of propargylamine undertakes the nucleophilic attack to
the carbonyl group (scheme 4.2).[54] The following step is the hydrogenation
of the occuring imin-function. According to Likhar et al., it is possible to per-
form a selective hydrogenation of a N C double bond orthogonal to an alkyne
group.[124]
To analyse the functionalisation and to enable further characterisation of
the HA species, again QCM-D experiments are performed. Therefore a click-
reaction is performed with the modified HA and an OEG-SAM with statisti-
cally distributed azide groups (ratio of terminal hydroxy to azide groups 3:2,
Appendix C) in the QCM-D. In a first step the mixture of thiol bearing OEGs
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Figure 4.2.: To characterise the short HA with an alkyne group at the re-
ducing end, the HA is coupled to an azide bearing OEG-SAM as pub-
lished in [54]. a) The surface is decorated with HS (CH2)11EG3 OH and
HS (CH2)11EG6 N3 in a ratio of 3:2. The CuAAC is performed in TRIS
buffer (100m TRIS-buffer, pH 8.5), 100mm ascorbic acid and 1mm CuSO4.
The reaction is observed via QCM-D (b). Shown is the 7th overtone of the
performed reaction with (∆f7: dark green, D: brown) and without (∆f7: light
green, D: orange) adding CuSO4. To simplify the diagram the preparation of
the OEG-SAM is not shown. B corresponds to the used TRIS buffer (100m,
pH 8.5).[54]
(HS (CH2)11EG3 OH and HS (CH2)11EG6 N3) is added at a total concen-
tration of 100µm in TRIS-buffer (100mm, pH 8.5) to the gold-coated crystal
(fig. 4.2 a). A dense SAM is formed. In a next step the end-alkyne, short HA
species (4, 100µm) is added in TRIS-buffer containing 100mm ascorbic acid
and 1mm CuSO4. After the system is equilibrated, the crystals are washed
with buffer again and the change in frequency was determined (fig. 4.2). The
performance of the click-reaction leads to an irreversible drop in frequency
(∆(∆f7) = 57Hz), which proves the covalent binding of the short HA species
to the OEG coated surface. Without adding CuSO4 to the click-buffer, no
change in frequency is observed. The kinetic of the side reaction, the uncatal-
ysed click-reaction between alkyne and azide is to small to be detectable.[125]
Due to the steric hindrance of the large HA molecule the contact of alkyne
and azide-group is a rare event, which decreases the kinetic of the side as well
as the main reaction.[54]
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The water contact angles for these surfaces are measured as well. For pure
gold surfaces a water contact angle of 69°, 48° for the OEG-SAM before adding
HA and an angle below 20° for the surfaces with HA is measured.[54]
Figure 4.3.: Because the incorporation of Cu-ions into the OEG-layer is found,
the usage of a Cu-THPTA-complex is tested unsecessful. a) The surface is
passivated with a 100% HS (CH2)11EG3 OH layer, formed in TRIS buffer
(100mm, pH 8.5, B), incubated with the click reaction solution (TRIS buffer
with ascorbic acid and CuSO4) with (light green, orange) or without short
HA-end-alkyne (dark green, dark brown). Afterwards, the surface is washed
with EDTA-solution (1mm) to remove the copper. b) An OEG-layer with a
1:1 ratio of azide terminus to hydroxy terminus is rinsed with the click reac-
tion mixtures with CuSO4 and HA-end-alkyne (positive control, lime green)
and with additional tris(3-hydroxypropyltriazolylmethyl)amine (THPTA)
with (dark green) and without short HA (green).
However, a more detailed analysis of the data revealed that the usage of the
CuI-species as catalyst has some disadvantages. The analysis indicates that
the CuI-species, which is necessary to catalyse the click-reaction, is incorpo-
rated into the OEG-layer. In a control experiment, an OEG-coated surface is
prepared only consisting of HS (CH2)11EG3 OH (fig. 4.3 a). After the forma-
tion of the SAM, the click solution, containing 100mm ascorbic acid and 1mm
CuSO4 in TRIS-buffer (100mm, pH 8.5), is added to the surfaces either with
0.4 g/L HA-end-alkyne or without HA. In both cases no click reaction can be
performed due to the absence of an azide-function. Because of this no change
in frequency should be observed. After washing with TRIS buffer (100mm,
pH 8.5), a ∆(∆f7)= of 14Hz (with HA-end-alkyne) and 12Hz (without HA-
end-alkyne) are observed. To remove copper ions, the layer is washed with a
1mm EDTA-solution in TRIS buffer. This will preferably remove the CuII ions.
The observed change in frequency decreases with the washing from 14Hz to
10Hz respectively from 12Hz to 11Hz. So it is observed that washing with
EDTA can not remove all copper from the SAM. Another possible explanation
is an unspecific interaction of one other compound of the system, which is not
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influenced by EDTA.
To exclude unspecific binding of copper or ascorbic acid, the potential of
a CuI specific chelater is investigated.[126–128] Therefore CuSO4 is mixed with
ascorbic acid and tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) in a
ratio of 1:50:5. So the CuII species is reduced by the ascorbic acid and CuI ions
are chelated by THPTA. The reaction solution is added to the surface with
(fig. 4.3 b) and without HA-end-alkyne (fig. 4.3), respectively. As positive con-
trol the classical click reaction is performed (fig. 4.3). While a ∆(∆f7) of 62Hz
is observed for the positive control, no click reaction can be detected in the
presence of the copper-THPTA complex. A possible explanation for this is the
steric hindrance due to the THPTA ligand and mainly the large HA, which
prevents the reaction. These results show that neither the application of the
CuI-THPTA complex nor washing with EDTA lead to a successful reaction
without the incorporation of copper ions. To solve this problem a different
approach without catalyst is examined. This is presented in the following sec-
tion.
4.1.3. Introducing Dibenzocyclooctyne-amine to Short Hyaluronan
For the application in a biological relevant context an alternative to the CuI-
catalysed [3+2]-cycloaddition is needed. Therefor, this work will focus on the
strain-promoted alkyne-azide cycloaddition (SPAAC). The reactivity of the
alkyne depends on the strain of the cyclooctyne-species.
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Figure 4.4.: Successful introduction of a dipenzocyclooctyne-amine to the
reducing-end of HA adapting the protocoll of Lee et al..[49] a) shows the
reaction scheme of this modification. b) The click reaction of this HA species
with an azide bearing surface (7.5% azide) is observed using QCM-D in
TRIS-buffer (100mm; pH 8.5) over night. Shown is the 7th overtone, in green
the change in frequency and in orange the dissipation is plotted. To simplify
the figure the formation step of the azide-bearing layer is not shown.
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To introduce a dibenzocyclooctyne-amine (DBCO-amine) to short HA (fig.
4.4 a) a variation of the protocol of Lee et al. is applied.[49] Again, the amine
substitutes the carbonyl-function (fig. 4.4) at the reducing end of the short HA,
followed by the hydrogenation of the occurring imine. Due to the solubility of
the reactants, the reaction is performed in DMSO. The sodium cyanoborhy-
dride for the hydrogenation is added in borate buffer (30 v%). After the pu-
rification via dialysis, the functionalised HA is characterised using QCM-D.
The ring strained alkyne is added to an azide bearing surface on the quartz-
crystal. After the system is equilibrated in TRIS-buffer (100mm; pH 8.5), the
short HA with DBCO (2.5mg/mL) is added to the surface. An example of the
change in frequency for the 7th overtone due to the SPAAC is shown in figure
4.4 b). Comparing the needed time until a plateau is reached for the CuAAC
and SPAAC a large decrease in reaction time is seen. The SPAAC takes about
24 h until the reaction is complete whereas the CuAAC needs less then 1 h.
This discrepancy is due to the different mechanisms behind the reactions. The
driving force in this case is the strain of the dibenzocyclooctyne. Due to the
sp-hybridisation of the alkyne carbon-atoms the resulting angle between those
atoms would be 180°. The cycle in which the triple bond is incorporated en-
forces a angle of approximately 160°.[55] So the high energetic triple bond
reacts spontaneously with the azide on the surface. This takes much longer
than the copper catalysed reaction. Additionally a sterical hindrance due to
the large HA molecule decreases the reaction speed. As a result of the rather
slow reaction kinetic of the SPAAC compared to the CuAAC, the reaction was
performed over night. The QCM-D experiments show a frequency change for
∆(∆f7) of 42Hz respectively of 58Hz.
Although the SPAAC with the DBCO bearing short HA and azide is slow, it
could be proven that the SPAAC is an appropriate alternative to the CuAAC
to immobilise hyaluronan to a surface.
4.1.4. Introducing an Alkyne Function within the Chain of Short
HA (6)
To enable the analysis of the influence of the position of the introduced modifi-
cation, an alkyne group is presented within the HA chain via functionalisation
of carboxy groups. To keep the amount of alkyne-groups within a single chain
low, the disaccharide units are used in high excess. The synthesis is performed
according to Crescenzi et al..[48] In a first step the carboxy group is activated
using N -(3-dimethylaminopropyl)-N ′-ethylcarbodiimide (EDC) (scheme 4.4).
The formed intermediate can either react with the primary amine-group of
propargylamine or further with N -hydroxysuccinimide (NHS) to form an ac-
tive ester, which enables the coupling to amine-groups as well.
The characterisation of the HA with alkyne groups within the chain is ob-
tained using QCM-D again. The CuAAC is performed outside the QCM-D
in TRIS buffer (100mm, pH 8.5) in the presence of 100mm ascorbic acid,
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Scheme 4.4.: Reaction scheme of the functionalisation of HA within the chain
using active ester chemistry applying EDC and NHS (R’ = HA).
1mm CuSO4, 100µm HS (CH2)11EG6 N3 and 100µm functionalised HA. Af-
ter the reaction, 1mm EDTA is added to chelate the remaining metal ions.
The HS (CH2)11EG6 sHA is mixed with the HS (CH2)11EG3 OH to a mo-
lar ratio of 2:1 and added to the QCM-D sensor using the flow module.[54]
Figure 4.5 shows a change in frequency for the HA-modified layer of ∆(∆f7)
of 53Hz. Disadvantage of the pre-clicking of the short HA in this case is that
the short HA has more alkyne-groups per chain and thus can bind to several
HS (CH2)11EG6 N3-molecules. This influences the formation of the SAM on
the surfaces. Although the density of alkyne-functionalities is kept low, the
groups are statistically distributed in the chain without control of their loca-
tion.
The degree of alkynation is determined via NMR analysis. The integral of
the alkyne-proton signal (δ = 2.67 - 2.54 ppm) is compared to the integral of
the methyl-group signal of the N -acetylglycosamine-unit (δ = 1.98 ppm; Ap-
pendix F). Considering the stoichiometric ratio of the integrals, normalised to
the number of represented protons, a degree of alkynation of 16% is calculated.
The results in the previous section show several strategies to chemical mod-
ify HA to immobilise HA on a surface. One the one hand modifications at the
reducing-end are performed using cysteamine hydrochloride, propargylamine
and dibenzocyclooctyne-amine. On the other hand the propargylamine is intro-
duced at the carboxy groups within the chain. In case of the end-thiolated HA
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Figure 4.5.: Successful immobilisation of HA with alkyne groups within
the chain on an OEG-SAM in the QCM-D. The OEG-SAM consists of
HS (CH2)11EG3 OH and HS (CH2)11EG6 side HA (ratio 3:2). Before-
hand 6 is coupled to HS (CH2)11EG6 N3 using the CuACC reaction. The
7th overtone is shown for an experiment on a gold surface with the change in
frequency in green and the dissipation in brown. The system is equilibrated
in PBS.[54]
a degree of thiolation of below 5% (Appendix B) and of the functionalisation
within the chain a degree of alkynation of 16% is determined. All synthesis
are possible and enable the immobilisation of the HA-species.
4.2. Bioactivity of Chemical Modified Short Hyaluronan
The possibility to immobilise short hyaluronan and to create surfaces with
well-controlled HA patterns enables the analysis of specific and unspecific in-
teractions between HA and biological samples. Therefore, it needs to be tested,
if the modified short HA is still bioactive. Due to the chemical modifications,
there is the risk that the short HA is not recognisable by some HA-binding
receptors, respectively other hyaladerins, if the reducing end is important for
these interactions. Therefore modifications at the reducing end are compared
with the modification within the chain. In case of the modification within the
chain, it is necessary to keep the modification degree low because typical HA
receptors need a defined number of disaccharide units to recognise HA (chap-
ter 1). To ensure the bioactivity, the interaction of the differently immobilised
HA species with aggrecan, a HA binding protein, and LYVE-1, a HA recep-
tor, as well as the passivation properties of HA are determined in QCM-D
experiments.[54]
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4.2.1. Passivation Properties of Immobilised sHA
HA can be used to prevent unspecific interactions between proteins and a
surface. To analyse the passivation properties of the different modified HA
species, the different prepared surfaces are incubated with a 4% solution of
BSA as a model protein. Compared are coated gold surfaces decorated with
the end-thiolated HA species (3) and the two different alkyne functionalised
surfaces with an additional passivating OEG background (fig. 4.6). The first
Figure 4.6.: Intact passivation properties of different chemical modified, im-
mobilised HA layers. For testing the passivation properties of a) a layer of
thiolated HA (3) (in PBS) and the two HA species with alkyne groups (in
TRIS buffer) b) at the reducing end (4) and c) within the chain (6, ∆f green,
∆D: orange) the surfaces are rinsed with a 4% solution of BSA in the corre-
sponding buffer. The 7th overtone is shown with the change in frequency in
green and the dissipation in orange.[54]
analysed surface is decorated with the end-thiolated HA species (3) (a). After
the incubation with a 4% BSA solution, the system is again equilibrated in
buffer, which removes all BSA. So no change in frequency due to BSA can
be obtained. The modification at the reducing end with a thiol has no influ-
ence on the passivation properties of the HA. In the cases of the OEG-SAM
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decorated with alkynated HA, neither an interaction between the BSA and
the functionalisation at the reducing end nor the functionalisation within the
chain is observed. The comparison of the three different surfaces shows, that
the position of the functionalisation of the HA does not influences the passi-
vation properties of the HA. Furthermore, the homogeneous immobilisation of
HA on a gold surface via a thiol group is sufficient to protect a surface against
unspecific interactions.
4.2.2. Specific Interaction of Immobilised sHA and Aggrecan
For this analysis on the one hand the OEG-SAM, consisting of 67% of the azide
bearing HS (CH2) EG6 N3 and 33% HS (CH2) EG3 OH, which was mod-
ified with both propargylated species before it is applied to the surface, and
on the other hand the homogeneous short HA-end-thiol modified surfaces are
compared. This enables the determination of the influence of the position of
the modification as well as the testing, if a very dense HA surface has a major
effect on the activity. Therefore a solution of aggrecan (100µg/mL) is applied
to the different surfaces and the change in frequency as well as the change in
dissipation in a QCM-D experiment is determined. The summary of the rela-
tive changes in frequency and dissipation are shown in figure 4.7 a. As expected,
no interaction between aggrecan and the OEG control can be observed (A).
Furthermore, no interaction between aggrecan and the HA-side-alkyne can be
found (D). Possibly, the HA structure is disturbed due to the binding of the
OEG-molecules. Because of this it is possible that the aggrecan can not recog-
nise the HA and thus prevent the binding of aggrecan to the HA. For both
end-modified HA-species a change in frequency is observed in a similar range.
The larger change in frequency and dissipation might be due to the different
amount of immobilised HA in the two systems. Because the aggrecan binds to
and thus recognises the HA, it is still bioactive after the chemical modification.
4.2.3. Specific Interaction of Immobilised sHA and LYVE-1
Complementary, the interaction of HA with LYVE-1, a HA-receptor, is inves-
tigated. Therefore, HA-modified surfaces are rinsed with a 20µg/mL solution
of LYVE-1. In this case only the OEG-HA-samples are compared, because it
is very important to have a passivated background to prevent unspecific inter-
actions between LYVE-1 and the pure gold surface. The low molecular weight
of LYVE-1 (30 kDa)[39] makes it difficult to measure binding to the HA with
QCM-D. To increase the weight, a LYVE-1-his tag is bound to a monoclonal
anti-polyhistidine-alkaline phosphatase antibody. A solution of this species
(39.9 ng/mL) is rinsed over the different surfaces. The results are summarised
in figure 4.7 b. For the interaction between LYVE-1 and the OEG-SAM surface
no change in frequency and dissipation is observed (A). In case of 4 a small de-
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Figure 4.7.: Verification of the specific interaction between chemical modified
HA and hyaladherin or HA receptor. Compared is the interaction of a HA
modified surface with a) aggrecan and b) LYVE-1 and a LYVE-1-antibody
construct to increase the weigth (C’, D’). Shown are the changes in frequency
and dissipation for A the negative control without HA, B the end-thiolated
HA (3), C the end-alkynated HA (4) and D the HA with the alkyne group
within the chain (6).
crease in frequency and dissipation can be observed (C), which can be slightly
increase by using the LYVE-1-antibody construct (C’). So it is still difficult to
prove a strong binding of LYVE-1 to the HA. For the HA modified within the
chain less binding is observed (D), which can not be increased be using the
LYVE-1-antibody construct (D’). The antibody itself is not able to bind to
the surfaces. So a interaction of LYVE-1 and the terminal functionalised HA
can be proven, even though the small change in frequency and dissipation indi-
cates only a weak interaction. In case of 6 the interaction seems more difficult
than in the other case because the found change in frequency and dissipation
is even smaller. An extensive discussion about the binding of LYVE-1 to the
immobilised HA is published in Minsky et al..[54]
After the chemical modification to immobilise HA, the bioactivity is verified
via the analysis of the interaction between the HA species and the hyaladerine
aggrecan as well as LYVE-1. Especially the interaction between aggrecan and
HA proves the conservation of the bioactivity during the modification.
4.3. Establishment of Different Cell Assays
In this section the concentration depended influence of hyaluronan on cell
behaviour in a lymphangiogenisis model is analysed. After enabling the immo-
bilisation of HA and the verification of the bioactivity of chemical modified
HA species, the influence of immobilised HA is compared to HA, which is di-
luted to different concentrations. To generate a surface with a well-defined HA
pattern, nanostructured surface are used (fig. 4.8). To vary the HA concentra-
tion, the density of gold nanoparticles is varied. This will be compared to the
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Figure 4.8.: Scheme of the surface applied in the study to investigate the
influence of HA on the behaviour of LECs. The glass surface is decorated
with gold nanoparticles (yellow dots) with different particle densities and
passivated with click-PEG (grey). The click-PEG is functionalised with
cRGD (triangles) as adhesive background and the nanoparticles with the
end-functionalised HA (green/orange).
variation of HA, diluted in different concentration. Analysed is the metabolic
activity of human primary lymphendothelial cells (HUPLEC) based on the
AlmarBlue® assay, the adhesion of the cells via the CyQuant® assay and the
toxicity of HA using the AlamarBlue® assay. The CyQuant® assay analyses
the amount of DNA, which is directly correlated to the number of cells on the
surface. To compare different samples, the determined metabolic activity is
normalised to the amount of DNA.
4.3.1. Establishment of the CyQuant® Assay
On different surfaces cells might adhere and behave in a different manner. To
compare the metabolic activity of cells on different surfaces, the amount of cells
on each surface is determined using the CyQuant® assay, which analysed the
amount of DNA in a sample. The CyQuant® assay is based on a colorimetric
change of the kit due to the binding of the dye to the DNA. The fluorescence
is measured at λex of 480 nm and λem of 520 nm. For the CyQuant® assay
the surface is washed twice with PBS to remove the complete media. After
freezing the cells at -80 ◦C 200µL of the CyQuant® kit are added containing
49.8% lysis buffer. Different numbers of cells are incubated for several minutes
before the fluorescence is measured at different time points. For an optimal
usage of this assay the responding fluorescence signal after the incubation of
the dye with cells needs to be within the linear range for the concentration
depended fluorescence signal. For this optimisation experiment 1000, 5000,
10 000, 20 000, 30 000, 40 000 and 50 000 cells are seeded in a 96 well plate
in 200µL media. To access the DNA after 48 h, the cells are frozen at -80 ◦C
so that the membrane is permeabilised. After freezing the cells with the sur-
faces 200µL of the CyQuant® kit are added. Additional, the dye is added in
a lysis buffer according to the protocol in section 2.10.2. The fluorescence is
measured with an excitation wavelength λex = 480 nm and an emission wave-
length λem = 520 nm after 5, 15, 25 and 35 min in each well (fig. 4.9). For a
cell number below 12 500 a linear increase of the fluorescence signal is deter-
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mined for all incubation times (fig. 4.9 a). The determination of the incubation
time leads to an optimal time of 5min for this number of cells. Analysing the
correlation between fluorescence and incubation time, a linear increase of the
signal is found up to an incubation time of 15min.
Figure 4.9.: Determination of optimal incubation time and cell number for
using the CyQuant® assay. The measured absorbance at excitation 480 nm
and emission 520 nm a) Incubation time  5min ◦ 15min ∆ 25min ∇ 35min
b)  1000 ◦ 5000 ∆ 10000 ∇ 20000 ♦ 30000 ⊳ 40000 ⊲ 50000
So an incubation time of 5min is chosen which is in the middle of the linear
range. Since the CyQuant® assay is performed right after the AlmarBlue®
assay (section 4.3.2), the cell number depends also on that assay.
4.3.2. Applicability of AlamarBlue
The system is checked for any interaction between resazurin, the dye used in
this assay, and the used HA species before it is used for further experiments.
For the cell experiments HA concentrations of 1.0, 2.5, 5.0 and 20.0µg/mL
are used. This different concentrations are tested in growth media with 10%
AlamarBlue® kit. The absorption of the solution is measured in a 96-well
plate at a wavelength of 570 and 600 nm after mixing and again after the
incubation for 1 and 2 h at 37 ◦C in the presence of 5% CO2 (fig. 4.10). The
relative amount of reduced resazurin is calculated according to equation 2.6
in section 2.10.1. The performed Kruskal-Wallis test with Dunn’s comparison
(non-parametric statistical analysis; Appendix E) shows neither a significant
difference between the different applied HA-concentrations nor the different
time-points of the measurement. This indicates no interaction between the
resazurin or resorfurin with HA.
In a second step, the system is checked for any interference between the
media with the supplements and the resazurin, which might falsify the fluores-
cence measurement. Therefore the fluorescence of resazurin, respectively the
AlamarBlue® kit, is measured of a mixture of media with 10% of the kit at
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Figure 4.10.: The analysis of the interaction of growth media for LECs,
resazurin and different concentrations of end-tiolated, short HA-end-thiol
shows no interference of the compounds. The absorption is measured at
570 nm and 600 nm after 0 h (dark grey), 1 h (light grey) and 2 h (light blue)
and the relative amount of resazurin calculated applying equation 2.6. The
Kruskal-Wallis test followed by Dunn’s multiple comparison showed no sig-
nificant difference between the samples (p > 0.05).
a excitation wavelength of 540 nm and an emission range of 550 to 700 nm.
For the measurement 0 to 50 000 cells are incubated at 37 ◦C for 0 to 27 h (fig.
4.11). The comparison shows an increase of the fluorescence at 585 nm with in-
creasing cell number (a) and increasing time frame (b), which correlates with
a raising amount of metabolic products. Because no disturbing interactions
Figure 4.11.: No interference of the used compound with resazurin is found
in the fluorescence spectra. The fluorescence intensity is measured of media
with 10% AlamarBlue®kit and 0 to 500 000 cells after 0 to 27 h. The results
are normalised to the background. a) shows the example of the measurement
after 2 h with the full range of cells and b) the example of 5000 cells from 0
to 4 h.
of the utilised components with the AlamarBlue® kit could be observed, the
assay is adaptable for the ongoing experiments.
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4.3.3. Establishment of the AlamarBlue® Assay
After exclusion of disturbing interference between resazurin, growth media
and HA, the optimal incubation time and cell number needs to be determined.
As described in section 2.10.1, the arising fluorescence is determined and it
needs to be ensured that only a small amount of dye is converted according
the scheme 4.5 to resofurin. If the number of cells is to high, the formation of
dihydroresorufin will falsify the result.
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Scheme 4.5.: Active species of the AlamarBlue®kit: Resazurin (blue in alkali,
pink acid, non-fluorescent), Resorufin (pink, fluorescent, colourless in acid),
Dihydroresorufin (colourless, nonfluorescent)
To identify this linear range, 0 to 50 000 cells were seeded in 200µL media
in a 96-well plate. After 48 h 100µL media are removed and 10µL of the
AlamarBlue®kit are added. The absorption is measured after 1, 2, 3, 4 and 27 h
incubation. The last value is needed to determine the maximal concentration
of reduced resazurin. The results are normalised to the mean of the pure media
and the relative fluorescence intensity is plotted against the number of cells or
the incubation time (fig. 4.12).
Figure 4.12.: Determination of optimal incubation time and cell number for
using the AlamarBlue®assay in LECs in a 96-well plate. The fluorescence
is measured with an excitation wavelength of λ = 540 nm and an emission
wavelength of λ = 585 nm. a) Incubation time  0 h ◦ 1 h ∆ 2h ∇ 3 h ♦ 4 h
⊳ 27 h b)  1000 ◦ 5000 ∆ 10000 ∇ 20000 ♦ 30000 ⊳ 40000 ⊲ 50000
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Figure 4.12 a) indicates a linear range for a cell number lower than 20 000
cells for 1 to 4 h, which is confirmed through b). In a) a linear range for an
incubation time of 1 to 3 h can be observed. In b) the curve for 1000 to 10 000
show a wide linear range within a good observable time frame (1 to 4 h). For
further experiments a cell number, in the middle of the linear range, of 4210
cells respectively 131/mm2 for a 96 well (tab. 4.1) and a incubation time of
2 h is chosen. The chosen number of cells is also suitable for the CyQuant®
assay, where a number of cells below 12 500 is needed for a useful application.
4.3.4. Summary of the Established Assays
The establishment of the CyQuant® and AlmarBlue® assays showed a suitable
number of cells of 131/mm2 on the used surface and an incubation time of
5min and 2 h. Also the performance of both assays right after each other shows
no further challenges. Because in the upcoming experiments surfaces with
different sizes are used and the recommended amount of kit were confirmed
for the use in a 96 well plate with LECs, the required amount of dye for the
glass surface (d = 22mm in 12 well) is calculated (table 4.1).
Table 4.1.: Summary of the used amount of liquid for the AlamarBlue® and
CyQuant® assay depending on the used surface areas and number of cells.
Additionally the quantity of the dye solution is noted.
# surface area [mm] cell number AB [µL]a CQ [µL]b
1 34.0 (96 well) 4210 110 200
2 380.1 (12 well) 50000 605 600
a) containing 10% AlamarBlue® kit
b) containing 5% CyQuant® kit
To determine the influence of hyaluronan on LECs the performance of the
AlamarBlue® and CyQuant® assay are established. A cell density of 131 /mm2,
an incubation time of 2 h (AlamarBlue® assay) and 5min (CyQuant® assay)
are established.
4.3.5. Toxicity of Different HA Species
Finally it is analysed if the different HA species and applications have a toxic
effect on the cells. Therefore the adsorption of the AlamarBlue® kit is mea-
sured at 570 nm and 600 nm after 2 h of incubation to enable the calculation
of reduction of resazurin according to equation 2.6. Compared are the effect
of the digested and short HA (a) with each other and the two end-thiolated
species in solution (fig. 4.13 b). Also the effect of both immobilised species
are compared (c). Shown is also the passivation control, which has no cells
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on top, to analyse effects of the surface without HA and cells on resazurin.
For the statistical analysis all samples are compared to the positive control
and the different species at the same concentration with each other. In case
Figure 4.13.: The comparison of the toxic effect of the different HA species
on LECs shows similar influences in all cases. The analysis is performed
using the AlamarBlue® assay (section 2.10.1). In a) the unfunctionalised
short (grey circles) and digested (black triangles) HA are compared. Their
end-thiolated analogues are presented in b) in solution and immobilised on
a nanostructured surface in c). C corresponds to the passivation control
without cells. The significant difference between the concentrations and the
species is analysed applying a Kruskal-Wallis test followed by the Dunn’s
multiple comparison (p > 0.05; Appendix E).
of the unfunctionalised HA species a splitting up between both species are
observed. Although the positive control (0µg/mL) has no HA incorporated.
The performed statistical analysis (Kruskal-Wallis test followed by the Dunn’s
multiple comparison, Appendix E) shows no significant difference between the
surfaces as well as between the applied species. Because no splitting up effect
is found for the negative control (C) the impact is not due to the surface itself
or the used equipment, but due to the cells used at different days, although it
is the same cell passage. In case of the end-thiolated HA the distribution of the
data points is less pronounced compared to the unfunctionalised HA species.
Again the statistical analysis (Kruskal-Wallis test followed by the Dunn’s mul-
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tiple comparison, Appendix E) shows no significant difference neither between
the different applied concentrations nor the different species. For the immo-
bilised HA species no separation in the data is observed due to the different
species. The performed Kruskal-Wallis test followed by the Dunn’s multiple
comparison (Appendix E) shows no significant difference between the different
species or different particle densities compared to the positive control. Whereas
a significant difference is found between positive and negative control. This is
expected, because no cells can contribute to the reduction of resazurin in case
of the negative control.
The determination of the toxic impact of digested and short HA species
applied in different concentrations or different densities shows no negative
effect to the metabolic activity.
4.4. Concentration Dependent Influence of Short
Hyaluronan on Human Primary Lymphendothelial
Cells
In this section the effect of short hyaluronan, a digested HA and their end-
thiolated analogues incubated with LECs are tested. Therefore experiments
are performed either on cell culture plastic (96 well-plate) or cRGD function-
alised click-PEG surfaces (cover slide, d = 22mm) with HA in solution or
immobilised on nanostructured surfaces with cRGD functionalised click-PEG
(cover slide, d = 22mm). The used short HA has a weight distribution of
10 000 to 20 000 Da. The enzymatically digested HA1, based on a HA with
an averaged weight of 4 000 000 Da, has a final weight distribution of 1000 to
10 000 Da.
4.4.1. Comparison of the Impact of sHA on Cell Culture Plastic
In a 96-well plate 4210 cells were seeded in growth medium containing 0, 1.0,
2.5, 5.0 and 20.0µg/mL of either short HA and digested HA (fig. 4.15) and
incubated for 46 h at 37 ◦C and 5% CO2. Afterwards the AlamarBlue
® and
the CyQuant® assay performed.
Do cells adhere differently when applying different concentrations of HA?
The permeabilised cells are incubated for 5min with the CyQuant® kit and
the fluorescence is measured (λex = 540 nm; λem = 585 nm). The results are
corrected to the background (well plate) and normalised to the average of the
control sample without HA. The comparison of the impact on the cell attach-
ment of the digested HA species (fig. 4.14 a) shows no significant difference.
1The digested HA-species was produced by Melanie Rothley (ITG, KIT) based on "Healon
5" (Abbott Medical Optics)
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Also no significant difference is determined for the short HA species according
Figure 4.14.: Results of CyQuant®assay of unfunctionalised HA in solution
with LECs in a 96-well plate: a) for enzymatically digested HA and b) short
HA. The performed Kruskal-Wallis test followed by a Dunn’s multiple com-
parison shows no significant difference between the different surfaces. The
results are baseline corrected and normalised to the average of the surfaces
without short HA.
to the performed Kruskal-Wallis test followed by the Dunn’s comparison (p <
0.05). Only a small decrease of DNA becomes apparent for the smallest short
HA concentration. The statistical analysis of the samples between the two
types of HA also showed no significant difference of the same concentration of
the different species (p < 0.05, Appendix E). No difference in the amount of
DNA on the surfaces, which were incubated with different concentrations of
HA as well as the different species is observed. So no evidence of a reduced
cell adhesion due to the HA is found.
Do the different HA species influence the metabolic activity of LECs?
After 46 h the cells are incubated for 2 h with the AlamarBlue® kit and the
fluorescence is measured (λex = 540 nm; λem = 585 nm) using a plate reader.
The results are corrected to the background (well plate) and normalised to the
average value of the control.
For the digested HA three data points are measured per concentration and
plotted in a scatter plot (fig. 4.15 a). Adding the HA leads to a small decrease
in the intensity compared to the control. The activity is slightly increasing
again, but stays below the control-level. The performed Kruskal-Wallis test
followed by Dunn’s comparison (p < 0.05, Appendix E) shows no significant
difference. As well in case of the short HA no significant difference according to
the results of the Kruskal-Wallis test followed by Dunn’s multiple comparison
(fig. 4.15 b) is found, although the same trend for the activity like for the
digested HA is visible.
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Figure 4.15.: Results of AlamarBlue®assay of unfunctionalised short HA in
solution with LECs in a 96-well plate: a) for enzymatically digested HA
and b) short HA. The performed Kruskal-Wallis test followed by Dunn’s
comparison shows no significant difference between the different surfaces (p
< 0.05, Appendix E). The results are baseline corrected and normalised to
the average of the surfaces without short HA.
Additionally, the influence of the two species are compared. For both the
same trend in activity is observed, which is not significant (fig. 4.16). The
performed Kruskal-Wallis test followed by the Dunn’s multiple comparison in-
dicated no significant difference between the same concentrations of the two
corresponding HA-species (p < 0.05, Appendix E). Due to this, no differenti-
ation in digested HA and short HA is necessary in this case.
The performed Kruskal-Wallis test followed by the Dunn’s multiple com-
parison shows no significant difference comparing the different applied con-
centrations of HA. This is found for both species. The comparison between
both species also shows no significant difference according to the performed
analysis.
Determination of the Relative Metabolic Activity
To enable the comparison between the different surfaces and concentrations,
the detected relative metabolic activity, based on the AlamarBlue® assay, is
normalised to the relative amount of DNA, based on the CyQuant® assay. The
results are shown in fig. 4.17. Neither for the digested HA (a) nor the short
HA (b) a significant difference can be obtained. Furthermore, no significant
difference between the two HA species can be detected at all so the results can
be pooled and analysed as a whole (fig. 4.17).
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Figure 4.16.: To compare the used HA species all data is plotted in one
figure, where black represents the digested HA and light grey the short HA.
The performance of the Kruskal-Wallis test followed by the Dunn’s multiple
comparison shows no significant difference between the species (Appendix
E).
Figure 4.17.: Presentation of the metabolic activity of LECs (based on
AlamarBlue®assay) normalised to the amount of DNA on the surface (based
on CyQuant®assay) for a) using digested HA and b) an short HA. The per-
formance of the Kruskal-Wallis test followed by the Dunn’s multiple com-
parison shows no significant difference between the control and the different
concentrations of the HA species (p < 0.05, Appendix E).
4.4.2. Comparison of the Impact of sHA in the Presence of cRGD
In a second step, the analysed system is transferred from cell culture plastic
to glass surfaces with click-PEG, which is statistically modified with cRGD
to enable cell adhesion. To prepare the surface, a glass slide is passivated
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with a mixture of PEG2000 silane (8) and PEG3000 alkyne (9) in a ratio of
1:100 (click-PEG). Afterwards the click-PEG is functionalised with cRGD via
CuAAC according to the protocol 2.9. 50 000 cells are seeded per glass surface,
which is added to a 12 well-plate, with 600µL media. The cells are incubated
with 1.0, 2.5, 5.0 and 20.0 mg/L of the HA for 46 h at 37 ◦C and 5%. In this
case the short HA, the digested HA and their end-thiolated analogous are
compared. To determine the HA influence the AlamarBlue® and CyQuant®
assays are performed.
Do cells adhere differently when applying different concentrations and
species of HA?
To determine the adhesion of the cells the amount of DNA per surface is
detected via the CyQuant® assay. Therefore the permeabilised cells are incu-
bated for 5min with the kit and the fluorescence (λex = 540 nm; λem = 585 nm)
measured, corrected to the background and normalised to the control surface
without HA.
In a first step the influence of the functionalised, digested HA in solution
is determined (fig. 4.18 a). Here no significant difference between the control
and the applied concentrations is observed. Although a small increased fluores-
cence signal is detected for a concentration of 5.0µg/mL. Figure 4.18 b) shows
the results of the measurements for the unfunctionalised, short HA. Here no
significant change is observed as well. Nevertheless, a decrease in fluorescence
intensity for a concentration of 2.5µg/mL and an increase in fluorescence for
5.0µg/mL compared to the mean value of the control is found. The mean val-
ues for the concentrations of 1.0 and 20.0µg/L are comparable to the control
level.
In a second step the terminal thiolated HA analogous are incubated with the
cells and the CyQuant® assay is performed. Figure c) shows the fluorescence
values for the application of the end-thiolated, digested HA. For the digested
HA species no significant difference can be observed. For a concentration of
5.0µg/mL a large distribution of the values is found. A possible explanation
for this might be a damaged surface due to the freezing-process at −80 ◦C
in the 12 well-plate to permeabilise the cells. If media or PBS, which was
used for washing, remains under the glass slide it can break it during freezing.
If the damage is clearly visible, the surface is not evaluated. Small damages,
which can not be seen, falsify the result. Nevertheless, no significant difference
between the concentrations is observed. For 20.0mg/mL only one surfaces
could be evaluated.
Do the different HA species influence the metabolic activity of LECs?
After incubating the cells with HA-containing medium for 46 h, 450µL are
removed and 55µL AlamarBlue® kit are added. After 2 h the fluorescence of
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Figure 4.18.: Results of CyQuant®assay of unfunctionalised and end-thiolated
HA in solution with LECs in a 12-well plate on glass surfaces, function-
alised with click-PEG: a) for enzymatically digested HA, b) short HA, c)
end-thiolated, digested HA and d) end-thiolated, short HA. The performed
Kruskal-Wallis test followed by the Dunn’s multiple comparison shows no
significant difference between the used concentrations and the control (Ap-
pendix E). The results are baseline corrected and normalised to the average
of the surfaces without HA.
the different solutions is measured. The comparison of the different applied
concentrations of digested HA on click-PEG surfaces shows no significant dif-
ference (p < 0.05, Appendix E). The mean value of the treated samples shows
a small decrease compared to the control (fig. 4.19 a). The lowest activity can
be found for the sample treated with 2.5mg/mL HA. In the cases of a higher
as well as a lower concentrations of HA, the relative intensity is increasing. The
same result is found for the cells, which are treated with the short HA species
(fig. 4.19 b). Between the different concentrations no significant difference can
be observed (p < 0.05, Appendix E), but a biphasic trend with its minimum
for the sample with 2.5mg/mL HA.
In the following the influence of the end-thiolated analogous are determined
and compared to the results of the unfunctionalised HA species. Applying the
end-thiolated, digested HA to the cells again no significant difference between
the added amounts of HA are observed (fig. 4.19 c; Kruskal-Wallis test followed
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Figure 4.19.: Results of AlamarBlue®assay of unfunctionalised and end-
thiolated HA species in solution with LECs in a 12-well plate on glass sur-
faces, functionalised with click-PEG: a) for enzymatically digested HA, b)
short HA, c) terminal functionalised, digested HA and c) end-thiolated, short
HA. The performed Kruskal-Wallis test followed by the Dunn’s multiple com-
parison shows no significant difference between the different surfaces (p <
0.05, Appendix E). The results are baseline corrected and normalised to the
average of the surfaces without HA.
by the Dunn’s multiple comparison, p < 0.05, Appendix E). Compared to the
unfunctionalised, digested HA a different trend can be seen. Here, the lowest
mean intensity is found for 1.0mg/mL. The value increases with increasing
HA-concentration up to the level of the control. A similar trend is found for
the end-thiolated, short HA (fig. 4.19 d). A decrease in the mean relative
intensity for 1.0 and 2.5mg/mL is observed, but the change is not significant.
The mean value for 5.0 and 20.0mg/mL is even higher than in the level of the
control.
Finally, the four different HA-species are compared with each other. There-
fore, the data is analysed sorted by concentration independent of the species
(fig. 4.20). Here again the mean value for 1.0 and 2.5mg/mL are below the
control level whereas 5.0 and 20.0mg/mL are at the comparable level. The
performed Kruskal-Wallis test followed by the Dunn’s multiple comparison (p
< 0.05, Appendix E) shows no significant difference between the species as well
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as between the different applied concentrations. This enables the summary of
the data.
Figure 4.20.: The comparison of both used HA species show no difference
in their impact. To compare the used HA-species all data is summarised in
one plot, where black represents the digested HA without a thiol-function
and light grey with the thiol-function, light blue the short HA without and
turquoise with thiol-function. The performance of the Kruskal-Wallis test
followed by the Dunn’s multiple comparison shows no significant difference
between the species (Appendix E)
Determination of the Relative Metabolic Activity
On click-PEG the same result as for the cell culture plastic is found. No sig-
nificant difference in the CyQuant® and AlamarBlue® assay is found neither
for the digested HA, the short HA nor their thiolated analogous. To reach a
better comparability between the different samples the metabolic activity of
different surfaces, the results of the AlamarBlue® assay, are normalised to the
relative amount of DNA, which was measured via the CyQuant® assay. The
performed Kruskal-Wallis test followed by the Dunn’s multiple comparison
shows no significant difference in the relative metabolic activity of the cells
due to the different concentrations and functionalisation of HA (fig. 4.21). Al-
though no significant difference between the applied concentrations can be
observed, a biphasic trend is identifiable. The lowest mean for the relative
metabolic intensity is found for adding 1.0mg/mL.
4.4.3. Comparison of the Impact of Immobilised sHA in the
Presence of cRGD
Finally, the two end-thiolated HA species are immobilised on gold nanostruc-
tured glass slides. Five different particle densities are used in this experiments:
29, 47, 123, 540 and 2714 particles/µm2. The surfaces are compared to a
surface without nanoparticles respectively without HA. The glass slides are
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Figure 4.21.: Presentation of the metabolic activity of LECs (based on
AlamarBlue®assay) normalised to the amount of DNA on the surface (based
on CyQuant®assay) on click-PEG for a) using digested HA and b) a different
short HA. The performance of the Kruskal-Wallis test followed by the Dunn’s
multiple comparison shows no significant difference between the control and
the different concentrations of the HA species (Appendix E).
passivated against unspecific cell adhesion utilizing click-PEG, a mixture of
PEG3000 azide (9) and PEG2000 silane (8) with a ration of 1:100, accord-
ing the protocol in section 2.7. Afterwards cRGD-alkyne is attached to the
azide via CuACC. The nanoparticles are functionalised with the thiolated
HA-species by incubating the surface with a 0.004% (w/v) solution of thiol
for 1 h. After washing the surface with sterile PBS the surfaces are inserted
in a 12 well plate and 50 000 cells are seeded in 1mL media. The cells are
incubated on the surface for 46 h at 37 ◦C and 5% CO2 before the assys are
performed.
Do cells adhere differently when applying different concentrations and
species of HA?
After washing and freezing of the cells on the surfaces 600µL of the diluted
CyQuant® kit are added. After the incubation for 5min the fluorescence is
measured (λex = 480 nm; λem = 520 nm). The results are normalised to the
mean value of the control surface without nanoparticles. This surface represent
100% of DNA. In case of the digested HA-species no significant difference due
to the various particle density can be determined (fig. 4.22). Although, a drop
in the relative DNA amount with increasing particle density becomes apparent.
This observed trend manifest in case of the short HA. A significant decrease
in the relative DNA amount can be detected for 540 particles/µm2 and even
larger for 2710 particles/µm2 compared to the control surfaces.
The decrease in the amount of DNA indicates a decrease in the number
of cells on the surfaces. Because all surfaces statistically present the same
amount of cRGD on the surface, the decrease in adhesion must be due to
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Figure 4.22.: Results of CyQuant®assay of immobilised, end-thiolated short
HA with LECs in a 12-well plate on nanostructured glass surfaces, function-
alised with click-PEG: a) for enzymatically digested HA and b) short HA.
The performed Kruskal-Wallis test followed by the Dunn’s multiple com-
parison shows a significant difference between the control surface without
HA and the particle density of 540 and 2714 particle/cm2. The results are
baseline corrected and normalised to the average of the surfaces without HA.
the nanoparticles decorated with HA. The large HA molecule on the surface
might cover some cRGD-groups respectively reduces the accessibility of it. As
a consequence less cells can adhere to the surface.
Do the different HA species influence the metabolic activity of LECs?
For the AlamarBlue® assay 450µL media are removed per well after 46 h and
55µL of the kit are added. After an incubation time of 2 h the fluorescence
(λex =540 nm; λem =585 nm) is measured. The results are normalised to the
mean value of the control surfaces as described before (fig. 4.23). In case of
the digested HA species a significant drop in the relative intensity between
control and the surface with the highest particle respectively HA density is
observed. The same result is found for the short HA species. The significant
decrease in the relative intensity is larger in case of the digested HA than for
the short HA. Both cases show the lowest metabolic activity for the highest
particle density. In case of the short HA species the comparison between the
mean values of the relative intensity show almost no difference between the
surface without and the lowest concentration of short HA. Then the intensity
decreases for 47 particles/µm2, normalises to the control level and drops to its
lowest value for 2714 particles/µm2. The direct comparison between the two
HA-species shows no significant difference between the two species (fig. 4.24).
Because no significant difference between the species can be found, the results
can be combined.
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Figure 4.23.: Results of AlamarBlue®assay of immobilised, end-thiolated HA
with LECs in a 12-well plate on nanostructured glass surfaces, functionalised
with click-PEG: a) for enzymatically digested HA and b) short HA. The
performed Kruskal-Wallis test followed by the Dunn’s multiple comparison
shows a significant difference between the control surface without HA and a
particle density of 2714 particle/cm2. The difference is larger in case of the
digested HA (**) than the short HA (*). The results are baseline corrected
and normalised to the average of the surfaces without HA.
Figure 4.24.: The comparison of both used HA species show no difference in
their influence. To compare the used HA species all data is plotted in one
figure, where black represents the control, grey the enzymatically digested
HA and light blue the short HA. The performance of the Kruskal-Wallis-test
followed by the Dunn’s multiple comparison shows no significant difference
between the two HA species (Anhang)
Determination of the Relative Metabolic Activity
The results of these experiments show that it is important to take the attach-
ment capability of the cells to the used surface into account when investigating
the metabolic activity of the cells. As well for the digested HA as the short HA
a decrease in the metabolic activity for a high particle density is found. But
the results of the CyQuant® assay show, that the amount of cells is decreasing
Experiments 93
as well with rising particle density. In the case of the short HA in a significant
manner. Due to this, the results of the AlamarBlue® assay are normalised to
the relative amount of DNA on the corresponding surface, to enable a com-
parison between the different surfaces and experiments. After normalising the
Figure 4.25.: Presentation of the relative metabolic activity of LECs (based on
AlamarBlue®assay) normalised to the relative amount of DNA on the surface
(based on CyQuant®assay) for a) the enzymatically digested HA and b) the
short HA. To analyse the significance of the results a Kruskal-Wallis test
followed by the Dunn’s multiple comparison (p < 0.05, Appendix E).
metabolic activity to the amount of DNA the picture changes. Instead of a
decreasing trend, now a biphasic development is found (fig. 4.25). The relative
metabolic activity increases for both HA-species with increasing particle re-
spectively HA density up to 540 particles/cm2. Afterwards it decreases again.
Only the difference between the point of inflexion and the control is found
to be significant different (Kruskal-Wallis test followed by the Dunn’s multi-
ple comparison, p < 0.05, Appendix E). The level of significance is identified
higher in case of the short HA than the enzymatically digested HA.
Summary of the analysis of the influence of short HA on human primary
lymphendothelial cells
Compared is the influence of a digested and short HA species which are applied
to LECs in different concentrations and densities. Between the different species
no difference in the cell behaviour is found. In the case of the application of
HA in solution no difference in the relative metabolic activity is found. For
the immobilised HA species a reduced ability to adhere to the surface is found
for the rising nanoparticle density. Here for both HA species a biphasic effect
in relative metabolic activity is found with maxima for a particle density of
540 /µm2.
94 Concentration Dependent Influence of sHA on HUPLECs
4.4.4. Influence of Immobilised sHA on the Clustering and
Adhesion of LECs
The previous experiments show the largest impact of immobilised, short HA
on the cells, when it is immobilised on a nanostructured surface with a particle
density of 540 particles/µm2. To investigate other effects than the metabolic
activity, a closer look is taken at the cells themselves. Therefore cells are
seeded again on a surface passivated with a mixture of PEG2000 silane (8) and
PEG3000 alkyne (9, ratio 1:100) functionalised with cRGD with no nanopar-
ticles and 540 particles/µm2. After 48 h the cells are fixed and several proteins,
which are part of the adhesion complex, the actin cytoskeleton and the nu-
clei are stained. The proteins talin, paxillin and vinculin are chosen to enable
the investigation of a difference in adhesion between both surfaces. Addition-
ally, the main HA receptor in lymphendothelial cells LYVE-1 is analysed. To
achieve a good staining, different antibodies and concentrations are applied
(section 2.11). The evaluation of the staining shows no staining for neither
talin, paxillin, vinculin nor LYVE-1. So no suitable antibody could be found
for an ICC staining of LECs.
Figure 4.26.: To analyse the influence of immobilised HA on LECs the actin
cytoskeleton (grey) and nuclei (black) are stained. Compared are the appear-
ance of cells on a surface with a particle density of 540 particles/µm2 (a) -
c)) and without immobilised HA (d) - f)). All pictures have the same scaling
(scale bar: 200µm).
In figure 4.26 examples are shown for the actin and nuclei staining on sur-
faces with and without hyaluronan. No difference can be seen between both
surface species. To analyse if more or less cells adhere on one surface type,
the number of nuclei is counted on each surface using ImageJ. Because of a
semi-automatic analysis the results are compared to a manual counting for 5
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surfaces (tab. 4.2).
Table 4.2.: Evaluation of the used semi-automatic counting of nuclei on a
surface using ImageJ.
counting I II III IV V
manual 85 84 143 150 148
automatic 85 84 132 145 149
difference 0 0 11 5 -1
Figure 4.27.: The analysis of the number of LECs on surfaces with (A) and
without (B) immobilised HA show no difference in the number of cells.
Also the analysis of cell number per surface shows no difference between
the surfaces with and without immobilised HA (fig. 4.27). Although a larger
distribution for the surface without HA is found. The clear decrease in number
of cells on the surface which is found in the CyQuant® assay is not observed
here.
Because it is not possible to use a scratch assay or a physical barrier the
observation of the migration of the cells is difficult. The comparison of HA-
free surface and a nanostructured surface with a particle density of 540 /µm2
shows no difference in the number and the appearances of the cells.
4.5. Influencing Collective Cell Migration
The aim of the second part is to study the influence of the cell adhesion
on their migration behaviour. Therefor nanostructured surfaces with different
interparticle distances are used, which were functionalised with an adhesive
background. The used surfaces are prepared according to the protocol in sec-
tion 2.8. Afterwards the surfaces are passivated using PEG2000 silane (8). The
adhesive molecule is immobilised on the gold nanoparticles via a thiol function.
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To create a defined collective of cells a photocleavable molecule is used to im-
mobilise on the gold nanoparticles. After partial irradiation with UV light, the
cells are able to adhere on cleaved molecules (fig. 4.28). After the cells become
confluent, the migration starts with a second irradiation step, which makes the
whole surface adhesive. Therefore two novel linker molecules are developed to
Figure 4.28.: Scheme of the surface applied in the study to investigate the
influence of the density of an adhesive background on MDCK II cells. The
glass surfaces is decorated with gold nanoparticles with different particle
densities and passivated with 8. The nanoparticles are functionalised with 1,
which can be cleaved using UV light to enable the adhesion of cells.
analyse unspecific as well as specific surface-integrin interactions (fig. 4.29). To
achieve an unspecific interaction 11-mercaptoundecanoic acid (7) is used where
the carboxy-group caged with the photolabile ligand 4,5-Dimethoxy-2-nitroace-
tophenone (DMNPE, 2, a). To aim a specific interaction between surface and
cells, the artificial antagonist (S)-3-(4-(3-(6-(3-mercaptopropanamido)hexan-
amido)propoxy)benzamido)-4-(4-(3-((4-methoxypyridin-2-yl)amino)propoxy)
phenyl)butanoic acid (13) to the integrin α5β1 is used.[21, 22] Here as well the
carboxy-group is caged with DMNPE (2) to prevent the specific interaction
with integrins (b).
4.5.1. Synthesis of 1-(4,5-dimethoxy-2-nitrophenyl)ethyl
11-mercaptoundecanoate (1)
The synthesis is started with a nitration of 3,4-dimethoxyacetophenone per-
formed in fuming nitric acid and glacial acetic acid (ratio 1:10; scheme 4.6).
This mild condition for the nitration can be used due to the directing effects
of the carbonyl- (-M and -I effect) and the methoxy-groups (+M and -I effect),
which enable the further substitution of the already highly substituted ben-
zene. The yellow product is crystallised by pouring the reaction solution on
ice. Because the solid is very fine the ice is kept at 4 ◦C to allow the crystals
to grow. After recrystallisation from acetone and filtration over silica gel the
yellow 4,5-dimethoxy-2-nitroacetophenone (10) can be isolated with a yield of
67%. The NMR-spectra shows that no further purification is required.
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Figure 4.29.: Noval photolabile linker for the a) unspecific (1-(4,5-
dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecanoate 1) and b) specific
(1-(4,5-dimethoxy-2-nitrophenyl)ethyl (3(S))-3-(4-(3-(6-(3-mercaptopropan-
amido)hexanamido)propoxy)benzamido)-4-(4-(3-((4-methoxypyridin-2-
yl)amino)propoxy)phenyl)butanoate 14) interaction with the integrin
α5β1.
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Scheme 4.6.: Schematic representation of the synthetic route to 1-(4,5-di-
methoxy-2-nitrophenyl)ethan-1-ol (2) starting from 3,4-dimethoxyacetophe-
none via 1-(4,5-dimethoxy-2-nitrophenyl)ethan-1-one (10).
In a second step the carbonyl-group of the acetophenone-body is hydro-
genated using sodium borohydride. Because of this rigorous washing and re-
crystallisation of 10 is required to remove the acid and prevent the reaction
of acid and borohydride. The hydrogenation is performed in a mixture of ı-
propanol and THF (ratio 2:1). During the reaction the colour of the reaction
solution changes from yellow to red, which indicates the end of the reaction.
After column chromatography the product is isolated with a yield of 93%
(scheme 4.6).
Before 11-mercapto-undecanoic acid (7) can be coupled to DMNPE (2) the
thiol-group needs to be protected using a trityl-group (scheme 4.7). Therefor
7 is stirred with trityl chloride according to a protocol of Ryan et al.[75] The
purification via column chromatography proves to be difficult due to the very
similar Rf-values in various eluents (table 4.3). Additionally the NMR shows
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Scheme 4.7.: Protection of the thiol-group of 11-mercaptoundecanoic acid (7)
with trityl chloride.
the presence of the side product trityl 11-mercaptoundecanoate (11), which is
the trityl-protection at the carboxy-terminus of the molecule. The retention
times of the two trityl protected species seems to be very similar. Due to the
difficulty of the purification, the raw product is filter over silica to remove the
unreacted acid. After removing the solvent, the resulting mixture is used for
the next step. The yield of 11 is calculated from the NMR with 52%.
Table 4.3.: Summary of the retention times (Rf) for the tested eluents for
column chromatography of 11. Compared are the values for the two educts
11-mercaptoundecanoic acid (7) and trityl chloride (Tr Cl) with the product
11.
# eluent Rf
Tr Cl 7 11
1 DCM/ MeOH 95:5 0.79 - 0.79
2 DCM/ MeOH 6:1 0.75 0.53 0.77/ 0.84
3 DCM/ MeOH 5:1 0.76 0.54 0.77/ 0.82
4 hexane/ EtOAc 3:1 0.44 0.21 0.15
5 hexane/ EtOAc 2:1 0.43 0.20 0.43/ 0.49
6 hexane/ EtOAc/ MeOH 3:1:0.04 0.32 0.03 0.38/ 0.45
Finally 2 is coupled to 11 via Steglich esterification (scheme 4.8).[67] The
carboxylic acid is activated using DCC. Because of the minor reactivity of the
hydroxy group compared to amines a catalyst is necessary for the final ester
formation. 4-N,N ′-dimethylaminopyridine (DMAP) is used as a catalyst in
this reaction. The carboxy group is transferred to the catalyst, which enables
the formation of the ester bond. As a side reaction an acyl migration is found,
which leads to the formation of N -aceylureas. This reaction is slow and can be
minimised with an excess of nucleophile.[129] After extracting the product with
CHCl3, the raw product is purified via column chromatography. The yellow,
crystalline product can be isolated with a yield of 33%.
After the esterification, the thiol-group is deprotected using a mixture of
trifluoroacetic acid (TFA), ddH2O and triisopropylsilane (TIPS) in a ratio
of 95.0:2.5:2.5.[21, 22] The reaction is quenched with ddH2O and the product
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Scheme 4.8.: Reaction scheme of the Steglich esterification: The carboxy
group of 11-mercaptoundecaonic acid (7) is activated using DCC. Afterwards
the acid is transfered to the catalyst DMAP under the release of 1,3-dicy-
clohexylurea (DHU), which enables the coupling to the hydroxy group of
2.
extracted with CHCl3. The raw product is purified via column chromatography.
The yellow 1-(4,5-dimethoxy-2-nitrophenyl)ethyl-11-mercaptoundecanoate (1)
can be isolated with a yield of 89%.
4.5.2. Characterisation of 1-(4,5-dimethoxy-2-nitrophenyl)ethyl
11-mercaptoundecanoate (1)
To analyse the cleavage behaviour of the 1-(4,5-dimethoxy-2-nitrophenyl)ethyl-
11-mercaptoundecanoate (1), the change in UV-VIS spectra during irradiation
is determined. Additional the absorption, cleavage and passivation properties
are observed using QCM-D.
Observation of the Cleavage of 1-(4,5-dimethoxy-2-nitrophenyl)ethyl
11-mercaptoundecanoate via UV VIS Spectroscopy
To analyse the cleavage behaviour of 1, a 1mm solution in acetonitrile is pre-
pared. The solution is irradiated with a laser (375 nm, 800µW) in a black,
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Scheme 4.9.: Scheme of the coupling of 1-(4,5-dimethoxy-2-nitrophenyl)ethan-
1-ol (2) with 11-(tritylthio)undecanoic acid (11) followed by the deprotecting
to 1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecanoate (1).
closed quartz cuvette. Compared are 1 and uncoupled 2. The adsorption spec-
tra of both compounds are recorded from 250 to 500 nm, starting before ir-
radiation and then after every 10min interval up to 70min of irradiation. All
spectra are corrected to the background, in this case the cuvette with pure
acetonitrile. The observation of the cleavage of 2 shows a rapid red shift of the
the maxima from 347 nm to a plateau at 375 ± 5 nm (fig. 4.30). The largest
Figure 4.30.: The cleavage of a 1mm solution of uncoupled 2 in acetonitrile
shows a red shift in the UV VIS spectra over time. The first measurement
was obtained before the irradiation (t0, black) with a 375 nm laser (800µW).
Afterwards the spectra is obtained in intervals of 10min over 30min. An
isobestic point is localised at 319 nm (green dotted line).
change in the absorbance spectrum is found after the first irradiation step. This
indicates, that the cleavage process is fast and almost complete. After 20min
no further conversion is observed. This proves, that the cleavage is finished
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within the first 20min. Additionally, an isobestic point is observed at 319 nm.
This shows, that only a two compound mixture takes part in the cleavage. In
Figure 4.31.: The cleavage of a 1mm solution of 1 in acetonitrile shows a blue
shift in the UV VIS spectra over time. The first measurement was obtained
before the irradiation (t0, black) with a 375 nm laser (800µW). Afterwards
the spectra is obtained in intervals of 10min over 70min. An isobestic point
is localised at 370 nm (green dotted line).
contrast, the irradiation of the 1 shows a blue shift in the absorbance maxima
from 345 nm towards 322 nm(fig. 4.31). Here still a change in the absorbance
maxima is found after 20min. The cleavage is complete after 60min, because
no further difference in the last spectra is found. In this case an isobestic point
is localised at 370 nm, which underlines that only a two component mixture
takes part in the cleavage. This correlates to the postulated mechanism of the
cleavage.
The change in the observed spectra of 2 is due to a photo-induced reaction
(scheme 4.10). Bochet et al. postulate that the irradiation leads to the forma-
tion of a diradical, which can be quickley delocalised, and a rearrangement,
which results in an isoxazolidin-derivative.[59] This molecule can decay spon-
taneously under the elimination of H2O respectively 7, to 1-(4,5-dimethoxy-2-
nitrosophenyl)ethan-1-one. This leads to the change in the adsorption spectra.
This also indicates a slower photoreaction for the 1 linker, because the increase
in size enhances the steric hindrance of the rearrangement. This observation
also proves that a cleavage is possible even though no functionality is attached
to the 2 and only H2O is eliminated. In case of the 1, R’ corresponds to 7,
which will remain on the surface after cleavage in further experiments on a
surface.
The major difference is found for the time frame, which is needed to cleave
the molecule. For 2 the reaction takes about 20min, the reaction of 1 is finished
after 60min. Due to the observed isobestic point a direct equilibrium between
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Scheme 4.10.: Postulated mechanism of the cleavage process of DMNP-
derivative for the example of DMNPE (R’: H, HS (CH2)9 C O). The
mechanism shows the formation of a diradical due to the irradiation and
the rearrangement to isoxazolidin-derivative. This can spontaneously decay
to H2O and the acid and 2.[59]
educt and product is observed, which fits to the postulated mechanism.
Observation of the Adsorption and Cleavage of
1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecanoate (1) via
QCM-D
In the QCM-D experiment the adsorption of the 1-(4,5-dimethoxy-2-nitro-
phenyl)ethyl 11-mercaptoundecanoate (1) is compared to the adsorption of
11-mercaptoundecanoic acid (7) and DMNPE (2). Therefore, a gold coated
quartz crystal is equilibrated in PBS with 1% EtOH and 100µm solution of
the different tested compounds are added. The EtOH is added because the 1
is not soluble in water. The pure 2 shows no interaction with the surface as
expected because 2 shows no functional group which would bind strongly to
the gold surface. In case of the adsorption of 7 a ∆(∆f7) of 44Hz is deter-
mined (fig. 4.32 a). The adsorption of the complete 1 linker leads to a change
in frequency of 161Hz (fig. 4.32 a). It is noticeable that the time, which is
necessary to form the monolayer on the surface varies significant between
11-mercaptoundecanoic acid (7) and 1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-
mercaptoundecanoate (1). The adsorption of the free acid takes 10min and
the adsorption of the linker seems still not complete after 24 h. Because the
adsorption takes over night a large drift is found. Even though the open mod-
ule is closed with a lid to prevent evaporation of the solvent, the volume of
the solvent on the crystal decreases slightly over night. To correct the effect of
the drift, the results of the control surface can be subtracted from the other
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Figure 4.32.: Observation of the successful adsorption and cleavage of 1. In
this study the adsorption a) of 1 (∆f: light green; ∆D: orange) is compared
to the adsorption of 7 (∆f: green; ∆D: light brown) and a pure gold surface
(∆f: dark green; ∆D: dark brown) and b) the behaviour under UV irradiation
(365 nm). The QCM-D experiments is performed in PBS with 1% EtOH.
Shown is the 7th overtone.
samples. After changing the PBS/EtOH mixture after 24 h, the system equili-
brates again and a good baseline is found for the control surface (fig. 4.32 b)
Afterwards, the crystal is irradiated with UV light (365 nm) to perform the
cleavage. Therefor, a UV hand-lamp is placed over the open modules, which
are covered with a quartz glass slide to prevent evaporation of the solvent.
In case of the acid no change in frequency can be observed, so no cleavage
occurs. In contrast, an in increases of frequency of ∆(∆f7) = (68.7± 7.6) Hz
is observed for the cleavage of 1. After cleavage, the change in frequency on
this surface is still larger than on the surfaces with 7. This can be explained
trough an incomplete cleavage or a difference in the formation of the SAM on
the surface due to the aromatic ring, which can disturb the packing.[122] The
last point is reflected in the extremely different adsorption times.
Characterisation of the Adsorption Process of
1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecanoate (1)
QCM-D based analysis of the adsorption of 1-(4,5-dimethoxy-2-nitrophenyl)-
ethyl 11-mercaptoundecanoate (1, c = 100µm, 21 ◦C; fig. 4.33 a) takes much
longer compared to the SAM formation of the OEG-layer on a gold surface
in the previous QCM-D experiments (c = 100µm, 24 ◦C; section 4.1).[54] In
literature a time frame between 12 to 18 h is found for the SAM formation
of alkanethiols (c = 1 to 10mm) on gold in ethanol at room temperature.
[122] Because of this difference in the adsorption time, it is analysed if the
process takes several steps to form the SAM. Due to the poor solubility of the
linker in water, a stock solution in ethanol is prepared and diluted into water.
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Thus, the formation of micelles of the linker after diluting is conceivable. This
micelles would descend to the surface, which would lead to a first change in
frequency, burst and form a SAM comparable to the formation of a supported
lipid bilayer (SLB), which would lead to another change in frequency. Because
both layers on the surface show different viscous properties two changes in
dissipation are expected as well. To analyse this correlation the change in
dissipation (∆D) is plotted against the change in frequency (∆f; fig. 4.33 b).
The figure shows a linear correlation between dissipation and frequency, which
proves the single-step SAM formation.
Figure 4.33.: To verify a single step absorption of 1 the change in frequency
and dissipation in a QCM-D experiment is used. Due to a drift, which occurs
over night, the adsorption process is corrected to the control surfaces (a). The
plotting of the change in dissipation (∆D) against the change in frequency
(∆fn) shows a linear correlation between the two parameters and so a single-
step process (b). The linear fit (Pearson R = -0.997 88) is shown in grey.
To characterise the adsorption in a timely manner, the adsorption is cor-
rected to the control, due to the drift, which occurs over night (fig. 4.33 a).
After the correction a plateau is observed after 24 h and so a kinetic analysis
is possible. Additionally the adsorption is observed and compared at 21 ◦C
and 37 ◦C (table 4.4). The found results show a change in the adsorption de-
Table 4.4.: The adsorption of 1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mer-
captoundecanoate (15) observed during a QCM-D experiment is fitted with
y = y0 + A1exp
[
− x
t1
]
+ A2exp
[
− x
t2
]
+ · · · . The decay times and the ratio
of the amplitudes A are summarised below.
Temperature t1 t2 ratio
[min] [min] A1 [%]
21 ◦C 83.03±68.17 1899.00±776.3 20.6±15.7
37 ◦C 320.88±58.36 98.6±2.0
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pending on the temperature like expected.[122] The first thing that is apparent
is the difference in the fitting function (Appendix G). Therefore, the decay
in-between two pipetting steps (liquid exchange) is fitted with an exponential
decay function. The decay at 21 ◦C could be fitted with a bi-exponential decay,
while at 37 ◦C, only a mono exponential fit was sufficient. The comparison of
the specific decay times show a fast and a slow process for 21 ◦C. The ampli-
tude of the fast component A1 of 20.6% means that this component is only
of minor importance to describe the decay and can be neglected. Therefore,
only the main decay components can be compared. The decay time for 37 ◦C
is roughly 6-fold shorter than the decay time for 21 ◦C.
Characterisation of the Cleavage Properties of
1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecanoate (1)
Figure 4.34.: To verify a single step cleavage of 1 the change in frequency
and dissipation in a QCM-D experiment is used. To reduce drift effects the
cleavage process is corrected to the control surfaces (a). The plotting of the
change in dissipation (∆D) against the change in frequency (∆fn) shows a
linear correlation between the two parameters and so a single-step process
(b). The linear fit (Pearson R = -0.999 61) is shown in grey.
To analyse the specific decay time of the cleavage the data is corrected to the
control to reduce drift effects during the measurement (fig. 4.34 a)). Addition-
ally, to ensure a single-step process, which is already forecast through the UV
VIS analysis, the dissipation is plotted against the frequency change (b). As
expected a linear correlation is found between dissipation and frequency which
points to a single-step process. The cleavage is performed at 21 ◦C and shows
like the adsorption a exponential correlation with two components (Appendix
G). Here the increase in frequency can be described best with equation 4.1.
Again, the decay is fitted in-between two exchange steps of the solvent. For
the evaluation of the change in frequency in the QCM-D experiment a plateau
of at least 5min is used, so in some circumstances a long linear segment is
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part of the otherwise exponential progression, which complicates the fitting.
y = y0 +A1exp
[
−
x− x0
t1
]
+A2exp
[
−
x− x0
t2
]
(4.1)
Again a very fast process with t1 = (2.52± 0.64) min and a slow process with t2
= (23.55 ± 7.38) min are found. The ratio between the two amplitudes shows a
large impact of the first process to the curve shape (x¯( A1A1+A2 ) = 76.4±2.7 %).
The slower process might be due to the plateau formation, which is necessary
for the evaluation of the data as described above and the fast process the
actual cleavage.
Analysis of the Passivation Properties of
1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecanoate (1)
To ensure that the surface decorated with 1-(4,5-dimethoxy-2-nitrophenyl)-
ethyl 11-mercaptoundecanoate (1) is passivated against unspecific interaction
in the first place and changes this behaviour after the cleavage, the surface
is incubated with BSA. Compared is a pure gold surface, a surface with 11-
mercaptoundecanoic acid (7) and two surfaces with 1 (table 4.5). After the
adsorption phase, the surfaces are rinsed with 0.4% BSA in PBS. A large
change in frequency is observed for the control surface (∆(∆f7) = −31Hz; #
4), whereas only a small change is found for the acid and DMNPE (2) surface
(# 5,6). The irradiation leads only to a desorption in case of the 1 (∆(∆f7) =
38Hz, #9). The second incubation step with 0.4% BSA causes a ∆(∆f7) of
−15Hz (# 12) for the now adhesive 1 surface. For the other surfaces only a
small decrease is observed, which is due to the adsorption of BSA onto the
BSA layer or the replacement of destroyed BSA after the UV irradiation.
The analysis of the passivation properties of 1 show a small adsorption of
BSA on top of the SAM (∆(∆f) = −8Hz; # 6). After cleavage a ∆(∆f) of
−15Hz (# 12) is observed. The change in frequency for 7 is in total about
−13Hz (# 5, 11) in two steps. So the BSA can adhere better on the cleaved
1 surface.
Characterisation of the Hydrophilicity of a
1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecanoate (1)
Decorated Surface
To characterise the hydrophilicity of a gold surface functionalised with 1-(4,5-
dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecanoate (1) before and after
cleavage of the linker the water contact angle (Θw) is measured. Therefore, a
glass surface is coated with a thin layer of titanium (3 nm) and of gold (30 nm).
Afterwards, the surface is incubated for 2 h with a 100µm solution of 1. The
surface is washed with water, dried under a stream of nitrogen and the contact
angle is measured with a drop of 1µL water. Compared are the angles on pure
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Table 4.5.: Shown are the change in frequency (∆(∆f7)) for the interaction
of BSA with an unfunctionalised (control), an 11-mercaptoundecanoic acid
(7) and an 1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecanoate
(1) functionalised gold surface before and after irradiation with UV light
(365 nm), as well as the change due to the irradiation.
# phase sample ∆(∆f7) [Hz]
1
BSA
control −31
2 7 −5
3 1 −8/ −9
4
cleavage
control 1
5 7 −2
6 1 31/ 46
7
BSA
control −4
8 7 −8
9 1 −15/ −14
gold and on the SAM formed by 1. Then the surface is irradiated with UV
light (365 nm) for 60min and the contact angle determined again.
Figure 4.35.: Change in water contact angle of a gold coated surface (A)
functionalised with 1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercaptounde-
canoate (1) before (B) and after the irradiation with UV light (365 nm, C).
Measured are 5 points on two surfaces with 1µL water.
The measured contact angles show an increase in Θw after the functionalisa-
tion with 1 (fig. 4.35). After the irradiation the contact angle decreases again.
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This is due to the end group of the SAM which changes from the aromatic
ring, which is hydrophobic, to an carboxy group, which is more hydrophilic
than the aromatic ring.
4.5.3. Toxicity Study
Before the cell experiments are performed, the set up is screened for possible
risks for the cells. Problematic are on the one hand the irradiation with UV
light and on the other hand the contact with chemicals with unknown charac-
teristics. Even though the surfaces are washed after the irradiation, the cells
get in contact with the cleavage products. To investigate a possible influence
of this on the cell behaviour, the metabolic activity is determined by using the
AlamarBlue® assay.
Establishment of the AlamarBlue® assay with MDCK II Cells
Before using the AlamarBlue® assay with MDCK II cells, the settings need to
be optimised. Therefore 1000, 5000, 10000, 20000, 30000 and 40000 cells were
seeded in a 96-well plate. After 18 h incubation at 37 ◦C and 5% CO2, the
AlamarBlue® kit is added to each well with 100µL medium. The absorbance
is measured at 570 nm and 600 nm. The relative reduction of resazurin is cal-
culated using equation 2.6 (section 2.10.1) and the results shown in figure 4.36.
The data indicates a linear range between 0 to 4 h for a cell number below
20 000 cells per well (a). The absorbance plotted against the incubation time
depending on the cell number shows a optimal incubation time between 1 to 2 h
and a number of cells between 1000 to 10 000 (b), which is in good agreement
with the first estimated parameters. For the following experiments an incuba-
tion time of one hour and a number of 5000 cells per well (156 cells/mm2) is
chosen.
Analysis of Toxicity of UV light
For the cleavage of the linker the surface needs to be irradiated with UV light,
which can damage the cells. The influence of UV-irradiation on MDCK II
cells is analysed. Therefor, 5000 cells are seeded in a 96 well plate. After 18 h
the cells are irradiated using a X-cite UV-lamp, a microscope with a BFP-
filter set (Excitation: 377/28 nm; Beamsplitter: 403 nm; Emission: 464/100
nm) and a 20x magnification. The samples are irradiated for 0, 15, 30 and
60 s. Afterwards, 100µL media are removed and 10µL AlamarBlue® kit are
added. Then, the absorbance is measured at 570 and 600 nm. Because Sauer
et al. report that the influence of irradiation on cells can even occur after
several hours after the irradiation,[90] the absorbance is measured after 1, 2
and 3 h. The relative reduction of resazurin is calculated according to equation
2.6 (section 2.10.1). The comparison of the different time points, represented
by the different colours in the scatter plot (fig. 4.37), do not show a significant
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Figure 4.36.: Determination of optimal incubation time and cell number for
using the Alamar Blue®assay with MDCK II cells. The relative absorbance
is calculated with equation 2.6 using absorbance measurements at 570 nm
and 600 nm, The results are plotted a) against number of cells for different
incubation times ( 0 h ◦ 1 h ∆ 2h ∇ 3 h ♦ 4 h ⊳ 24 h) and b) against the
incubation time for different cell numbers ( 1000 ◦ 5000 ∆ 10000 ∇ 20000
♦ 30000 ⊳ 40000).
Figure 4.37.: The analysis of the toxicity of UV irradiation applied to MDCK
II cells shows no difference between the applied irradiation time. The differ-
ent colours represent the time between irradiation and adsorption measure-
ments (black: 1 h; grey: 2 h; blue: 3 h). For the statistical analysis between
irradiation time as well as the incubation time a Kruskal-Wallis test followed
by the Dunn’s multiple comparison (p < 0.05) is performed and shows no
significant difference.
difference for each irradiation time. Also, no significant difference is found for
the increasing irradiation time. If the cells would have been damaged or killed,
a decrease in metabolic activity is expected. Because this is not observed, the
irradiation conditions are applicable for the following experiments and the
subsequent observation time frame of the cell experiments of two hours.
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Analysis of the Toxicity of 1-(4,5-dimethoxy-2-nitrophenyl)ethyl
11-mercaptoundecanoate (1)
Besides the testing of the toxicity of the UV light, which is needed for the cell
experiment, the toxicity of the applied 1-(4,5-dimethoxy-2-nitrophenyl)ethyl
11-mercaptoundecanoate (1) is investigated. Therefore the thiol is added with
final concentrations of 5, 50 and 500 µm with 5000 cells in a 96-well plate.
Because the linker is not soluble in water an organic solvent needs to be used.
In literature, drugs are often dissolved in DMSO, when they are used in cell
experiments.[79] So DMSO is used as solvent in a first try (Appendix H fig.
H.1 a). But the test with the AlamarBlue® kit without cells (A) shows already
a higher reduction potential than the positive control (B). The sample with
DMSO and cells also show a higher reduction of the resazurin. Because of the
influence of DMSO itself on the assay ethanol is tested as solvent, which is
also used in the QCM-D experiments. The comparison of the positive control
(Appendix H fig. H.1 b, A), the control with ethanol and the AlamarBlue® kit
without (B) and with (C) cells show no difference. For this reason, ethanol is
chosen as solvent for the assay.
From a stock solution of 1 and 2 (10mm) the final concentrations are di-
luted. Ethanol is added in a manner that all samples contain 5% ethanol. No
ethanol is added of course to the positive control. The cells are incubated for
18 h with the compounds, before 100µL media are removed and 10% of the
kit are added. After incubation of 1 h the absorbance is measured at 570 nm
and 600 nm and the reduction of the resazurin calculated with equation 2.6
(section 2.10.1). The results are shown in figure 4.38. A small increase in the re-
duction is found especially for 2. The performed Kruskal-Wallis test followed
by the Dunn’s multiple comparison shows no significant difference between
the positive control and any other sample (Appendix E). So an insignificantly
increased cell activity is found. Due to this it will be necessary to change the
media in a cell experiment after the irradiation to remove the soluble cleavage
products. A closer look at the samples shows a crystal formation after 18 h
probably of 1 due to its bad water solubility. Because of the incubation of the
cells at 37 ◦C it is possible, that part of the ethanol evaporates over night and
the remaining amount is not enough to dissolve the complete linker. So the
results of the toxicity analysis of the high concentration are unclear. Besides
this, the cells look similar on all compared surfaces (fig. 4.39).
The toxicity test indicates that contact of the cleavage product and the
cells do not have a negative influence on cell behaviour. Although, the time
the cells get in contact with the 2 is much shorter than 18 h because the
medium is exchanged right after the cleavage. So the linker can be used for
the modification of the gold nanoparticles in cell experiments without having
a negative influence on cell behaviour.
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Figure 4.38.: An increasing metabolic activity is found for MDCK II cells
incubated with DMNPE (2). For the toxicity assay of MDCK II cells with
1 or 2 different concentration of both compounds are applied and compared
with the positive control (A) without additives and with only adding the
solvent ethanol (B).
4.5.4. Migration of MDCK II Cells on Photopatterned Surfaces
After the characterisation of 1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercap-
toundecanoate (1) the linker is tested in cell experiments. Aim of this study is
to analyse the influence of the adhesion properties of MDCK II cells on their
migration behaviour. Therefore the linker is immobilised on nanostructured
glass surfaces with interparticle spacings of 30, 60 and 90 nm. The glass sur-
faces are nanostructured using the BCML method (section 2.6) and afterwards
passivated using PEG2000 silane (8). To functionalise the gold nanoparticles,
the surfaces are glued to Teflon rings using Twinsil and incubated for 24 h
with a solution of 100µm 1 in PBS containing 1% EtOH. After washing, the
surfaces are irradiated using a microscope with a 5x magnification objective
at the Zeiss "Observer" (BFP filter set (Excitation: 377/28 nm; Beamsplitter:
403 nm; Emission: 464/100 nm)) and a X-cite UV lamp. Parts of the surface
are covered during the irradiation using a rectangular aperture. Afterwards
the surfaces are washed with sterile PBS and 200 000 cells are seeded on each
surface. After 18 h the surfaces are evaluated at the microscope. To ensure,
that the surface stays intact during the UV irradiation and the passivation is
working, additional glass slides (22 x 22mm) are passivated and some are also
irradiated with UV light before seeding 200 000 cells on top. The passivation
controls shows almost no cells on top and the found cells look dead, so the
passivation is working (fig. 4.40 B). But on the unfunctionalised, passivated
surface as well as on the photopattered surface cells are found on the whole
surface (A). This strongly indicates the possibility to remove the PEG passiva-
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Figure 4.39.: The closer look at the cells of the positive control (a), the
control with ethanol (b) and samples with the application of 2 show no
major difference of the cells on the surface. This is also found for the cells
incubated with 5 or 50µm solutions of 1. On the last surface large crystals
are found on the surfaces (scale bar 200µm).
tion with UV light. The surfaces are washed with PBS and the cells fixed with
a 4% PFA solution. The nuclei are stained with DAPI, using the protocol in
section 2.11. Compared is the number of cells on three surfaces, which were
irradiated with UV light, and three control surfaces. Therefore, the number
of cells respectively the number of nuclei are determined at five positions on
each surface. The counting is operated using ImageJ with the same procedure
described for the LECs (section 4.4.4).
4.5.5. Modification of α5β1-specific Antagonist
To enable the analysis of the influence of the specific interaction of the artificial
antagonist of the integrine α5β1 ((S))-3-(4-(3-(6-(3-mercaptopropanamido)-
hexanamido)propoxy)benzamido)-4-(4-(3-((4-methoxypyridin-2-yl)amino)pro-
poxy)phenyl)butanoic acid (13) with the integrin α5β1, the antagonist is caged
with DMNPE (2). Therefore the 2 is coupled in a Steglich esterification to the
carboxy-group of the antagonist 13 (scheme 4.11). As described in the synthe-
sis of 1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecanoate (1), the
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Figure 4.40.: The analysis of the PEG 2000 silane (8) coating before and
after UV irradiation with MDCK II cells shows the instability of PEG. Three
surfaces are irradiated with UV light (365 nm) for 60 s (A), whereas two are
kept in the dark before (B) the cells are seeded on top (scale bar: 250µm).
After 18 h the nuclei are stained and the number of cells on the surfaces
determined
carboxy-group is activated using DCC. Because of the slow reaction between
the acid and the alcohol, DMAP is used as catalyst, which enables the coupling
between carboxy and hydroxy group. The raw product is purified using HPLC.
The analysis of the isolated product shows the deprotection of the thiol func-
tion during the purification step. This is possible because the eluent contains
TFA, which is used for the deprotection of the thiol group. So no additional
deprotection must be performed. Because the batch size is to small, it is not
possible to determine the yield, but successful coupling is obtained as seen by
the NMR analysis.
Summary of Influencing Collective Cell Migration
1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecanoate (1) can be syn-
thesised with a yield of 18%. In QCM-D experiments, the adsorption happens
with a specific decay time of (320.88 ± 58.36) min at 37 ◦C and (1899.00 ±
776.30) min at 21 ◦C, while the cleavage after UV irradiation takes (2.52 ±
0.64) min (21 ◦C). The absorption spectrum of the molecule shows a band at
345 nm, which is blue shifted to 322 nm upon irradiation with UV light. Also,
an isobestic point can be observed at 370 nm. An analysis of the toxicity of 2
shows an increasing of metabolic activity of the cells for 2, but no effect for 1
is found. Because the passivation with PEG does not withstand the irradiation
with UV light, no migration experiments can be performed.
Additionally it is possible to synthesis a caged specific antagonist of the
integrin α5β1 (14).
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Scheme 4.11.: 13 is protected with DMNPE (2) via Steglich esterification.
The thiol group is deprotected during the purification and results in 14.
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Chapter 5.
Discussion
In this thesis chemical synthesis and material science is combined to address bi-
ological questions in a biological chemistry approach. This enables the analysis
of the influence of different extracellular matrix modules on cell behaviour. On
the one hand a concentration and density depending effect of short hyaluronan
is analysed. On the other hand a novel specific and unspecific binding model
for the extracellular matrix is developed.
5.1. Chemical Modification of Hyaluronan
It is important to have a high control over the concentration of HA during
experiments which deal with the influence of HA concentrations on these cells.
So the first step is to find a suitable method to immobilise HA molecules on a
surface.
The results in the previous section show several strategies to chemically
modify HA to immobilise it on a surface. One the one hand modifications
at the reducing-end are performed using cysteamine hydrochloride, propargy-
lamine and dibenzocyclooctyne-amine. On the other hand the propargylamine
is introduced at the carboxy groups within the chain (fig. 5.1). In case of the
end-thiolated HA a degree of thiolation of below 4.0±0.5 % (Appendix B) and
of the functionalisation within the chain a degree of alkynation of 16% is deter-
mined. All syntheses are performed successfully and enable the immobilisation
of the HA-species.
In literature different approaches are found to functionalise HA (chapter
1.4.2). The easiest modification is the functionalisation at the carboxy-group
within the HA chain.[45–48,50,51] Because short HA is used, a terminal mod-
ification is preferred to ensure the bioactivity of the HA, because the HA
receptors address multiple disaccharide units.[15, 39] Here the modification at
the reducing-end described by Lee et al. is performed.[49]
5.2. Bioactivity of Chemical Modified Hyaluronan
After the chemical modification to immobilise HA, the bioactivity is verified
via the analysis of the interaction between the HA species and the hyaladerine
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Figure 5.1.: Overview of the successfully synthesised HA species: the end-
modified thiol, DBCO and alkyne species as well as the alkyne function
within the chain.
aggrecan as well as LYVE-1. Especially the interaction between aggrecan and
HA proves the conservation of the bioactivity during the modification.
To verify the bioactivity a modification within the chain is compared to the
modification at the reducing-end. Via introduced thiol groups it is possible to
immobilise the HA directly to gold surfaces like gold coated QCM-D crystals
or gold nanoparticles. The usage of orthogonal functionalised gold nanostruc-
tured surfaces with the copresentation of cRGD enables the application in cell
experiments.[120]
On the other hand a two layer system is established, where alkyne function-
alised HA is immobilised on a previous formed OEG-SAM which bears azide
groups as we published in [54] (fig. 5.2). The immobilisation is based on the
copper catalysed azide-alkyne cycloaddition (CuAAC). Therefore, two oligo-
ethylene glycol species with a thiol terminus are used. To enable the CuAAC,
a mixture of HS (CH2)6 EG3 and HS (CH2)6 EG6 N3 (ratio 2:1) is used.
Additionally to the possibility to immobilise HA , the OEG-SAM provides a
passivating background against unspecific interactions.[45, 53] Because the use
of copper in biological samples bears the risk of incorporation of copper ions
into the surface layer, it is possible to use the strain promoted azide-alkyne cy-
cloaddition (SPAAC) reaction which also clicks an azide to an aklyne group.[50]
In this case the driving force is the strained alkyne in the cyclooctenyl-ring.
Having two different strategies, respectively two positions to immobilise the
HA, is of great advantage. This enables also the possibility to analyse, if the
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Figure 5.2.: A gold surface can be modified with an OEG-SAM decorated
with azid groups, which enables the immobilisation of alkyne functionalised
HA either at the reducing end or within the chain. By varying the azide ratio
the concentration of HA on the surface can be tuned.
position of the modification influences the bioactivity of HA. So it can give
evidences to the mechanism of the recognition of HA. Furthermore the us-
age of an azide bearing OEG-SAM and alkyne functionalised HA enables a
well-controlled way to vary the density of HA on a surface (fig. 5.2). Because
Figure 5.3.: The thiol-modification at the reducing end of HA enables the
immobilisation of HA (hexagons) on a glass surface decorated with gold
nanoparticles (dots). The surface can be orthogonal functionalised with an
adhesive background using click-PEG (black lines) with cRGD (triangles).
QCM-D is used as technique to ensure the bioactivity of the HA after the
chemical modification, it is also used to verify the success of the modification
itself. The end-thiolated HA species can be immobilised directly onto the gold
coated quartz crystal, whereas the alkyne functionalised species are immo-
bilised via CuAAC to an azide bearing OEG-SAM. Because it is possible to
immobilise all modified species on the corresponding surfaces, the modification
was successful in each case (tab. 5.1). However, a problem occurs during the
click reaction. The observed change in frequency indicates the incorporation
of the used copper species into the OEG-SAM (fig. 4.3). The effect cannot be
undone by washing the surfaces with an EDTA solution, which would complex
divalent ions, the CuI-species, the actual catalyst of the CuAAC, which is in-
corporated into the SAM. To overcome this problem a complex of CuI with
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tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) is used.[128] But the per-
formed QCM-D experiment shows no reaction between azide and alkyne when
the complex is used as catalyst. The sterical hinderance of the ligand seems
to prevent the reaction which is proven to be possible in solution.[126–128] An-
Table 5.1.: Summary of the changes in frequency due to the immobilisa-
tion of the different HA species to a gold surface respectively conjugated
to HS (CH2)11 EG6 N3. The QCM-D experiments are performed in PBS.
For the analysis the 7th overtone is used (n = 2).[54]
# sample ∆∆f7 [Hz]
1 sHA-end-thiol (3) 50.5 ± 12.1
2 OEG 52.4 ± 10.1
3 OEG/ sHA-end-alkyne (4) 41.9 ± 0.1
4 OEG/ sHA-side-alkyne (6) 49.5 ± 0.1
5 sHA-end-DBCO (5) 50.0 ± 5.7
other option to ensure that no copper remains on the surface is using the
strain-promoted alkyne-azide cycloaddition (SPAAC). As described before a
ring strained triple bond can be used as driving force to couple an azide to an
alkyne function. [50, 55,56] The HA is again modified at the reducing end mod-
ifying the protocol by Lee et al.[49] Because of this the commercially available
dibenzocyclooctyne-amine is chosen. The QCM-D experiment shows as well
this successful modification and immobilisation. Disadvantage of this method
is the prolonged reaction time. To improve the reaction kinetics another ring
strained system needs to be tested because the reactivity depends strongly on
the substitution of the cyclooctine. Otherwise a different biocompatible reac-
tion can be tested to immobilise the HA.[130] Thinkable is the immobilisation
via NHS chemistry. Therefore an active ester OEG needs to be immobilised
on the surface and an amine function introduced to the HA. The amine is in-
teresting because the reaction speed in this reaction is highest between active
ester and amine compared to hydroxy- or thiol groups.
To analyse the bioactivity of the chemical modified HA species the different
prepared surfaces are rinsed with a solution of either BSA, aggrecan or LYVE-
1. QCM-D is used to observe this interaction.
HA forms a layer which prevents unspecific interactions with proteins. To
analyse if this behaviour is still intact after the modification, the HA layer is
incubated with a solution of BSA. Analysed are the homogeneous HA surfaces
with the end-thiolated HA, as well as the two layer system of OEG-SAM
with the two propargylamine bearing HA species. For none of these surfaces
a binding of BSA is observed. This shows that the passivation properties of
the HA are still intact after the chemical modification. To analyse also specific
interactions with HA, the HA binding proteins aggrecan and LYVE-1 are
chosen for further experiments.
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Table 5.2.: Summary of the changes in frequency of the interaction of aggrecan
or LYVE-1 with surfaces with different immobilised sHA. The used immobil-
isation strategies are the end-thiolation, end-alkynation and side-alkynation
of sHA.[54] For the analysis the 7th overtone is used.
# sample ∆∆f7 [Hz]
Aggrecan LYVE-1
1 EG3 OH/EG6 N3 0.6 1.66
2 sHA-end-thiol (3) 3.9 ± 1.2 -
3 OEG/sHA-end-alkyne (4) 2.8 ± 2.3 0.02 ± 0.41
4 OEG/sHA-side-alkyne (6) 0.3 ± 0.6 0.48 ± 0.40
Aggrecan is a cartilage-specific proteoglycan core protein with a weight over
2500 kDA. It forms a hydrated gel structure in combination with HA and the
link protein.[36] It is known that aggrecan needs at least 10-mers of HA to
form strong binding. But between 4 and 8-mers still a weak interaction can be
found.[37] The used HA has an average weight of 20 kDa, which correspond to
a 50-mer. Because of this a good, strong interaction should be observable. The
summary of the observed changes in frequency (tab. 5.2) shows the binding
of aggrecan to each HA-species. Only a weak interaction is found for 6, which
is due to the relative high density of alkyne groups at the chain. A degree of
alkynation of 16% corresponds to a modification at every 8th unit. To improve
the recognisability of this species, the synthesis needs to be repeated with an
higher excess of HA compared to the used propargylamine to decrease the
alkyne groups attached to the chain.
The used LYVE-1 is a homologous to the HA-receptor CD44, which is char-
acteristic for lymphendothelial cells. For CD44 it is known that 6 to 10-mers
of HA are necessary for an interaction.[131] Because both receptors show a very
similar binding domain it is obvious that LYVE-1 needs as well 6 to 10-mers
of HA.[39, 40] In the QCM-D experiment only the ectodomain with the binding
domain of the receptor is used. Because it is rather light in weight (30 kDa)[39]
its weight is increased by creating a conjugate with an antibody. Nevertheless
the QCM-D experiment shows only a very weak interaction between LYVE-1
and the different surfaces. Possible explanations for this are high off-rates of
the interaction as well as missing so far unknown co-factors which are needed
for the binding. Also a needed clustering of the LYVE-1 receptors as it is re-
ported for CD44 is thinkable. Therefore the intracellular part of the receptor
is necessary.[132]
Although only a weak interaction between LYVE-1 and the HA modified
surface is found the interaction with aggrecan proves the bioactivity of the
chemical modified HA. The experiments show also that the modification at
the reducing end does not interfere with the bioactivity. This indicates, that
the reducing end is not the key player in the recognition of HA. In case of
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the functionalisation within the chain a weaker interaction is found, which
correlates to a dense functionalisation within the chain. But the HA is still
bioactive.[54]
5.3. Influence of Short Hyaluronan on LECs
To determine the influence of short HA on LECs the performance of the
AlamarBlue® and CyQuant® assay are established. A cell density of 131 /mm2,
an incubation time of 2 h (AlamarBlue® assay) and 5min (CyQuant® assay)
are established.
After showing that the immobilisation of hyaluronan is possible and the
bioactivity stays intact, the HA is used in cell experiments. In the cell experi-
ments two different HA species - on the one hand the short HA with an average
weight of 20 kDa (50-mer) and on the other hand the digested HA with an
average weight of 10 kDa (20-mer) - are compared. Both species are thiolated
to enable the immobilisation of the HA on a nanostructured glass surface (fig.
5.3). Additionally, both species are added to the cells in solution in their func-
tionalised and unfunctionalised version to analyse if any inhibition occurs due
to the functionalisation at the reducing end. These experiments are performed,
although the QCM-D experiments prove the bioactivity of the functionalised
HA species. Besides the influence of the HA species the impact of the surface
is compared as well. Therefore cells are seeded in a 96 well plate and on click
PEG with and without gold nanoparticles. The analysed parameters are the
toxicity of the HA species, the influence on the metabolic activity and the
adhesion of the cells to the different concentrations either applied in solution
or immobilised on the surface.
Toxicity Analysis of Short Hyaluronan
The determination of the toxic impact of digested and short HA species applied
in different concentrations or different densities shows no negative effect to the
metabolic activity.
The toxic effect of the different HA species is analysed (fig. 5.4). The com-
parison of the two end-thiolated HA species (fig. 5.4 a) shows no change in the
activity of the cells, so the immobilised HA does not damage the cells. Figure
5.4 b) shows the influence of the end-thiolated and unfunctionalised species,
which are incubated in solution. Here as well no difference between the species
and concentrations is found. This shows that no toxic effect occurs through
the thiolation of the HA and the HA itself on the LECs.
The Relative Metabolic Activity
Compared is the influence of a digested and short HA species which are applied
to LECs in different concentrations and densities. Between the different species
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Figure 5.4.: Toxic effect of different HA species on LEC on nanostructured
surfaces (a) and with HA in solution (b). Shown are mean and standard
deviation for the incubation with the end-thiolated, short (black •) and end-
thiolated, digested HA (grey ), short (light grey △) and digested HA (grey
∇) and the passivation control (light grey ).
no difference in the cell behaviour is found. In the case of the application of
HA in solution no difference in the relative metabolic activity is found. For the
immobilised HA species a reduced ability to adhere to the surface is found for
the increasing nanoparticle density. Here for both HA species a biphasic effect
in relative metabolic activity is found with maxima for a particle density of
540 /µm2.
The analysis of the amount of DNA per surface (CyQuant® assay) shows an
effect on the cell adhesion for the immobilised HA species. This is due to the
sterical hindrance of the cell adhesion. Especially for high HA densities the
large HA molecules (50 disaccharide units) will cover some cRGD molecules
on the surface and so less cells are able to adhere to the surface. To enable
the comparison of the different surfaces after all, the results of the relative
metabolic activity (AlamarBlue® assay (AB); I(ABc)/I(AB0)) are normalised
to the relative amount of DNA (CyQuant® assay (CQ); I(CQc)I(CQ0)) on
the same surface. The comparison of the digested and short HA species shows
no significant difference so the results of the analysis of short HA on the
normalised metabolic activity of LECs (fig. 5.5). The comparison between the
experiments performed on cell culture plastic (a) to the experiments performed
on click PEG (b) shows no significant difference due to the different surface
types with the same concentration of HA. As well no significant difference is
found for the different applied HA concentrations on the same surface type.
This finding is contrary to discoveries described in literature. So Wu et al.
describe a biphasic effect of low molecular weight (2.5 kDa, 3-10 mer) on lym-
phendothelial cells.[44] They use a stable cell line of mouse lymphendothelial
cell, which is postulated to behave in the same way LECs do. Due to the
applied HA in solution a biphasic effect is shown with a maximum at a con-
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Figure 5.5.: Results of the influence of HA on the relative metabolic activity
of LECs (based on the AlamarBlue®assay) normalised to the relative amount
of DNA (based on the CyQuant®assay) on a) cell culture plastic in a 96-well
plate with HA in solution, b) on a click-PEG surfaces with HA in solution and
c) on nanostuctured, click-PEG surfaces with immobilised HA. To analyse
the significance of the samples a Kruskal-Wallis test (p < 0.05 with Dunn’s
comparison is performed, Appendix E).
centration of 3.13µg/mL which decreases even under the level of untreated
cells for concentrations above 25.0µg/mL. Additionally a scratch assay is per-
formed to analyse the effect on the migration velocity and an increase in the
migration ability is found. In the study presented here a biphasic effect is found
for the immobilised HA only. Up to a particle density of 540 particles/µm2 the
relative metabolic activity increases. For the application of a higher density
of HA on the surface the activity decreases again. So there is a critical sur-
face density which leads to a higher activity level of the cells compared to
untreated cells (positive control). The different results of our study compared
to the results by Wu et al. are possibly due to the use of the different cells
respectively because primary cells are used, which can show variations in their
behaviour depending on the cell batch. To verify and strengthen the findings
the experiments can be repeated with different batches of cells or cells from
different donors. Additionally this indicates a different effect of the orientation
of the cells to the HA. For the immobilised HA the cells have only contact to
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the HA at the basal side. Seeding the cells with diluted HA enables the contact
from all sides until the cells adhere to the surface. Afterwards the HA can only
interfere at the apical side with the cells. It is also reported, that HA supports
the adhesion of cells to a substrate, because the interaction between HA and
HA receptors is faster than the interaction between integrin and their corre-
sponding binding domains on the surface.[133] This can also effect the response
of the cells to the HA.
5.4. Influence of Immobilised, Short HA on Cell
Migration
Due to the nanostructured surfaces to immobilise the HA in these experiments
it is not possible to perform a scratch assay to analyse the migration behaviour
of the cells. The passivation and functionalised nanoparticles would be removed
with the cells during the assay. Due to this another method needs to be found.
Unfortunately also the usage of a physical barrier like a PDMS-stencil,[79] other
PDMS-blocks,[80] or commercially available masks[83] to create a collective is
not possible because these barriers do not stick to the passivated glass surface
and so no defined border can be created.
So cells are seeded to surfaces without the application of HA and on nanos-
tructured surfaces with a particle density of 540 /µm2, which should result in
the highest effect on the cells. But the results indicate no change due to the
HA application (fig. 4.26). Also various antibodies are tested to enable the
determination of an effect on the adhesion via staining the focal complex and
of the interaction between HA and LYVE-1. In case of the staining for the
focal complex the proteins talin, paxillin and vinculin are chosen, but it is not
possible to achieve an appropriate staining of any of these proteins. Likewise
no antibody is found which can be used for ICC staining of LYVE-1. Stainings
of LYVE-1 which are found in literature are mainly performed in micro sec-
tions.[14, 19,134] A possibility to overcome this problem could be to use indirect
labelling of the receptor by using a fluorescent labelled HA species or to stain
a protein that colocalises with the receptor. To create a fluorescent labelled
HA it would be possible to combine modification within the chain with a mod-
ification at the reducing end. To have a high accessibility of the HA on the
nanostructured surface end-thiolation is still the best choice. So a dye could
be introduced via CuAAC to alkyne groups within the chain. Therefore the
degree of alkynation should be decreased so that the bioactivity is ensured.
The disadvantage of using a labelled HA is, that due to the addition of a dye
the sterical demand of the HA is increased which has an negative effect on the
accessibility of the cRGD and so the adhesion of the cells. The problem with
staining of a colocalised protein of LYVE-1 is that so far it is unclear which
proteins would be suitable. To allow this, further investigations are necessary.
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5.5. Summary of the Influence of Short Hyaluronan on
LECs
In summary the analysis of immobilised short HA showed that it is possible to
perform a chemical modification of HA within the chain or the reducing end
while the bioactivity is conserved. The incubation of different concentrations
of HA with LECs on either cell culture plastic or click-PEG shows no signif-
icant difference in the relative metabolic activity of the cells. Contrary the
variation of the HA density on a surface leads to a biphasic effect in relative
metabolic activity with a maximum at a density of 540 particle/µm2. This
shows a higher response to the application of HA on the basal side. Further
studies to investigate the influence of immobilised, short HA on cell migration
or the binding mechanism of HA to its receptors are difficult. On the one hand
no scratch or migration assays with a physical barrier can be performed due to
the nanostructured surface. On the other hand no antibodies are found which
enable the staining of the HA receptor LYVE-1.
5.6. Synthesis and Characterisation of Noval
Photocleavable Ligands to Study Cell Migration
To study collective cell migration on nanostructured surfaces two novel pho-
tocleavable ligands are developed. Synthesised are an unspecific ligand 1--
(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecanoate (1) and the spe-
cific, caged antagonist of the intergrine α5β1 1-(4,5-dimethoxy-2-nitrophenyl)-
ethyl (3(S))-3-(4-(3-(6-(3-mercaptopropanamido)hexanamido)propoxy)benza-
mido)-4-(4-(3-((4-methoxypyridin-2-yl)amino)propoxy)phenyl)butanoate (14).
To analyse the migration of cells on a substrate, various methods are re-
ported (chapter 1). Several methods accept that cells get damaged and so
additional unknown signals influence the migration. Aim of this study is to
enable the comparison of the influence of the surface density of adhesion mo-
tives on collective migration. Therefore the well-established nanostructured
glass surfaces are used.[24, 25,27,135,136] Via BCML, gold nanostructures on glass
surfaces with different interparticle distances are produced.[24] To prevent un-
specific interactions of the cells with the surface, the glass is passivated with
PEG2000 silane (8) via silanisation reaction.
[25] The gold nanoparticles are ei-
ther decorated with an unspecific, caged adhesion molecule a) or an artificial,
caged, specific intergrine antagonist b), fig. 5.6).[21]
1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecanoate (1)
1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecanoate (1) can be syn-
thesised with a yield of 18%. In QCM-D experiments, the adsorption happens
with a specific decay time of (320.88 ± 58.36) min at 37 ◦C and (1899.00 ±
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Figure 5.6.: Shown are the a) unspecific, caged adhesion molecule (1) and b)
the artificial, caged, adhesion ligand 14.
776.30) min at 21 ◦C, while the cleavage after UV irradiation takes (2.52 ±
0.64) min (21 ◦C). The absorption spectrum of the molecule shows a band at
345 nm, which is blue shifted to 322 nm upon irradiation with UV light. Also,
an isobestic point can be observed at 370 nm. An analysis of the toxicity of
DMNPE shows an increasing of metabolic activity of the cells for 2, but no
effect for 1 is found. Because the passivation with PEG does not withstand
the irradiation with UV light, no migration experiments can be performed.
To establish all parameters for further cell experiments a simplified ligand
is synthesised, which interacts unspecifically with integrins. Therefore 4,5-
dimethoxy-2-nitrophenyl ethanol (2) is synthesised and its photochemistry
characterised. It is known from studies with caged RGD that this molecule
is sufficient to prevent cell adhesion. So this is also the targeted group in case
of the artificial antagonist. The ligand to study the unspecific interaction is
a minimalistic model for this. 11-mercaptoundecanoic acid (7) was chosen as
a model compound, as it combines both necessary functions - a thiol and a
carboxy group. In the beginning the 2 is synthesised with a yield of 62% regard-
ing acetophenone. This is successful coupled via Steglich esterification to 11--
(tritylthio)undecanoic acid (11). After the deprotection of 1-(4,5-dimethoxy-2-
nitrophenyl)ethyl-11-mercaptoundecanoate (1) could be achieved with a yield
of 18% regarding acetophenone.
The comparison of the adhesion of the unspecific ligand at 21 ◦C and 37 ◦C
shows a 6-fold faster adsorption at the higher temperature. The cleavage anal-
ysis via QCM-D indicates a single-step process what corresponds to the postu-
lated mechanism. The determined specific decay time is t1 = (2.52 ± 0.64) min.
The observation of the cleavage using the UV VIS spectra is in good agreement
with this finding. The isobestic point at 370 nm proves also the single-step pro-
cess of the cleavage. The analysis of the spectra before irradiation shows also a
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maximum at 345 nm which is the optimal cleavage wavelength of the molecule.
The comparison of the irradiation of 2 and 1 shows much faster process for
DMNPE which might be due to the faster rearrangement of the molecule be-
cause no substitutent with sterical demand is attached. Because the ligand is
Figure 5.7.: The results of the toxicity assays for the cell assays with 1-(4,5-
dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecanoate (1) are summarised.
In a) the influence of the irradiation time on MDCK II cells is evaluated after
different incubations times (1 h: black circles; 2 h: dark grey squares; 3 h: grey
triangles). The effect of the incubation with DMNPE (2, grey squares) and
1 (black circles) is shown in b).
used in cell experiments and UV light is needed to cleave the molecule, which
can damage the cells, the toxicity of the ligand as well as the UV light is deter-
mined. The performed toxicity assay analyses the influence of the irradiation
time of 15, 30 and 60 s and without irradiation after 1, 2 and 3 h. This long
observation time is meaningful because it is found that it is possible to fix
cells with UV light, so that the cells still appear healthy, or to damage the
cells formatively. This effects can still appear several hours after the actual
irradiation.[90]
The irradiation times which are used for the toxicity assay show no difference
in the metabolic activity (fig. 5.7 a). As well no significant difference is found
for the application of 2 or 1 although an increase in the reduction is found
which correlates to an higher metabolic activity (b).
Cell Experiments on Nanostructured Surfaces Decorated with
1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercaptoundecanoate (1)
For cell experiments nanostructured surfaces with interparticle distances of
30, 60 and 90 nm are passivated with PEG2000 silane (8). Afterwards the
surfaces are incubated with the ligand. Additionally surfaces are prepared
without nanostructures to ensure on the one hand a successful passivation
and that the ligand does not stick to the PEG. On the other hand it is tested
if the passivation withstands the UV irradiation. To create a pattern on the
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surface a rectangular aperture is used during the irradiation, which leads to a
rectangular area in middle of the surface where the cells can adhere and so four
edges which can be observed for the migration assay. While the negative control
shows no cell adhesion and so demonstrates the the passivation worked out,
the passivated surfaces which are irradiated with UV light show cell adhesion.
This strongly indicates, that the PEG is removed during the irradiation with
UV light. So it is unclear if the cells adhere on the nanostructured surfaces
due to the cleaved ligand or because the PEG is removed. To perform the
migration assay it is necessary to find a passivation which is stable against
the irradiation with UV light. For the synthesis of the 8, which is used in this
study, a PEG amine is coupled to 3-triethoxysilylpropyl isocyanate under the
formation of a urea group. 8 used in this study has an urea bridge (fig. 5.8
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Figure 5.8.: Overview of different PEG-species which can be used as passi-
vating background in cell experiments. In case of a) in two steps a silane is
immobilised on the surface and afterwards coupled to a PEG species result-
ing in a carbamate. The urea species (b) and the urethane species (c) are
immobilised as whole molecule.[25]
a). Known are also species with an internal urethane function and a two-step
passivation resulting in a carbamate. Disadvantage of this two systems are
worse passivating properties.[25] Nevertheless, both species can be tested, if
they withstand the UV light. Other used photocleavable ligands, which are
found in literature, are also immobilised via silanisation on a glass surface.
[73, 85,88,137] So it is unlikely, that the silane function is responsible for the
instability.
1-(4,5-dimethoxy-2-nitrophenyl)ethyl (3-(S))-3-(4-(3-(6-(3-mercap-
topropanamido)hexanamido)propoxy)benzamido)-4-(4-(3-((4-me-
thoxypyridin-2-yl)amino)propoxy)phenyl)butanoate
Beside the unspecific ligand, the specific antagonist 131 is coupled to DM-
NPE (2) via Steglich esterification. Here the determination of the yield is not
possible because the batch size was to low. Because of the unstable passiva-
1The artificial, specific anatagonist is synthesised by Dr. Stefanie Neubauer, Institute for
Advanced Study at the Department of Chemistry, Group of Prof. Dr. H. Kessler, Tech-
nische Universitaet Muenchen (Germany).
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tion on the nanostructured surfaces, no further cell experiments with 14 are
performed.
Chapter 6.
Outlook
Various strategies are found to immobilised HA on a surface. To overcome
the problematic application of the CuAAC the usage of the SPAAC needs
further investigation. So other ring strained species can be tested to increase
the reaction speed. Possible alternatives are the use of bicyclo[6.1.0]non-4-yne-
or 3,3-difluoro-6-methylcyclooct-1-yne-derivatives (fig. 6.1).[55, 57]
F
F
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Figure 6.1.: Strained ring species which can be used for the SPAAC: a) bicyclo-
[6.1.0]non-4-yne- and b) 3,3-difluoro-6-methylcyclooct-1-yne-derivatives.
Primary cells are used in the experiments to analyse the influence of im-
mobilised HA. The behaviour of these cells can vary form batch to batch. To
see, if the biphasic effect in the metabolic activity for the incubation of the
cells with immobilised HA is only found for this batch other cell batches would
have to be tested. Also a concentration depended effect in the activity is found
for lymphatic cells which are incubated with diluted HA.[44] This enables the
further investigation if cells react different when HA is applied in an immo-
bilised (basal) density depending or diluted (apical) concentration depending
way. Therefore it is also interesting to investigate if the immobilised HA in-
teracts differently with the cells at different concentrations. For this study an
orthogonal modified HA is of interest. In the synthesis two immobilisation
strategies can be combined. On the one hand HA can be immobilised on gold
nanoparticles by introducing a thiol group at the reducing end. On the other
hand the alkynation within the chain can be used to click a dye to the HA chain
using CuAAC. Therefor a lower degree of alkynation should be used than in
this study to ensure the bioactivity. The interaction between the modified HA
within the chain with a functionalisation degree of 16% and aggrecan is found
to be weak, which indicates that the degree of alkynation is too high for an
effective interaction between receptor and HA. Additionally a possibility needs
to be found to stain the HA receptor LYVE-1 to investigate the colocalisation
131
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between HA and receptor. Instead of directly staining the receptor itself, it
is possible to detect proteins which bind to the receptor on the intracellular
domain. Because it is not well studied which proteins bind to LYVE-1 so far,
this needs to be tested first. Due to the similarity between CD44 and LYVE-1
proteins which bind to CD44 can be tested first. Interesting candidates are
ezrin and merlin which are also know to be important in migration.[17, 30]
In literature the terms short HA or small HA fragments contains a wide
range of chain length from 2500 to 40 000 kDA.[2, 43,44] In this study the im-
pact of HA with an average size of 10 kDa is compared to a HA with an
average size of 20 kDa and no difference is determined. The effective size of
HA fragments that influence cell behaviour remains unknown. To investigate
this, different sizes between 2.5 and 40 kDa can be tested. Important here is
to use HA with a good defined size to ensure that the right size is tested. Be-
sides it is interesting how small the fragments can get to increase the relative
metabolic activity. To degrade HA three different methods can be used which
lead to a different fragmentation of the HA. The usage of hyaluronan synthase
(HAS) leads to a cleavage of the β-(1→3) glycosidic bond and a N -acetyl-d-
glucosamine at the reducing end. The usage of lyases leads to a β-elimination
at the β-(1→4) glycosidic bond with d-glucoronic acid at the reducing end.
The third method is the application of reactive oxygen species (ROS) which
lead to an uncontrollable fragmentation of the HA. Because all three methods
are found in natural conditions it would be interesting to study the effect of
the different cleavage methods with the different end-groups.
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Figure 6.2.: To enable the use of the two DMNPE (2) caged molecules on
different surfaces, the terminus can be varied. Besides the thiol function (-
SH), it could be interesting to immobilise them directly to a glass surface via
a Si(OMe)3 group. For applying a orthogonal functionalised surface with
click-PEG either an alkyne (CuAAC) or a strained alkyne species (SPAAC)
can be introduced or the molecule can be immobilised via NHS chemistry.
To enable the chemical barrier method to study collective cell migration, a
working passivation needs to be found. Tested can be PEG-derivatives which
are attached to the silane group under the formation of a carbamate or ure-
thane group. After solving the passivation problem, the migration of cells can
be analysed depending on the density of a adhesive background on the sur-
face. It will be possible to compare an unspecific interaction of the cells with
11-mercaptoundecanoic acid (7) and the specific interaction with the integrin
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α5β1 via 13. To enable the use of an orthogonal functionalised surfaces with
this biological chemistry approach, different motifs can be used to immobilise
the ligand to a surface. Thinkable are a silane group to immobilise the lig-
ands directly to a glass surface or silicon wafer or either an alkyne group or a
strained ring octenyl derivative to enable the CuAAC respectively the SPAAC
(fig. 6.2).
Figure 6.3.: Scheme of orthogonal functionalised surfaces which combine both
strategies developed in this study: a) The density of immobilised HA can be
varied by using surfaces with different particle densities in the presence of a
photocleavable adhesive background. b) The density of the photocleavable,
adhesive ligand can be varied by using surfaces with different particle densi-
ties in the presence of short HA.
Finally both developments of this study can be combined. Therefore a gold
nanostructured surface can be created with a passivating PEG-background
with either the photocleavable ligand attached to the gold particles via a thiol
group and short HA is immobilised via CuAAC/ SPAAC to the PEG or vice
versa. These strategies enable the determination of density depending effects
on cell behaviour especially migration. The surface can be decorated either
with varying HA density in the presence of a photocleavable adhesive back-
ground or by varying the density of the adhesive ligands in the presence of
short HA fragments (fig. 6.3).
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Appendix A.
Abbreviations and Synthesised
Compounds
A.1. Abbreviations
∆(∆fn) change in frequency in QCM-D experiments for overtone
n
BCML block copolymer nanolithography
BSA bovine serum albumin
CCD charge coupled device
CD44 cell-surface glycoprotein involved in cell-HA interactions
CLEC-2 c-type lectin-like receptor
COSY correlation spectroscopy (NMR method)
cRGD cyclic RGD
CuAAC copper catalysed azide alkyne cycloaddition
DAPI 4′,6-diamidino-2-phenylindole
DART direct analysis in real time (MS method)
DBCO dibenzocyclooctin
DCC N,N ′-dicyclohexylcarbodiimide
DCM dichloromethane
DIPEA diisopropylethylamine
DMF dimethylformamide
DMNPE 4,5-dimethoxy-2-nitrophenyl)ethanol
DMSO dimethylsulfoxide
DNA deoxyribonucleic acid
DTNB 5,5′-dithio-bis-2-nitrobenzoic acid
ECM extracellular matrix
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
EDTA ethylenediaminetetraacetic acid
EG ethylenglycol
EGM-2 MV microvascular endothelial cell growth medium
ESI electron spray ionisation
EtOH ethanol
FADH2 flavin adenine dinucleotide
FAK focal adhesion kinase
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FBS fetal bovine serum
FITC fluorescein isothiocyanate
FMNH Flavin mononucleotide
GAG glycosaminoglycans
HA hyaluronic acid
HAS hyaluronan synthase
HPLC. high performance liquid chromatography
HSQC heteronuclear single quantum coherence (NMR method)
ICC Immunocytochemistry
IgG Immunoglobulin G
LEC lymphendothelial cells
LYVE-1 lymphatic vessel endothelial hyaluronic acid receptor 1
MALDI MS matrix-assisted laser desorption ionisation mass spec-
trometry
MDCK II Madin-Darby canine kidney strain II cell line
MEM minimum essential medium eagle with phenolred
MS mass spectrometry
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide
MWCO molecular weight cut off
NAD(P)H nicotinamide adenine dinucleotide (phosphate)
NHS N -hydroxysuccinimide
NMR nuclear magnetic resonance spectroscopy
OEG oligoethylenglycol
PBS phosphate buffered saline
PDMS polydimethylsiloxane
PEG polyethylenglycol
PFA paraformaldehyde
QCM-D quartz crystal microbalance with dissipation monitoring
RGD amino acid sequence arginine-glycine-aspartic acid
RHAMM receptor for hyaluronan mediated motility
RNA ribonucleic acid
ROS reactive oxygen species
SAM self-assembled monolayer
SDS sodium dodecyl sulphate
sHA short HA
SPAAC cooper-free strain-promoted azide-alkyne cycloaddition
Src tyrosine-protein kinase
TEAA triethylammonium acetate
TFA trifluoroacetic acid
THF tetrahydrofuran
THPTA tris(3-hydroxypropyltriazolylmethyl)amine
TIPS triisopropylsilane
TLC thin layer chromatography
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TRIS tris(hydroxymethyl)aminomethane
UV ultraviolet
UV VIS absorption spectroscopy at the ultraviolet/visible range
of electromagnetic spectrum
VEGF(R) vascular endothelial growth factor (receptor)
Θw water contact angle
ǫλmax attenuation coefficient at the wavelength of the absorp-
tion maximum
λmax wavelength of the absorption maximum
HUPLEC human primary lymphendothelial cells
λex/em excitation/ emission wavelength
SLB supported lipid bilayer
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A.2. Synthesised Compounds
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HO OH
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SH OH
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HA-end-thiol HA-end-alkyne
HA-end-DBCO HA-side-alkyne
3 4
5 6
HO
O
O
O2N
1-(4,5-dimethoxy-2-nitrophenyl)-
ethan-1-ol
SHO
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1-(4,5-dimethoxy-2-nitrophenyl)ethyl 
11-mercaptoundecanoate
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1-(4,5-dimethoxy-2-nitrophenyl)ethyl (3S)-3-(4-(3-(6-(3-mercaptopropanamido)-
hexanamido)propoxy)benzamido)-4-(4-(3-((4-methoxypyridin-2-yl)-
amino)propoxy)phenyl)butanoate
O
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Appendix B.
Ellman’s Assay
The degree of thiolation of a sample is determined according to the protocol in
section 2.10.4. An example for a calibration curve with its linear fit equation
is shown in fig. B.1. The calculated degree of thiolation for three different
batches is summarised in table B.1 (4).
Figure B.1.: Example of a calibration curve for determining the degree of
thiolation using the Ellman’s assay. The measured absorbance at 420 nm is
plotted versus the concentration of cysteamine hydrochloride and the linear
equation determined.
Table B.1.: Summary of the results of the determination of the degree of thi-
olation (%) for three batches of short, end-thiolated HA with the according
linear fit equations.
mean absorbance (st.dev)
# ratio batch A1 batch B2 batch C3
1 1:41.5 0.0659 ± 0.0007 0.0685 ± 0.0059 0.0616 ± 0.0215
2 1:16.0 0.1016 ± 0.0008 0.0924 ± 0.0038 0.0871 ± 0.0567
3 1:9.6 0.1372 ± 0.0021 0.1215 ± 0.0081 0.0861 ± 0.0340
4 d.o.t. 4.47 3.33 4.12
1 y = 0.007542x + 0.05421; 2 y = 0.008138x + 0.0572; 3 y = 0.01075x + 0.03055
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Appendix C.
Determination of the Optimal Azide
Concentration for Performing a
CuAAC in the QCM-D
To enable the adhesion of alkyne functionalised HA for a QCM-D experiment a
SAM of OEGs is formed, which also bears azide groups. A pure surface coating
with HS (CH2)11 EG6 N3 is not appropriate so the linker is mixed with
HS (CH2)11 EG3 OH. To find the optimal ratio between the two compounds,
the ratio is systematically varied and the HA clicked to it (fig. C.1). The change
0,001 0,01 0,1 1 10 100
-60
-40
-20
0
f n/
n 
[H
z]
log (ratio of HS-(CH 2)11-EG6-N3) [%]
Figure C.1.: To determine the optimal azide concentration on the sur-
face for performing the CuAAC in the QCM-D the ratio between
HS (CH2)11 EG3 OH and HS (CH2)11 EG6 N3 is varied and the
change in frequency of the reaction measured.
in frequency is determined after performing the click reaction and the ∆f is
plotted against the logarithm of the azide concentration. For concentrations
between 1 to 40% a good response is observed. With concnetrations higher
than 40% no further change in frequency is observed, which corresponds to
no further immobilisation of HA to the surface.
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Appendix D.
Control Experiments for the Analysis
of the Influence of Hyaluronan on
LECs
For performing the AlamarBlue® and CyQuant® assay additionally to the
applied different concentrations several controls are performed as well. For the
experiments on cell culture plastic the controls are the measurement of the
background (cell culture plastic) and the positive control without adding HA.
For the experiments on click-PEG either with HA in solution or immobilised
HA a passivation control is necessary (tab. D.1 #1) as well as a wash control for
the cRGD (#2), where the surface is functionalised via CuAAC without adding
copper sulfate. On these two no cell adhesion should be observed. Additionally
the background is determined with a sample on a passivated surface decorated
with cRGD, media and kit, but without cells (#3). To check if the cells are
okay, cells are also seeded on cell culture plastic (# 4). The positive control
is the passivated glass surface decorated with cRGD and cells but without
adding HA (# 5). All shown data is normalised to the background.
Table D.1.: Summary of the composition of the different performed control
experiments for the Alamar® and CyQuant®assay
# type cRGD cells HA
1 pass. control + + +
2 wash cRGD +a + -
3 background + - -
4 plastic control - + -
5 positiv control + + -
a) click reaction without adding CuSO4
As expected for the AlamarBlue® assay, a large difference in the relative
intensities is found between the samples without an with cells. Even though the
performed Kruskal-Wallis test with Dunn’s comparison indicates a significant
difference between them and the positive control only for the experiments
with HA in solution (fig. D.1). A similar result is found for the CyQuant®
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Figure D.1.: Summarised are the control experiments performed for the
AlamarBlue® assay: A passivation control; B cRGD wash control; C cell
culture plastic; D positive control for the experiments with HA in solution
a) and immobilised on the gold nanoparticles b).
assay. The relative intensity is much smaller for the two control experiments
without cells. The results found for the control on cell culture plastic and
the positive control are similar to each other so the cells behave similar on
both surfaces. In the end the results of the AlamarBlue® of each surface are
Figure D.2.: Summarised are the control experiments performed for the
CyQuant® assay: A passivation control; B cRGD wash control; C cell cul-
ture plastic; D positive control for the experiments with HA in solution a)
and immobilised on the gold nanoparticles b).
normalised to the results of the CyQuant® assay on the same surface. For the
experiments with diluted HA no significant difference between the samples
is found (fig. D.3 a), Kruskal-Wallis test with Dunn’s comparison, Appendix
E). The relative metabolic activity found for the cell culture plastic control
is higher than for the positive control. In case of the immobilised HA species
the relative metabolic activity for the controls without cells is higher than
the positive control, which is due to the normalisation of the result of the
AlamarBlue® to a very low amount of DNA. The comparison of the positive
and plastic control show similar results, so that the cell are not damaged on
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the click-PEG surface.
Figure D.3.: Summarised are the control experiments for the relativ metabolic
activity of the LECs. Therefore the results of the AlamarBlue® are nor-
malised to the results of the CyQuant® assay: A passivation control; B cRGD
wash control; C cell culture plastic; D positive control for the experiments
with HA in solution a) and immobilised on the gold nanoparticles b).

Appendix E.
Statistical Analysis
The Kruskal-Wallis-test (one-way Anova test) is a non-parametric method to
analyse if samples belong to the same distribution. The statistical analysis is
based on a rank which is called H test.[138]
H =
12
N(N−1)
∑C
i=1
R2
i
ni
− 3(N + 1)
1−
∑ T
(N3−N)
(E.1)
It is possible to describe the the mean rank for the cases with and without
ties (equation E.1), where C represents the number of samples, ni the number
of observations in the ith sample, N the the number of observations in all
samples, Ri the sum of the ranks in the ith sample and T the expression of
ties with
∑
T = 0, if no ties exist.[138]
For the comparison of different samples all values are ranked independent
of there origin. The p-value is estimated using Pr(χ2g−1 ≥ H). To enable the
identification of the differing sample the Kruskal-Wallis test is followed by the
Dunn’s multiple comparison test.[139] The first step is the calculation of the
value of the contrasts (ym) for the rank sums (Ti) (equation E.2).
ym =
∑
i Ti∑
i ni
−
∑
i′ Ti′∑
i′ ni′
(with m = 1, . . . , p) (E.2)
The standard deviation for each value is calculated using equation E.3 consid-
ering possible ties (ts). The comparison of the values for
ym
σm
are compared to
the standard normal distribution and so vote as different or not.
σ2m =
[
N(N + 1)
12
−
∑s
s=1(t
3
s − ts
12(N − 1)
] [
1∑
i ni
+
1∑
i′ ni′
]
(E.3)
The calculation for both tests is performed using "GraphPad Prism" (version
6.0e/ 7.0c, GraphPad Software Inc, USA).
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Statistical Analysis of the Toxicity of the Different HA Species
Influence of Applied HA Concentrations on Assay
Table E.1.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.5460
Exact or approximate P value? Exact
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 4
Kruskal-Wallis statistic 2.333
Number of treatments (columns) 4
Number of values (total) 12
Dunn’s comparisons Mean rank diff. Significant Summary P
1 vs. 2.5 2 No ns >0.9999
1 vs. 5 -0.6667 No ns >0.9999
1 vs. 20 3.333 No ns >0.9999
2.5 vs. 5 -2.667 No ns >0.9999
2.5 vs. 20 1.333 No ns >0.9999
5 vs. 20 4 No ns >0.9999
Mean
Test details rank 1 rank 2 rank diff n1 n2
1 vs. 2.5 7.667 5.667 2 3 3
1 vs. 5 7.667 8.333 -0.6667 3 3
1 vs. 20 7.667 4.333 3.333 3 3
2.5 vs. 5 5.667 8.333 -2.667 3 3
2.5 vs. 20 5.667 4.333 1.333 3 3
5 vs. 20 8.333 4.333 4 3 3
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Influence of Applied HA on Assay Depending on the Incubation
Time
Table E.2.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.4636
Exact or approximate P value? Approximate
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 3
Kruskal-Wallis statistic 1.538
Number of treatments (columns) 3
Number of values (total) 36
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1 5.333 No ns
0 vs. 2 2.667 No ns
1 vs. 2 -2.667 No ns
Mean
Test details rank 1 rank 2 rank diff n1 n2
0 vs. 1 21.17 15.83 5.333 12 12
0 vs. 2 21.17 18.5 2.667 12 12
1 vs. 2 15.83 18.5 -2.667 12 12
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Comparison of different immobilised HA species
Table E.3.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0061
Exact or approximate P value? Approximate
P value summary ∗∗
Do the medians vary signif. (P < 0.05)? Yes
Number of groups 14
Kruskal-Wallis statistic 29.2
Number of treatments (columns) 14
Number of values (total) 77
Dunn’s comparisons Mean rank diff. Significant Summary Padj
0µg/mL vs. 0µg/mL 0 No ns >0.9999
20µg/mL vs. 20µg/mL 4.4 No ns >0.9999
50µg/mL vs. 50µg/mL 0.3333 No ns >0.9999
100µg/mL vs. 100µg/mL -5.667 No ns >0.9999
150µg/mL vs. 150µg/mL -0.6667 No ns >0.9999
190µg/mL vs. 190µg/mL 10.17 No ns >0.9999
Pass. control vs. Pass. control 0 No ns >0.9999
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0µg/mL vs. 0µg/mL 48 48 0 6 6
20µg/mL vs. 20µg/mL 33 28.6 4.4 5 5
50µg/mL vs. 50µg/mL 52.83 52.5 0.3333 6 6
100µg/mL vs. 100µg/mL 45 50.67 -5.667 6 6
150µg/mL vs. 100µg/mL 32 32.67 -0.6667 5 6
190µg/mL vs. 100µg/mL 47.4 37.33 10.17 4 4
Pass. con. vs. Pass. con. 6 6 0 4 4
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Toxicity Comparison of different applied concentrations of
unfunctionalised HA species in solution
Table E.4.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.1771
Exact or approximate P value? Approximate
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 6
Kruskal-Wallis statistic 7.643
Number of treatments (columns) 6
Number of values (total) 36
Dunn’s comparisons Mean rank diff. Significant Summary Padj
0µg/mL vs. 1µg/mL 8.333 No ns 0.8534
0µg/mL vs. 2.5µg/mL 2.5 No ns >0.9999
0µg/mL vs. 5µg/mL 3.5 No ns >0.9999
0µg/mL vs. 20µg/mL 3 No ns >0.9999
0µg/mL vs. Pass. control 14.67 No ns 0.0795
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0µg/mL vs. 1µg/mL 23.83 15.5 8.333 6 6
0µg/mL vs. 2.5µg/mL 23.83 21.33 2.5 6 6
0µg/mL vs. 5µg/mL 23.83 20.33 3.5 6 6
0µg/mL vs. 20µg/mL 23.83 20.83 3 6 6
0µg/mL vs. Pass. control 23.83 9.167 14.67 6 6
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Toxicity Comparison of the concentrations of different applied thiolated
HA in solution
Table E.5.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0620
Exact or approximate P value? Approximate
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 6
Kruskal-Wallis statistic 10.51
Number of treatments (columns) 6
Number of values (total) 36
Dunn’s comparisons Mean rank diff. Significant Summary Padj
0µg/mL vs. 1µg/mL 2.833 No ns >0.9999
0µg/mL vs. 2.5µg/mL -2.833 No ns >0.9999
0µg/mL vs. 5µg/mL -0.8333 No ns >0.9999
0µg/mL vs. 20µg/mL 0.3333 No ns >0.9999
0µg/mL vs. Pass. control 14.5 No ns 0.0857
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0µg/mL vs. 1µg/mL 20.83 18 2.833 6 6
0µg/mL vs. 2.5µg/mL 20.83 23.67 -2.833 6 6
0µg/mL vs. 5µg/mL 20.83 21.67 -0.8333 6 6
0µg/mL vs. 20µg/mL 20.83 20.5 0.3333 6 6
0µg/mL vs. Pass. control 20.83 6.333 14.5 6 6
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Toxicity Comparison of different concentrations of immobilised HA
Table E.6.: Kruskal-Wallis-Test with Dunn’s multiple comparison test
P value <0.0001
Exact or approximate P value? Approximate
P value summary ∗ ∗ ∗∗
Do the medians vary signif. (P < 0.05)? Yes
Number of groups 7
Kruskal-Wallis statistic 28.29
Number of treatments (columns) 7
Number of values (total) 77
Dunn’s comparisons Mean rank diff. Significant Summary Padj
0 nm vs. 20 nm 17.2 No ns 0.4353
0 nm vs. 50 nm -4.667 No ns >0.9999
0 nm vs. 100 nm 0.1667 No ns >0.9999
0 nm vs. 150 nm 15.64 No ns 0.5642
0 nm vs. 190 nm 5.583 No ns >0.9999
0 nm vs. Pass. control 42 Yes ∗ ∗ ∗ 0.0002
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 nm vs. 20 nm 48 30.8 17.2 12 10
0 nm vs. 50 nm 48 52.67 -4.667 12 12
0 nm vs. 100 nm 48 47.83 0.1667 12 12
0 nm vs. 150 nm 48 32.36 15.64 12 11
0 nm vs. 190 nm 48 42.42 5.583 12 12
0 nm vs. Pass. control 48 6 42 12 8
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E.1. Statistical Analysis of Samples with short HA in
Solution on Cell Culture Plastic
CyQuant® Assay for digested HA
Table E.7.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.5718
Exact or approximate P value? Exact
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 5
Kruskal-Wallis statistic 3.233
Number of treatments (columns) 5
Number of values (total) 15
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1 -0.6667 No ns
0 vs. 2.5 4.333 No ns
0 vs. 5 1.333 No ns
0 vs. 20 -1.667 No ns
1 vs. 2.5 5 No ns
1 vs. 5 2 No ns
1 vs. 20 -1 No ns
2.5 vs. 5 -3 No ns
2.5 vs. 20 -6 No ns
5 vs. 20 -3 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1 8.667 9.333 -0.6667 3 3
0 vs. 2.5 8.667 4.333 4.333 3 3
0 vs. 5 8.667 7.333 1.333 3 3
0 vs. 20 8.667 10.33 -1.667 3 3
1 vs. 2.5 9.333 4.333 5 3 3
1 vs. 5 9.333 7.333 2 3 3
1 vs. 20 9.333 10.33 -1 3 3
2.5 vs. 5 4.333 7.333 -3 3 3
2.5 vs. 20 4.333 10.33 -6 3 3
5 vs. 20 7.333 10.33 -3 3 3
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CyQuant® Assay for short HA
Table E.8.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.6441
Exact or approximate P value? Approximate
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 5
Kruskal-Wallis statistic 2.503
Number of treatments (columns) 5
Number of values (total) 34
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1 8.143 No ns
0 vs. 2.5 5.571 No ns
0 vs. 5 5.357 No ns
0 vs. 20 2.786 No ns
1 vs. 2.5 -2.571 No ns
1 vs. 5 -2.786 No ns
1 vs. 20 -5.357 No ns
2.5 vs. 5 -0.2143 No ns
2.5 vs. 20 -2.786 No ns
5 vs. 20 -2.571 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1 22 13.86 8.143 6 7
0 vs. 2.5 22 16.43 5.571 6 7
0 vs. 5 22 16.64 5.357 6 7
0 vs. 20 22 19.21 2.786 6 7
1 vs. 2.5 13.86 16.43 -2.571 7 7
1 vs. 5 13.86 16.64 -2.786 7 7
1 vs. 20 13.86 19.21 -5.357 7 7
2.5 vs. 5 16.43 16.64 -0.2143 7 7
2.5 vs. 20 16.43 19.21 -2.786 7 7
5 vs. 20 16.64 19.21 -2.571 7 7
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AlamarBlue® Assay for digested HA
Table E.9.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0368
Exact or approximate P value? Exact
P value summary ∗
Do the medians vary signif. (P < 0.05)? Yes
Number of groups 5
Kruskal-Wallis statistic 8.733
Number of treatments (columns) 5
Number of values (total) 15
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1 7 No ns
0 vs. 2.5 7.333 No ns
0 vs. 5 10 No ns
0 vs. 20 4 No ns
1 vs. 2.5 0.3333 No ns
1 vs. 5 3 No ns
1 vs. 20 -3 No ns
2.5 vs. 5 2.667 No ns
2.5 vs. 20 -3.333 No ns
5 vs. 20 -6 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1 13.67 6.667 7 3 3
0 vs. 2.5 13.67 6.333 7.333 3 3
0 vs. 5 13.67 3.667 10 3 3
0 vs. 20 13.67 9.667 4 3 3
1 vs. 2.5 6.667 6.333 0.3333 3 3
1 vs. 5 6.667 3.667 3 3 3
1 vs. 20 6.667 9.667 -3 3 3
2.5 vs. 5 6.333 3.667 2.667 3 3
2.5 vs. 20 6.333 9.667 -3.333 3 3
5 vs. 20 3.667 9.667 -6 3 3
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AlamarBlue® Assay for short HA
Table E.10.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.7760
Exact or approximate P value? Approximate
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 5
Kruskal-Wallis statistic 1.781
Number of treatments (columns) 5
Number of values (total) 34
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1 5.667 No ns
0 vs. 2.5 3.524 No ns
0 vs. 5 1.81 No ns
0 vs. 20 -0.4762 No ns
1 vs. 2.5 -2.143 No ns
1 vs. 5 -3.857 No ns
1 vs. 20 -6.143 No ns
2.5 vs. 5 -1.714 No ns
2.5 vs. 20 -4 No ns
5 vs. 20 -2.286 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1 19.67 14 5.667 6 7
0 vs. 2.5 19.67 16.14 3.524 6 7
0 vs. 5 19.67 17.86 1.81 6 7
0 vs. 20 19.67 20.14 -0.4762 6 7
1 vs. 2.5 14 16.14 -2.143 7 7
1 vs. 5 14 17.86 -3.857 7 7
1 vs. 20 14 20.14 -6.143 7 7
2.5 vs. 5 16.14 17.86/-1.714 7 7
2.5 vs. 20 16.14 20.14 -4 7 7
5 vs. 20 17.86 20.14 -2.286 7 7
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Comparison of the results for the AlamarBlue® assay for digested
and short HA
Table E.11.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0773
Exact or approximate P value? Approximate
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 9
Kruskal-Wallis statistic 14.18
Number of treatments (columns) 9
Number of values (total) 49
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Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1.0 18.78 No ns
0 vs. 2.5 17.44 No ns
0 vs. 5.0 22.44 No ns
0 vs. 20.0 9.611 No ns
0 vs. 1_2 21.18 No ns
0 vs. 2.5_2 15.83 No ns
0 vs. 5_2 13.25 No ns
0 vs. 20_2 5.254 No ns
1.0 vs. 2.5 -1.333 No ns
1.0 vs. 5.0 3.667 No ns
1.0 vs. 20.0 -9.167 No ns
1.0 vs. 1_2 2.405 No ns
1.0 vs. 2.5_2 -2.952 No ns
1.0 vs. 5_2 -5.524 No ns
1.0 vs. 20_2 -13.52 No ns
2.5 vs. 5.0 5 No ns
2.5 vs. 20.0 -7.833 No ns
2.5 vs. 1_2 3.738 No ns
2.5 vs. 2.5_2 -1.619 No ns
2.5 vs. 5_2 -4.19 No ns
2.5 vs. 20_2 -12.19 No ns
5.0 vs. 20.0 -12.83 No ns
5.0 vs. 1_2 -1.262 No ns
5.0 vs. 2.5_2 -6.619 No ns
5.0 vs. 5_2 -9.19 No ns
5.0 vs. 20_2 -17.19 No ns
20.0 vs. 1_2 11.57 No ns
20.0 vs. 2.5_2 6.214 No ns
20.0 vs. 5_2 3.643 No ns
20.0 vs. 20_2 -4.357 No ns
1_2 vs. 2.5_2 -5.357 No ns
1_2 vs. 5_2 -7.929 No ns
1_2 vs. 20_2 -15.93 No ns
2.5_2 vs. 5_2 -2.571 No ns
2.5_2 vs. 20_2 -10.57 No ns
5_2 vs. 20_2 -8 No ns
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Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1.0 37.11 18.33 18.78 9 3
0 vs. 2.5 37.11 19.67 17.44 9 3
0 vs. 5.0 37.11 14.67 22.44 9 3
0 vs. 20.0 37.11 27.5 9.611 9 3
0 vs. 1_2 37.11 15.93 21.18 9 7
0 vs. 2.5_2 37.11 21.29 15.83 9 7
0 vs. 5_2 37.11 23.86 13.25 9 7
0 vs. 20_2 37.11 31.86 5.254 9 7
1.0 vs. 2.5 18.33 19.67 -1.333 3 3
1.0 vs. 5.0 18.33 14.67 3.667 3 3
1.0 vs. 20.0 18.33 27.5 -9.167 3 3
1.0 vs. 1_2 18.33 15.93 2.405 3 7
1.0 vs. 2.5_2 18.33 21.29 -2.952 3 7
1.0 vs. 5_2 18.33 23.86 -5.524 3 7
1.0 vs. 20_2 18.33 31.86 -13.52 3 7
2.5 vs. 5.0 19.67 14.67 5 3 3
2.5 vs. 20.0 19.67 27.5 -7.833 3 3
2.5 vs. 1_2 19.67 15.93 3.738 3 7
2.5 vs. 2.5_2 19.67 21.29 -1.619 3 7
2.5 vs. 5_2 19.67 23.86 -4.19 3 7
2.5 vs. 20_2 19.67 31.86 -12.19 3 7
5.0 vs. 20.0 14.67 27.5 -12.83 3 3
5.0 vs. 1_2 14.67 15.93 -1.262 3 7
5.0 vs. 2.5_2 14.67 21.29 -6.619 3 7
5.0 vs. 5_2 14.67 23.86 -9.19 3 7
5.0 vs. 20_2 14.67 31.86 -17.19 3 7
20.0 vs. 1_2 27.5 15.93 11.57 3 7
20.0 vs. 2.5_2 27.5 21.29 6.214 3 7
20.0 vs. 5_2 27.5 23.86 3.643 3 7
20.0 vs. 20_2 27.5 31.86 -4.357 3 7
1_2 vs. 2.5_2 15.93 21.29 -5.357 7 7
1_2 vs. 5_2 15.93 23.86 -7.929 7 7
1_2 vs. 20_2 15.93 31.86 -15.93 7 7
2.5_2 vs. 5_2 21.29 23.86 -2.571 7 7
2.5_2 vs. 20_2 21.29 31.86 -10.57 7 7
5_2 vs. 20_2 23.86 31.86 -8 7 7
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Results for relative metabolic activity digested HA
Table E.12.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.5493
Exact or approximate P value? Exact
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 5
Kruskal-Wallis statistic 3.345
Number of treatments (columns) 5
Number of values (total) 15
Dunn’s comparisons Mean rank diff. Significant Summary P
0 vs. 1.0 5 No ns >0.9999
0 vs. 2.5 0 No ns >0.9999
0 vs. 5.0 4.167 No ns >0.9999
0 vs. 20.0 3.333 No ns >0.9999
1.0 vs. 2.5 -5 No ns >0.9999
1.0 vs. 5.0 -0.8333 No ns >0.9999
1.0 vs. 20.0 -1.667 No ns >0.9999
2.5 vs. 5.0 4.167 No ns >0.9999
2.5 vs. 20.0 3.333 No ns >0.9999
5.0 vs. 20.0 -0.8333 No ns >0.9999
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1.0 10.5 5.5 5 3 3
0 vs. 2.5 10.5 10.5 0 3 3
0 vs. 5.0 10.5 6.333 4.167 3 3
0 vs. 20.0 10.5 7.167 3.333 3 3
1.0 vs. 2.5 5.5 10.5 -5 3 3
1.0 vs. 5.0 5.5 6.333 -0.8333 3 3
1.0 vs. 20.0 5.5 7.167 -1.667 3 3
2.5 vs. 5.0 10.5 6.333 4.167 3 3
2.5 vs. 20.0 10.5 7.167 3.333 3 3
5.0 vs. 20.0 6.333 7.167 -0.8333 3 3
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Results for relative metabolic activity short HA
Table E.13.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.8102
Exact or approximate P value? Approximate
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 5
Kruskal-Wallis statistic 1.592
Number of treatments (columns) 5
Number of values (total) 34
Dunn’s comparisons Mean rank diff. Significant Summary P
0 vs. 1.0 -5.69 No ns >0.9999
0 vs. 2.5 -5.69 No ns >0.9999
0 vs. 5.0 -2.69 No ns >0.9999
0 vs. 20.0 -2.119 No ns >0.9999
1.0 vs. 2.5 0 No ns >0.9999
1.0 vs. 5.0 3 No ns >0.9999
1.0 vs. 20.0 3.571 No ns >0.9999
2.5 vs. 5.0 3 No ns >0.9999
2.5 vs. 20.0 3.571 No ns >0.9999
5.0 vs. 20.0 0.5714 No ns >0.9999
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1.0 14.17 19.86 -5.69 6 7
0 vs. 2.5 14.17 19.86 -5.69 6 7
0 vs. 5.0 14.17 16.86 -2.69 6 7
0 vs. 20.0 14.17 16.29 -2.119 6 7
1.0 vs. 2.5 19.86 19.86 0 7 7
1.0 vs. 5.0 19.86 16.86 3 7 7
1.0 vs. 20.0 19.86 16.29 3.571 7 7
2.5 vs. 5.0 19.86 16.86 3 7 7
2.5 vs. 20.0 19.86 16.29 3.571 7 7
5.0 vs. 20.0 16.86 16.29 0.5714 7 7
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Results for relative metabolic activity for digested HA
Table E.14.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.5493
Exact or approximate P value? Exact
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 5
Kruskal-Wallis statistic 3.345
Number of treatments (columns) 5
Number of values (total) 15
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1.0 5 No ns
0 vs. 2.5 0 No ns
0 vs. 5.0 4.167 No ns
0 vs. 20.0 3.333 No ns
1.0 vs. 2.5 -5 No ns
1.0 vs. 5.0 -0.8333 No ns
1.0 vs. 20.0 -1.667 No ns
2.5 vs. 5.0 4.167 No ns
2.5 vs. 20.0 3.333 No ns
5.0 vs. 20.0 -0.8333 No ns
Test details Mean rank 2 Mean rank diff. n1 n2
0 vs. 1.0 5.5 5 3 3
0 vs. 2.5 10.5 06 3 3
0 vs. 5.0 6.333 4.167 3 3
0 vs. 20.0 7.167 3.333 3 3
1.0 vs. 2.5 10.5 -5 3 3
1.0 vs. 5.0 6.333 -0.8333 3 3
1.0 vs. 20.0 7.167 -1.667 3 3
2.5 vs. 5.0 6.333 4.167 3 3
2.5 vs. 20.0 7.167 3.333 3 3
5.0 vs. 20.0 7.167 -0.8333 3 3
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Results for the relative metabolic activity for short HA
Table E.15.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.8102
Exact or approximate P value? Approximate
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 5
Kruskal-Wallis statistic 1.592
Number of treatments (columns) 5
Number of values (total) 34
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1.0 -5.69 No ns
0 vs. 2.5 -5.69 No ns
0 vs. 5.0 -2.69 No ns
0 vs. 20.0 -2.119 No ns
1.0 vs. 2.5 0 No ns
1.0 vs. 5.0 3 No ns
1.0 vs. 20.0 3.571 No ns
2.5 vs. 5.0 3 No ns
2.5 vs. 20.0 3.571 No ns
5.0 vs. 20.0 0.5714 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1.0 14.17 19.86 -5.69 6 7
0 vs. 2.5 14.17 19.86 -5.69 6 7
0 vs. 5.0 14.17 16.86 -2.69 6 7
0 vs. 20.0 14.17 16.29 -2.119 6 7
1.0 vs. 2.5 19.86 19.86 0 7 7
1.0 vs. 5.0 19.86 16.86 3 7 7
1.0 vs. 20.0 19.86 16.29 3.571 7 7
2.5 vs. 5.0 19.86 16.86 3 7 7
2.5 vs. 20.0 19.86 16.29 3.571 7 7
5.0 vs. 20.0 19.86 16.29 0.5714 7 7
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Results for relative metabolic activity
Table E.16.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.8754
Exact or approximate P value? Approximate
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 5
Kruskal-Wallis statistic 1.217
Number of treatments (columns) 5
Number of values (total) 49
Dunn’s comparisons Mean rank diff. Significant Summary P
0 vs. 1.0 -0.1333 No ns >0.9999
0 vs. 2.5 -4.483 No ns >0.9999
0 vs. 5.0 0.8667 No ns >0.9999
0 vs. 20.0 2.117 No ns >0.9999
1.0 vs. 2.5 -4.35 No ns >0.9999
1.0 vs. 5.0 1 No ns >0.9999
1.0 vs. 20.0 2.25 No ns >0.9999
2.5 vs. 5.0 5.35 No ns >0.9999
2.5 vs. 20.0 6.6 No ns >0.9999
5.0 vs. 20.0 1.25 No ns >0.9999
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1.0 24.67 24.8 -0.1333 9 10
0 vs. 2.5 24.67 29.15 -4.483 9 10
0 vs. 5.0 24.67 23.8 0.8667 9 10
0 vs. 20.0 24.67 22.55 2.117 9 10
1.0 vs. 2.5 24.8 29.15 -4.35 10 10
1.0 vs. 5.0 24.8 23.8 1 10 10
1.0 vs. 20.0 24.8 22.55 2.25 10 10
2.5 vs. 5.0 29.15 23.8 5.35 10 10
2.5 vs. 20.0 29.15 22.55 6.6 10 10
5.0 vs. 20.0 23.8 22.55 1.25 10 10
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Results for relative metabolic activity for the controls
Table E.17.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.1243
Exact or approximate P value? Approximate
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 4
Kruskal-Wallis statistic 5.752
Number of treatments (columns) 4
Number of values (total) 33
Dunn’s comparisons Mean rank diff. Significant Summary
A vs. B -0.75 No ns
A vs. C -9.951 No ns
A vs. D -2.75 No ns
B vs. C -9.201 No ns
B vs. D -2 No ns
C vs. D 7.201 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
A vs. B 13.44 14.19 -0.75 8 8
A vs. C 13.44 23.39 -9.951 8 9
A vs. D 13.44 16.19 -2.75 8 8
B vs. C 14.19 23.39 -9.201 8 9
B vs. D 14.19 16.19 -2 8 8
C vs. D 23.39 16.19 7.201 9 8
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E.2. Statistical Analysis of Samples with short HA in
Solution in Presence of cRGD
CyQuant® Assay for digested, unfunctionalised HA
Table E.18.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.4598
Exact or approximate P value? Exact
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 5
Kruskal-Wallis statistic 3.919
Number of treatments (columns) 5
Number of values (total) 15
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1.0 -0.1667 No ns
0 vs. 2.5 0.1667 No ns
0 vs. 5.0 -1.667 No ns
0 vs. 20.0 5 No ns
1.0 vs. 2.5 0.3333 No ns
1.0 vs. 5.0 -1.5 No ns
1.0 vs. 20.0 5.167 No ns
2.5 vs. 5.0 -1.833 No ns
2.5 vs. 20.0 4.833 No ns
5.0 vs. 20.0 6.667 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1.0 8.667 8.833 -0.1667 3 3
0 vs. 2.5 8.667 8.5 0.1667 3 3
0 vs. 5.0 8.667 10.33 -1.667 3 3
0 vs. 20.0 8.667 3.667 5 3 3
1.0 vs. 2.5 8.833 8.5 0.3333 3 3
1.0 vs. 5.0 8.833 10.33 -1.5 3 3
1.0 vs. 20.0 8.833 3.667 5.167 3 3
2.5 vs. 5.0 8.5 10.33 -1.833 3 3
2.5 vs. 20.0 8.5 3.667 4.833 3 3
5.0 vs. 20.0 10.33 3.667 6.667 3 3
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CyQuant® Assay for short, unfunctionalised HA
Table E.19.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0828
Exact or approximate P value? Approximate
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 5
Kruskal-Wallis statistic 8.25
Number of treatments (columns) 5
Number of values (total) 32
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1.0 3.257 No ns
0 vs. 2.5 7.043 No ns
0 vs. 5.0 -6.433 No ns
0 vs. 20.0 -2.957 No ns
1.0 vs. 2.5 3.786 No ns
1.0 vs. 5.0 -9.69 No ns
1.0 vs. 20.0 -6.214 No ns
2.5 vs. 5.0 -13.48 No ns
2.5 vs. 20.0 -10 No ns
5.0 vs. 20.0 3.476 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1.0 16.9 13.64 3.257 5 7
0 vs. 2.5 16.9 9.857 7.043 5 7
0 vs. 5.0 16.9 23.33 -6.433 5 6
0 vs. 20.0 16.9 19.86 -2.957 5 7
1.0 vs. 2.5 13.64 9.857 3.786 7 7
1.0 vs. 5.0 13.64 23.33 -9.69 7 6
1.0 vs. 20.0 13.64 19.86 -6.214 7 7
2.5 vs. 5.0 9.857 23.33 -13.48 7 6
2.5 vs. 20.0 9.857 19.86 -10 7 7
5.0 vs. 20.0 23.33 19.86 3.476 6 7
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CyQuant® Assay for digested, end-thiolated HA
Table E.20.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.4275
Exact or approximate P value? Exact
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 5
Kruskal-Wallis statistic 4.136
Number of treatments (columns) 5
Number of values (total) 15
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1.0 -2.5 No ns
0 vs. 2.5 -0.6667 No ns
0 vs. 5.0 2.333 No ns
0 vs. 20.0 4.167 No ns
1.0 vs. 2.5 1.833 No ns
1.0 vs. 5.0 4.833 No ns
1.0 vs. 20.0 6.667 No ns
2.5 vs. 5.0 3 No ns
2.5 vs. 20.0 4.833 No ns
5.0 vs. 20.0 1.833 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1.0 8.667 11.17 -2.5 3 3
0 vs. 2.5 8.667 9.333 -0.6667 3 3
0 vs. 5.0 8.667 6.333 2.333 3 3
0 vs. 20.0 8.667 4.5 4.167 3 3
1.0 vs. 2.5 11.17 9.333 1.833 3 3
1.0 vs. 5.0 11.17 6.333 4.833 3 3
1.0 vs. 20.0 11.17 4.5 6.667 3 3
2.5 vs. 5.0 9.333 6.333 3 3 3
2.5 vs. 20.0 9.333 4.5 4.833 3 3
5.0 vs. 20.0 6.333 4.5 1.833 3 3
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CyQuant® Assay for short, end-thiolated HA
Table E.21.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.6272
Exact or approximate P value? Exact
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 4
Kruskal-Wallis statistic 2.026
Number of treatments (columns) 4
Number of values (total) 12
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1.0 3 No ns
0 vs. 2.5 1 No ns
0 vs. 5.0 3.333 No ns
1.0 vs. 2.5 -2 No ns
1.0 vs. 5.0 0.3333 No ns
2.5 vs. 5.0 2.333 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1.0 8 5 3 5 2
0 vs. 2.5 8 7 1 5 2
0 vs. 5.0 8 4.667 3.333 5 3
1.0 vs. 2.5 5 7 -2 2 2
1.0 vs. 5.0 5 4.667 0.3333 2 3
2.5 vs. 5.0 7 4.667 2.333 2 3
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AlamarBlue® Assay for digested, unfunctionalised HA
Table E.22.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.2128
Exact or approximate P value? Exact
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 5
Kruskal-Wallis statistic 5.864
Number of treatments (columns) 5
Number of values (total) 14
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1.0 3.333 No ns
0 vs. 2.5 7.333 No ns
0 vs. 5.0 4.833 No ns
0 vs. 20.0 1.167 No ns
1.0 vs. 2.5 4 No ns
1.0 vs. 5.0 1.5 No ns
1.0 vs. 20.0 -2.167 No ns
2.5 vs. 5.0 -2.5 No ns
2.5 vs. 20.0 -6.167 No ns
5.0 vs. 20.0 -3.667 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1.0 10.83 7.5 3.333 3 2
0 vs. 2.5 10.83 3.5 7.333 3 3
0 vs. 5.0 10.83 6 4.833 3 3
0 vs. 20.0 10.83 9.667 1.167 3 3
1.0 vs. 2.5 7.5 3.5 4 2 3
1.0 vs. 5.0 7.5 6 1.5 2 3
1.0 vs. 20.0 7.5 9.667 -2.167 2 3
2.5 vs. 5.0 3.5 6 -2.5 3 3
2.5 vs. 20.0 3.5 9.667 -6.167 3 3
5.0 vs. 20.0 6 9.667 -3.667 3 3
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AlamarBlue® Assay for short, unfunctionalised HA
Table E.23.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.1959
Exact or approximate P value? Approximate
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 5
Kruskal-Wallis statistic 6.043
Number of treatments (columns) 5
Number of values (total) 31
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1.0 7.524 No ns
0 vs. 2.5 11.58 No ns
0 vs. 5.0 3.75 No ns
0 vs. 20.0 2.583 No ns
1.0 vs. 2.5 4.06 No ns
1.0 vs. 5.0 -3.774 No ns
1.0 vs. 20.0 -4.94 No ns
2.5 vs. 5.0 -7.833 No ns
2.5 vs. 20.0 -9 No ns
5.0 vs. 20.0 -1.167 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1.0 21.17 13.64 7.524 6 7
0 vs. 2.5 21.17 9.583 11.58 6 6
0 vs. 5.0 21.17 17.42 3.75 6 6
0 vs. 20.0 21.17 18.58 2.583 6 6
1.0 vs. 2.5 13.64 9.583 4.06 7 6
1.0 vs. 5.0 13.64 17.42 -3.774 7 6
1.0 vs. 20.0 13.64 18.58 -4.94 7 6
2.5 vs. 5.0 9.583 17.42 -7.833 6 6
2.5 vs. 20.0 9.583 18.58 -9 6 6
5.0 vs. 20.0 17.42 18.58 -1.167 6 6
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AlamarBlue® Assay for digested, end-thiolated HA
Table E.24.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.1411
Exact or approximate P value? Exact
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 5
Kruskal-Wallis statistic 6.653
Number of treatments (columns) 5
Number of values (total) 14
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1.0 4.833 No ns
0 vs. 2.5 0 No ns
0 vs. 5.0 -4 No ns
0 vs. 20.0 -2.167 No ns
1.0 vs. 2.5 -4.833 No ns
1.0 vs. 5.0 -8.833 No ns
1.0 vs. 20.0 -7 No ns
2.5 vs. 5.0 -4 No ns
2.5 vs. 20.0 -2.167 No ns
5.0 vs. 20.0 1.833 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1.0 7.5 2.667 4.833 3 3
0 vs. 2.5 7.5 7.5 0 3 3
0 vs. 5.0 7.5 11.5 -4 3 2
0 vs. 20.0 7.5 9.667 -2.167 3 3
1.0 vs. 2.5 2.667 7.5 -4.833 3 3
1.0 vs. 5.0 2.667 11.5 -8.833 3 2
1.0 vs. 20.0 2.667 9.667 -7 3 3
2.5 vs. 5.0 7.5 11.5 -4 3 2
2.5 vs. 20.0 7.5 9.667 -2.167 3 3
5.0 vs. 20.0 11.5 9.667 1.833 2 3
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AlamarBlue® Assay for short, end-thiolated HA
Table E.25.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.1442
Exact or approximate P value? Exact
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 5
Kruskal-Wallis statistic 6.541
Number of treatments (columns) 5
Number of values (total) 13
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1.0 3.833 No ns
0 vs. 2.5 2.667 No ns
0 vs. 5.0 -2 No ns
0 vs. 20.0 -3.5 No ns
1.0 vs. 2.5 -1.167 No ns
1.0 vs. 5.0 -5.833 No ns
1.0 vs. 20.0 -7.333 No ns
2.5 vs. 5.0 -4.667 No ns
2.5 vs. 20.0 -6.167 No ns
5.0 vs. 20.0 -1.5 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1.0 7.5 3.667 3.833 2 3
0 vs. 2.5 7.5 4.833 2.667 2 3
0 vs. 5.0 7.5 9.5 -2 2 3
0 vs. 20.0 7.5 11 -3.5 2 2
1.0 vs. 2.5 3.667 4.833 -1.167 3 3
1.0 vs. 5.0 3.667 9.5 -5.833 3 3
1.0 vs. 20.0 3.667 11 -7.333 3 2
2.5 vs. 5.0 4.833 9.5 -4.667 3 3
2.5 vs. 20.0 4.833 11 -6.167 3 2
5.0 vs. 20.0 9.5 11 -1.5 3 2
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Comparison of different applied unfunctionalised HA species in solution
Table E.26.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.2887
Exact or approximate P value? Approximate
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 10
Kruskal-Wallis statistic 10.81
Number of treatments (columns) 10
Number of values (total) 45
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Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1 9.333 No ns
0 vs. 2.5 18.83 No ns
0 vs. 5 10.83 No ns
0 vs. 20 2.167 No ns
0 vs. 0_2 -0.4167 No ns
0 vs. 1_2 11.4 No ns
0 vs. 2.5_2 17.5 No ns
0 vs. 5_2 5.417 No ns
0 vs. 20_2 3.917 No ns
1 vs. 2.5 9.5 No ns
1 vs. 5 1.5 No ns
1 vs. 20 -7.167 No ns
1 vs. 0_2 -9.75 No ns
1 vs. 1_2 2.071 No ns
1 vs. 2.5_2 8.167 No ns
1 vs. 5_2 -3.917 No ns
1 vs. 20_2 -5.417 No ns
2.5 vs. 5 -8 No ns
2.5 vs. 20 -16.67 No ns
2.5 vs. 0_2 -19.25 No ns
2.5 vs. 1_2 -7.429 No ns
2.5 vs. 2.5_2 -1.333 No ns
2.5 vs. 5_2 -13.42 No ns
2.5 vs. 20_2 -14.92 No ns
5 vs. 20 -8.667 No ns
5 vs. 0_2 -11.25 No ns
5 vs. 1_2 0.5714 No ns
5 vs. 2.5_2 6.667 No ns
5 vs. 5_2 -5.417 No ns
5 vs. 20_2 -6.917 No ns
20 vs. 0_2 -2.583 No ns
20 vs. 1_2 9.238 No ns
20 vs. 2.5_2 15.33 No ns
20 vs. 5_2 3.25 No ns
20 vs. 20_2 1.75 No ns
0_2 vs. 1_2 11.82 No ns
0_2 vs. 2.5_2 17.92 No ns
0_2 vs. 5_2 5.833 No ns
0_2 vs. 20_2 4.333 No ns
1_2 vs. 2.5_2 6.095 No ns
1_2 vs. 5_2 -5.988 No ns
1_2 vs. 20_2 -7.488 No ns
2.5_2 vs. 5_2 -12.08 No ns
2.5_2 vs. 20_2 -13.58 No ns
5_2 vs. 20_2 -1.5 No ns
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Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1 30.83 21.5 9.333 3 2
0 vs. 2.5 30.83 12 18.83 3 3
0 vs. 5 30.83 20 10.83 3 3
0 vs. 20 30.83 28.67 2.167 3 3
0 vs. 0_2 30.83 31.25 -0.4167 3 6
0 vs. 1_2 30.83 19.43 11.4 3 7
0 vs. 2.5_2 30.83 13.33 17.5 3 6
0 vs. 5_2 30.83 25.42 5.417 3 6
0 vs. 20_2 30.83 26.92 3.917 3 6
1 vs. 2.5 21.5 12 9.5 2 3
1 vs. 5 21.5 20 1.5 2 3
1 vs. 20 21.5 28.67 -7.167 2 3
1 vs. 0_2 21.5 31.25 -9.75 2 6
1 vs. 1_2 21.5 19.43 2.071 2 7
1 vs. 2.5_2 21.5 13.33 8.167 2 6
1 vs. 5_2 21.5 25.42 -3.917 2 6
1 vs. 20_2 21.5 26.92 -5.417 2 6
2.5 vs. 5 12 20 -8 3 3
2.5 vs. 20 12 28.67 -16.67 3 3
2.5 vs. 0_2 12 31.25 -19.25 3 6
2.5 vs. 1_2 12 19.43 -7.429 3 7
2.5 vs. 2.5_2 12 13.33 -1.333 3 6
2.5 vs. 5_2 12 25.42 -13.42 3 6
2.5 vs. 20_2 12 26.92 -14.92 3 6
5 vs. 20 20 28.67 -8.667 3 3
5 vs. 0_2 20 31.25 -11.25 3 6
5 vs. 1_2 20 19.43 0.5714 3 7
5 vs. 2.5_2 20 13.33 6.667 3 6
5 vs. 5_2 20 25.42 -5.417 3 6
5 vs. 20_2 20 26.92 -6.917 3 6
20 vs. 0_2 28.67 31.25 -2.583 3 6
20 vs. 1_2 28.67 19.43 9.238 3 7
20 vs. 2.5_2 28.67 13.33 15.33 3 6
20 vs. 5_2 28.67 25.42 3.25 3 6
20 vs. 20_2 28.67 26.92 1.75 3 6
0_2 vs. 1_2 31.25 19.43 11.82 6 7
0_2 vs. 2.5_2 31.25 13.33 17.92 6 6
0_2 vs. 5_2 31.25 25.42 5.833 6 6
0_2 vs. 20_2 31.25 26.92 4.333 6 6
1_2 vs. 2.5_2 19.43 13.33 6.095 7 6
1_2 vs. 5_2 19.43 25.42 -5.988 7 6
1_2 vs. 20_2 19.43 26.92 -7.488 7 6
2.5_2 vs. 5_2 13.33 25.42 -12.08 6 6
2.5_2 vs. 20_2 13.33 26.92 -13.58 6 6
5_2 vs. 20_2 25.42 26.92 -1.5 6 6
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Comparison of different applied thiolated HA species in solution
Table E.27.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.1023
Exact or approximate P value? Approximate
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 10
Kruskal-Wallis statistic 14.61
Number of treatments (columns) 10
Number of values (total) 27
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Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1 10.17 No ns
0 vs. 2.5 -0.1667 No ns
0 vs. 5 -7.083 No ns
0 vs. 20 -3.333 No ns
0 vs. 0_2 -0.8333 No ns
0 vs. 1_2 7 No ns
0 vs. 2.5_2 4.833 No ns
0 vs. 5_2 -6 No ns
0 vs. 20_2 -8.583 No ns
1 vs. 2.5 -10.33 No ns
1 vs. 5 -17.25 No ns
1 vs. 20 -13.5 No ns
1 vs. 0_2 -11 No ns
1 vs. 1_2 -3.167 No ns
1 vs. 2.5_2 -5.333 No ns
1 vs. 5_2 -16.17 No ns
1 vs. 20_2 -18.75 No ns
2.5 vs. 5 -6.917 No ns
2.5 vs. 20 -3.167 No ns
2.5 vs. 0_2 -0.6667 No ns
2.5 vs. 1_2 7.167 No ns
2.5 vs. 2.5_2 5 No ns
2.5 vs. 5_2 -5.833 No ns
2.5 vs. 20_2 -8.417 No ns
5 vs. 20 3.75 No ns
5 vs. 0_2 6.25 No ns
5 vs. 1_2 14.08 No ns
5 vs. 2.5_2 11.92 No ns
5 vs. 5_2 1.083 No ns
5 vs. 20_2 -1.5 No ns
20 vs. 0_2 2.5 No ns
20 vs. 1_2 10.33 No ns
20 vs. 2.5_2 8.167 No ns
20 vs. 5_2 -2.667 No ns
20 vs. 20_2 -5.25 No ns
0_2 vs. 1_2 7.833 No ns
0_2 vs. 2.5_2 5.667 No ns
0_2 vs. 5_2 -5.167 No ns
0_2 vs. 20_2 -7.75 No ns
1_2 vs. 2.5_2 -2.167 No ns
1_2 vs. 5_2 -13 No ns
1_2 vs. 20_2 -15.58 No ns
2.5_2 vs. 5_2 -10.83 No ns
2.5_2 vs. 20_2 -13.42 No ns
5_2 vs. 20_2 -2.583 No ns
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Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1 14.17 4 10.17 3 3
0 vs. 2.5 14.17 14.33 -0.1667 3 3
0 vs. 5 14.17 21.25 -7.083 3 2
0 vs. 20 14.17 17.5 -3.333 3 3
0 vs. 0_2 14.17 15 -0.8333 3 2
0 vs. 1_2 14.17 7.167 7 3 3
0 vs. 2.5_2 14.17 9.333 4.833 3 3
0 vs. 5_2 14.17 20.17 -6 3 3
0 vs. 20_2 14.17 22.75 -8.583 3 2
1 vs. 2.5 4 14.33 -10.33 3 3
1 vs. 5 4 21.25 -17.25 3 2
1 vs. 20 4 17.5 -13.5 3 3
1 vs. 0_2 4 15 -11 3 2
1 vs. 1_2 4 7.167 -3.167 3 3
1 vs. 2.5_2 4 9.333 -5.333 3 3
1 vs. 5_2 4 20.17 -16.17 3 3
1 vs. 20_2 4 22.75 -18.75 3 2
2.5 vs. 5 14.33 21.25 -6.917 3 2
2.5 vs. 20 14.33 17.5 -3.167 3 3
2.5 vs. 0_2 14.33 15 -0.6667 3 2
2.5 vs. 1_2 14.33 7.167 7.167 3 3
2.5 vs. 2.5_2 14.33 9.333 5 3 3
2.5 vs. 5_2 14.33 20.17 -5.833 3 3
2.5 vs. 20_2 14.33 22.75 -8.417 3 2
5 vs. 20 21.25 17.5 3.75 2 3
5 vs. 0_2 21.25 15 6.25 2 2
5 vs. 1_2 21.25 7.167 14.08 2 3
5 vs. 2.5_2 21.25 9.333 11.92 2 3
5 vs. 5_2 21.25 20.17 1.083 2 3
5 vs. 20_2 21.25 22.75 -1.5 2 2
20 vs. 0_2 17.5 15 2.5 3 2
20 vs. 1_2 17.5 7.167 10.33 3 3
20 vs. 2.5_2 17.5 9.333 8.167 3 3
20 vs. 5_2 17.5 20.17 -2.667 3 3
20 vs. 20_2 17.5 22.75 -5.25 3 2
0_2 vs. 1_2 15 7.167 7.833 2 3
0_2 vs. 2.5_2 15 9.333 5.667 2 3
0_2 vs. 5_2 15 20.17 -5.167 2 3
0_2 vs. 20_2 15 22.75 -7.75 2 2
1_2 vs. 2.5_2 7.167 9.333 -2.167 3 3
1_2 vs. 5_2 7.167 20.17 -13 3 3
1_2 vs. 20_2 7.167 22.75 -15.58 3 2
2.5_2 vs. 5_2 9.333 20.17 -10.83 3 3
2.5_2 vs. 20_2 9.333 22.75 -13.42 3 2
5_2 vs. 20_2 20.17 22.75 -2.583 3 2
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Comparison of unfunctionalised and functionalised HA species in solution
Table E.28.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0054
Exact or approximate P value? Approximate
P value summary ∗∗
Do the medians vary signif. (P < 0.05)? Yes
Number of groups 5
Kruskal-Wallis statistic 14.71
Number of treatments (columns) 5
Number of values (total) 67
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1 19.34 No ns
0 vs. 2.5 18.38 No ns
0 vs. 5 1.992 No ns
0 vs. 20 -0.4008 No ns
1 vs. 2.5 -0.9667 No ns
1 vs. 5 -17.35 No ns
1 vs. 20 -19.75 No ns
2.5 vs. 5 -16.39 No ns
2.5 vs. 20 -18.78 No ns
5 vs. 20 -2.393 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1 42.78 23.43 19.34 9 15
0 vs. 2.5 42.78 24.4 18.38 9 15
0 vs. 5 42.78 40.79 1.992 9 14
0 vs. 20 42.78 43.18 -0.4008 9 14
1 vs. 2.5 23.43 24.4 -0.9667 15 15
1 vs. 5 23.43 40.79 -17.35 15 14
1 vs. 20 23.43 43.18 -19.75 15 14
2.5 vs. 5 24.4 40.79 -16.39 15 14
2.5 vs. 20 24.4 43.18 -18.78 15 14
5 vs. 20 40.79 43.18 -2.393 14 14
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Table E.29.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0042
Exact or approximate P value? Approximate
P value summary ∗∗
Do the medians vary signif. (P < 0.05)? Yes
Number of groups 9
Kruskal-Wallis statistic 22.4
Number of treatments (columns) 9
Number of values (total) 67
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Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1 15.06 No ns
0 vs. 2.5 24.39 No ns
0 vs. 5 8.556 No ns
0 vs. 20 4.5 No ns
0 vs. 1_2 25.78 No ns
0 vs. 2.5_2 9.361 No ns
0 vs. 5_2 -9.822 No ns
0 vs. 20_2 -9.222 No ns
1 vs. 2.5 9.333 No ns
1 vs. 5 -6.5 No ns
1 vs. 20 -10.56 No ns
1 vs. 1_2 10.72 No ns
1 vs. 2.5_2 -5.694 No ns
1 vs. 5_2 -24.88 No ns
1 vs. 20_2 -24.28 No ns
2.5 vs. 5 -15.83 No ns
2.5 vs. 20 -19.89 No ns
2.5 vs. 1_2 1.389 No ns
2.5 vs. 2.5_2 -15.03 No ns
2.5 vs. 5_2 -34.21 No ns
2.5 vs. 20_2 -33.61 No ns
5 vs. 20 -4.056 No ns
5 vs. 1_2 17.22 No ns
5 vs. 2.5_2 0.8056 No ns
5 vs. 5_2 -18.38 No ns
5 vs. 20_2 -17.78 No ns
20 vs. 1_2 21.28 No ns
20 vs. 2.5_2 4.861 No ns
20 vs. 5_2 -14.32 No ns
20 vs. 20_2 -13.72 No ns
1_2 vs. 2.5_2 -16.42 No ns
1_2 vs. 5_2 -35.6 No ns
1_2 vs. 20_2 -35 No ns
2.5_2 vs. 5_2 -19.18 No ns
2.5_2 vs. 20_2 -18.58 No ns
5_2 vs. 20_2 0.6 No ns
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Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1 42.78 27.72 15.06 9 9
0 vs. 2.5 42.78 18.39 24.39 9 9
0 vs. 5 42.78 34.22 8.556 9 9
0 vs. 20 42.78 38.28 4.5 9 9
0 vs. 1_2 42.78 17 25.78 9 6
0 vs. 2.5_2 42.78 33.42 9.361 9 6
0 vs. 5_2 42.78 52.6 -9.822 9 5
0 vs. 20_2 42.78 52 -9.222 9 5
1 vs. 2.5 27.72 18.39 9.333 9 9
1 vs. 5 27.72 34.22 -6.5 9 9
1 vs. 20 27.72 38.28 -10.56 9 9
1 vs. 1_2 27.72 17 10.72 9 6
1 vs. 2.5_2 27.72 33.42 -5.694 9 6
1 vs. 5_2 27.72 52.6 -24.88 9 5
1 vs. 20_2 27.72 52 -24.28 9 5
2.5 vs. 5 18.39 34.22 -15.83 9 9
2.5 vs. 20 18.39 38.28 -19.89 9 9
2.5 vs. 1_2 18.39 17 1.389 9 6
2.5 vs. 2.5_2 18.39 33.42 -15.03 9 6
2.5 vs. 5_2 18.39 52.6 -34.21 9 5
2.5 vs. 20_2 18.39 52 -33.61 9 5
5 vs. 20 34.22 38.28 -4.056 9 9
5 vs. 1_2 34.22 17 17.22 9 6
5 vs. 2.5_2 34.22 33.42 0.8056 9 6
5 vs. 5_2 34.22 52.6 -18.38 9 5
5 vs. 20_2 34.22 52 -17.78 9 5
20 vs. 1_2 38.28 17 21.28 9 6
20 vs. 2.5_2 38.28 33.42 4.861 9 6
20 vs. 5_2 38.28 52.6 -14.32 9 5
20 vs. 20_2 38.28 52 -13.72 9 5
1_2 vs. 2.5_2 17 33.42 -16.42 6 6
1_2 vs. 5_2 17 52.6 -35.6 6 5
1_2 vs. 20_2 17 52 -35 6 5
2.5_2 vs. 5_2 33.42 52.6 -19.18 6 5
2.5_2 vs. 20_2 33.42 52 -18.58 6 5
5_2 vs. 20_2 52.6 52 0.6 5 5
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Results for relative metabolic activity of unfunctionalised HA
Table E.30.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0738
Exact or approximate P value? Approximate
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 5
Kruskal-Wallis statistic 8.537
Number of treatments (columns) 5
Number of values (total) 43
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1.0 2.508 No ns
0 vs. 2.5 -2.992 No ns
0 vs. 5.0 13.17 No ns
0 vs. 20.0 5.397 No ns
1.0 vs. 2.5 -5.5 No ns
1.0 vs. 5.0 10.67 No ns
1.0 vs. 20.0 2.889 No ns
2.5 vs. 5.0 16.17 No ns
2.5 vs. 20.0 8.389 No ns
5.0 vs. 20.0 -7.778 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1.0 25.79 23.28 2.508 7 9
0 vs. 2.5 25.79 28.78 -2.992 7 9
0 vs. 5.0 25.79 12.61 13.17 7 9
0 vs. 20.0 25.79 20.39 5.397 7 9
1.0 vs. 2.5 23.28 28.78 -5.5 9 9
1.0 vs. 5.0 23.28 12.61 10.67 9 9
1.0 vs. 20.0 23.28 20.39 2.889 9 9
2.5 vs. 5.0 28.78 12.61 16.17 9 9
2.5 vs. 20.0 28.78 20.39 8.389 9 9
5.0 vs. 20.0 12.61 20.39 -7.778 9 9
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Results for relative metabolic activity for functionalised HA
Table E.31.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.2392
Exact or approximate P value? Approximate
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 5
Kruskal-Wallis statistic 5.506
Number of treatments (columns) 5
Number of values (total) 25
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 1.0 4.471 No ns
0 vs. 2.5 1.271 No ns
0 vs. 5.0 -4.929 No ns
0 vs. 20.0 -4.929 No ns
1.0 vs. 2.5 -3.2 No ns
1.0 vs. 5.0 -9.4 No ns
1.0 vs. 20.0 -9.4 No ns
2.5 vs. 5.0 -6.2 No ns
2.5 vs. 20.0 -6.2 No ns
5.0 vs. 20.0 0 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1.0 12.57 8.1 4.471 7 5
0 vs. 2.5 12.57 11.3 1.271 7 5
0 vs. 5.0 12.57 17.5 -4.929 7 5
0 vs. 20.0 12.57 17.5 -4.929 7 3
1.0 vs. 2.5 8.1 11.3 -3.2 5 5
1.0 vs. 5.0 8.1 17.5 -9.4 5 5
1.0 vs. 20.0 8.1 17.5 -9.4 5 3
2.5 vs. 5.0 11.3 17.5 -6.2 5 5
2.5 vs. 20.0 11.3 17.5 -6.2 5 3
5.0 vs. 20.0 17.5 17.5 0 5 3
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Results for relative metabolic activity
Table E.32.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.4917
Exact or approximate P value? Approximate
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 5
Kruskal-Wallis statistic 3.41
Number of treatments (columns) 5
Number of values (total) 61
Dunn’s comparisons Mean rank diff. Significant Summary P
0 vs. 1.0 6.321 No ns >0.9999
0 vs. 2.5 -2.571 No ns >0.9999
0 vs. 5.0 8.536 No ns >0.9999
0 vs. 20.0 2.732 No ns >0.9999
1.0 vs. 2.5 -8.893 No ns >0.9999
1.0 vs. 5.0 2.214 No ns >0.9999
1.0 vs. 20.0 -3.589 No ns >0.9999
2.5 vs. 5.0 11.11 No ns 0.9777
2.5 vs. 20.0 5.304 No ns >0.9999
5.0 vs. 20.0 -5.804 No ns >0.9999
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 1.0 34.36 28.04 6.321 7 14
0 vs. 2.5 34.36 36.93 -2.571 7 14
0 vs. 5.0 34.36 25.82 8.536 7 14
0 vs. 20.0 34.36 31.63 2.732 7 12
1.0 vs. 2.5 28.04 36.93 -8.893 14 14
1.0 vs. 5.0 28.04 25.82 2.214 14 14
1.0 vs. 20.0 28.04 31.63 -3.589 14 12
2.5 vs. 5.0 36.93 25.82 11.11 14 14
2.5 vs. 20.0 36.93 31.63 5.304 14 12
5.0 vs. 20.0 25.82 31.63 -5.804 14 12
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,E.3. Statistical Analysis of Samples with Immobilised
HA in the presence of cRGD
CyQuant® assay for immobilised, digested HA
Table E.33.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0141
Exact or approximate P value? Approximate
P value summary ∗
Do the medians vary signif. (P < 0.05)? Yes
Number of groups 6
Kruskal-Wallis statistic 14.25
Number of treatments (columns) 6
Number of values (total) 31
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 2714 14.6 No ns
0 vs. 540 16.7 No ns
0 vs. 123 10.77 No ns
0 vs. 47 7.8 No ns
0 vs. 29 1.3 No ns
2714 vs. 540 2.1 No ns
2714 vs. 123 -3.833 No ns
2714 vs. 47 -6.8 No ns
2714 vs. 29 -13.3 No ns
540 vs. 123 -5.933 No ns
540 vs. 47 -8.9 No ns
540 vs. 29 -15.4 No ns
123 vs. 47 -2.967 No ns
123 vs. 29 -9.467 No ns
47 vs. 29 -6.5 No ns
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Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 2714 24.6 10 14.6 5 5
0 vs. 540 24.6 7.9 16.7 5 5
0 vs. 123 24.6 13.83 10.77 5 6
0 vs. 47 24.6 16.8 7.8 5 5
0 vs. 29 24.6 23.3 1.3 5 5
2714 vs. 540 10 7.9 2.1 5 5
2714 vs. 123 10 13.83 -3.833 5 6
2714 vs. 47 10 16.8 -6.8 5 5
2714 vs. 29 10 23.3 -13.3 5 5
540 vs. 123 7.9 13.83 -5.933 5 6
540 vs. 47 7.9 16.8 -8.9 5 5
540 vs. 29 7.9 23.3 -15.4 5 5
123 vs. 47 13.83 16.8 -2.967 6 5
123 vs. 29 13.83 23.3 -9.467 6 5
47 vs. 29 16.8 23.3 -6.5 5 5
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CyQuant® assay for immobilised, short HA
Table E.34.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0025
Exact or approximate P value? Approximate
P value summary ∗∗
Do the medians vary signif. (P < 0.05)? Yes
Number of groups 6
Kruskal-Wallis statistic 18.38
Number of treatments (columns) 6
Number of values (total) 31
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 2714 20.2 Yes ∗∗
0 vs. 540 19.5 Yes ∗
0 vs. 123 8.5 No ns
0 vs. 47 11.5 No ns
0 vs. 29 6.8 No ns
2714 vs. 540 -0.7 No ns
2714 vs. 123 -11.7 No ns
2714 vs. 47 -8.7 No ns
2714 vs. 29 -13.4 No ns
540 vs. 123 -11 No ns
540 vs. 47 -8 No ns
540 vs. 29 -12.7 No ns
123 vs. 47 3 No ns
123 vs. 29 -1.7 No ns
47 vs. 29 -4.7 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 2714 27 6.8 20.2 5 5
0 vs. 540 27 7.5 19.5 5 5
0 vs. 123 27 18.5 8.5 5 6
0 vs. 47 27 15.5 11.5 5 5
0 vs. 29 27 20.2 6.8 5 5
2714 vs. 540 6.8 7.5 -0.7 5 5
2714 vs. 123 6.8 18.5 -11.7 5 6
2714 vs. 47 6.8 15.5 -8.7 5 5
2714 vs. 29 6.8 20.2 -13.4 5 5
540 vs. 123 7.5 18.5 -11 5 6
540 vs. 47 7.5 15.5 -8 5 5
540 vs. 29 7.5 20.2 -12.7 5 5
123 vs. 47 18.5 15.5 3 6 5
123 vs. 29 18.5 20.2 -1.7 6 5
47 vs. 29 15.5 20.2 -4.7 5 5
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CyQuant® assay - Controls
Table E.35.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0018
Exact or approximate P value? Exact
P value summary ∗∗
Do the medians vary signif. (P < 0.05)? Yes
Number of groups 4
Kruskal-Wallis statistic 10.54
Number of treatments (columns) 4
Number of values (total) 15
Dunn’s comparisons Mean rank diff. Significant Summary
A vs. B -0.5833 No ns
A vs. C -7.917 No ns
A vs. D -7.65 No ns
B vs. C -8 No ns
B vs. D -7.333 No ns
C vs. D 0.2667 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
A vs. B 3.75 4.333 -0.5833 4 3
A vs. C 3.75 11.67 -7.917 4 3
A vs. D 3.75 11.4 -7.65 4 5
B vs. C 4.333 11.67 -7.333 3 3
B vs. D 4.333 11.4 -7.067 3 5
C vs. D 11.67 11.4 0.2667 3 5
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AlamarBlue® assay for immobilised, digested HA
Table E.36.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0221
Exact or approximate P value? Approximate
P value summary ∗
Do the medians vary signif. (P < 0.05)? Yes
Number of groups 6
Kruskal-Wallis statistic 13.14
Number of treatments (columns) 6
Number of values (total) 32
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 2714 19.3 Yes ∗
0 vs. 540 3.15 No ns
0 vs. 123 5.4 No ns
0 vs. 47 4.7 No ns
0 vs. 29 3.5 No ns
2714 vs. 540 -16.15 No ns
2714 vs. 123 -13.9 No ns
2714 vs. 47 -14.6 No ns
2714 vs. 29 -15.8 No ns
540 vs. 123 2.25 No ns
540 vs. 47 1.55 No ns
540 vs. 29 0.35 No ns
123 vs. 47 -0.7 No ns
123 vs. 29 -1.9 No ns
47 vs. 29 -1.2 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 2714 22.4 3.1 19.3 5 5
0 vs. 540 22.4 19.25 3.15 5 6
0 vs. 123 22.4 17 5.4 5 6
0 vs. 47 22.4 17.7 4.7 5 5
0 vs. 29 22.4 18.9 3.5 5 5
2714 vs. 540 3.1 19.25 -16.15 5 6
2714 vs. 123 3.1 17 -13.9 5 6
2714 vs. 47 3.1 17.7 -14.6 5 5
2714 vs. 29 3.1 18.9 -15.8 5 5
540 vs. 123 19.25 17 2.25 6 6
540 vs. 47 19.25 17.7 1.55 6 5
540 vs. 29 19.25 18.9 0.35 6 5
123 vs. 47 17 17.7 -0.7 6 5
123 vs. 29 17 18.9 -1.9 6 5
47 vs. 29 17.7 18.9 –1.23 5 5
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AlamarBlue® assay for immobilised, short HA
Table E.37.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0067
Exact or approximate P value? Approximate
P value summary ∗∗
Do the medians vary signif. (P < 0.05)? Yes
Number of groups 6
Kruskal-Wallis statistic 16.05
Number of treatments (columns) 6
Number of values (total) 32
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 2714 16.6 No ns
0 vs. 540 4.8 No ns
0 vs. 123 4.9 No ns
0 vs. 47 13.1 No ns
0 vs. 29 -2.183 No ns
2714 vs. 540 -11.8 No ns
2714 vs. 123 -11.7 No ns
2714 vs. 47 -3.5 No ns
2714 vs. 29 -18.78 Yes ∗
540 vs. 123 0.1 No ns
540 vs. 47 8.3 No ns
540 vs. 29 -6.983 No ns
123 vs. 47 8.2 No ns
123 vs. 29 -7.083 No ns
47 vs. 29 -15.28 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 2714 22.4 5.8 16.6 5 5
0 vs. 540 22.4 17.6 4.8 5 5
0 vs. 123 22.4 17.5 4.9 5 6
0 vs. 47 22.4 9.3 13.1 5 5
0 vs. 29 22.4 24.58 -2.183 5 6
2714 vs. 540 5.8 17.6 -11.8 5 5
2714 vs. 123 5.8 17.5 -11.7 5 6
2714 vs. 47 5.8 9.3 -3.5 5 5
2714 vs. 29 5.8 24.58 -18.78 5 6
540 vs. 123 17.6 17.5 0.1 5 6
540 vs. 47 17.6 9.3 8.3 5 5
540 vs. 29 17.6 24.58 -6.983 5 6
123 vs. 47 17.5 9.3 8.2 6 5
123 vs. 29 17.5 24.58 -7.083 6 6
47 vs. 29 9.3 24.58 -15.28 5 6
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AlamarBlue® assay - Controls
Table E.38.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0018
Exact or approximate P value? Exact
P value summary ∗∗
Do the medians vary signif. (P < 0.05)? Yes
Number of groups 4
Kruskal-Wallis statistic 10.54
Number of treatments (columns) 4
Number of values (total) 15
Dunn’s comparisons Mean rank diff. Significant Summary
A vs. B 0.5833 No ns
A vs. C -7.417 No ns
A vs. D -7.15 No ns
B vs. C -8 No ns
B vs. D -7.733 No ns
C vs. D 0.2667 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
A vs. B 4.25 3.667 0.5833 4 3
A vs. C 4.25 11.67 -7.417 4 3
A vs. D 4.25 11.4 -7.15 4 5
B vs. C 3.667 11.67 -8 3 3
B vs. D 3.667 11.4 -7.733 3 5
C vs. D 11.67 11.4 0.2667 3 5
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Comparison between different HA species
Table E.39.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0002
Exact or approximate P value? Approximate
P value summary ∗ ∗ ∗
Do the medians vary signif. (P < 0.05)? Yes
Number of groups 6
Kruskal-Wallis statistic 24.52
Number of treatments (columns) 6
Number of values (total) 59
Dunn’s comparisons Mean rank diff. Significant Summary
0 vs. 2714 33.35 Yes ∗∗
0 vs. 540 6.8 No ns
0 vs. 123 9.092 No ns
0 vs. 47 16.7 No ns
0 vs. 29 1.073 No ns
2714 vs. 540 -26.55 Yes ∗∗
2714 vs. 123 -24.26 Yes ∗
2714 vs. 47 -16.65 No ns
2714 vs. 29 -32.28 Yes ∗ ∗ ∗
540 vs. 123 2.292 No ns
540 vs. 47 9.9 No ns
540 vs. 29 -5.727 No ns
123 vs. 47 7.608 No ns
123 vs. 29 -8.019 No ns
47 vs. 29 -15.63 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 2714 41.8 8.45 33.35 5 10
0 vs. 540 41.8 35 6.8 5 11
0 vs. 123 41.8 32.71 9.092 5 12
0 vs. 47 41.8 25.1 16.7 5 10
0 vs. 29 41.8 40.73 1.073 5 11
2714 vs. 540 8.45 35 -26.55 10 11
2714 vs. 123 8.45 32.71 -24.26 10 12
2714 vs. 47 8.45 25.1 -16.65 10 10
2714 vs. 29 8.45 40.73 -32.28 10 11
540 vs. 123 35 32.71 2.292 11 12
540 vs. 47 35 25.1 9.9 11 10
540 vs. 29 35 40.73 -5.727 11 11
123 vs. 47 32.71 25.1 7.608 12 10
123 vs. 29 32.71 40.73 -8.019 12 11
47 vs. 29 25.1 40.73 -15.63 10 11
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Results of the relative metabolic activity for digested, immobilised
HA
Table E.40.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0249
Exact or approximate P value? Approximate
P value summary ∗
Do the medians vary signif. (P < 0.05)? Yes
Number of groups 6
Kruskal-Wallis statistic 12.84
Number of treatments (columns) 6
Number of values (total) 31
Dunn’s comparisons Mean rank diff. Significant Summary P
0 vs. 2714 -2.4 No ns >0.9999
0 vs. 540 -16.6 No ns 0.0584
0 vs. 123 -10.9 No ns 0.7159
0 vs. 47 -6.4 No ns >0.9999
0 vs. 29 -1.2 No ns >0.9999
2714 vs. 540 -14.2 No ns 0.2030
2714 vs. 123 -8.5 No ns >0.9999
2714 vs. 47 -4 No ns >0.9999
2714 vs. 29 1.2 No ns >0.9999
540 vs. 123 5.7 No ns >0.9999
540 vs. 47 10.2 No ns >0.9999
540 vs. 29 15.4 No ns 0.1111
123 vs. 47 4.5 No ns >0.9999
123 vs. 29 9.7 No ns >0.9999
47 vs. 29 5.2 No ns >0.9999
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 2714 9.6 12 -2.4 5 5
0 vs. 540 9.6 26.2 -16.6 5 5
0 vs. 123 9.6 20.5 -10.9 5 6
0 vs. 47 9.6 16 -6.4 5 5
0 vs. 29 9.6 10.8 -1.2 5 5
2714 vs. 540 12 26.2 -14.2 5 5
2714 vs. 123 12 20.5 -8.5 5 6
2714 vs. 47 12 16 -4 5 5
2714 vs. 29 12 10.8 1.2 5 5
540 vs. 123 26.2 20.5 5.7 5 6
540 vs. 47 26.2 16 10.2 5 5
540 vs. 29 26.2 10.8 15.4 5 5
123 vs. 47 20.5 16 4.5 6 5
123 vs. 29 20.5 10.8 9.7 6 5
47 vs. 29 16 10.8 5.2 5 5
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Results of the relative metabolic activity for short, immobilised HA
Table E.41.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0155
Exact or approximate P value? Approximate
P value summary ∗
Do the medians vary signif. (P < 0.05)? Yes
Number of groups 6
Kruskal-Wallis statistic 14.01
Number of treatments (columns) 6
Number of values (total) 31
Dunn’s comparisons Mean rank diff. Significant Summary P
0 vs. 2714 -10.4 No ns >0.9999
0 vs. 540 -20.2 Yes ∗∗ 0.0067
0 vs. 123 -7.033 No ns >0.9999
0 vs. 47 -4.6 No ns >0.9999
0 vs. 29 -7.2 No ns >0.9999
2714 vs. 540 -9.8 No ns >0.9999
2714 vs. 123 3.367 No ns >0.9999
2714 vs. 47 5.8 No ns >0.9999
2714 vs. 29 3.2 No ns >0.9999
540 vs. 123 13.17 No ns 0.2517
540 vs. 47 15.6 No ns 0.1001
540 vs. 29 13 No ns 0.3566
123 vs. 47 2.433 No ns >0.9999
123 vs. 29 -0.1667 No ns >0.9999
47 vs. 29 -2.6 No ns >0.9999
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 2714 7.8 18.2 -10.4 5 5
0 vs. 540 7.8 28 -20.2 5 5
0 vs. 123 7.8 14.83 -7.033 5 6
0 vs. 47 7.8 12.4 -4.6 5 5
0 vs. 29 7.8 15 -7.2 5 5
2714 vs. 540 18.2 28 -9.8 5 5
2714 vs. 123 18.2 14.83 3.367 5 6
2714 vs. 47 18.2 12.4 5.8 5 5
2714 vs. 29 18.2 15 3.2 5 5
540 vs. 123 28 14.83 13.17 5 6
540 vs. 47 28 12.4 15.6 5 5
540 vs. 29 28 15 13 5 5
123 vs. 47 14.83 12.4 2.433 6 5
123 vs. 29 14.83 15 -0.1667 6 5
47 vs. 29 12.4 15 -2.6 5 5
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Results of the relative metabolic activity
Table E.42.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0002
Exact or approximate P value? Approximate
P value summary ∗ ∗ ∗
Do the medians vary signif. (P < 0.05)? Yes
Number of groups 6
Kruskal-Wallis statistic 24.39
Number of treatments (columns) 6
Number of values (total) 62
Dunn’s comparisons Mean rank diff. Significant Summary P
0 vs. 2714 -11.1 No ns >0.9999
0 vs. 540 -37.05 Yes ∗ ∗ ∗∗ <0.0001
0 vs. 123 -18.43 No ns 0.2552
0 vs. 47 -11.95 No ns >0.9999
0 vs. 29 -8.3 No ns >0.9999
2714 vs. 540 -25.95 Yes ∗ 0.0195
2714 vs. 123 -7.333 No ns >0.9999
2714 vs. 47 -0.85 No ns >0.9999
2714 vs. 29 2.8 No ns >0.9999
540 vs. 123 18.62 No ns 0.2392
540 vs. 47 25.1 Yes ∗ 0.0280
540 vs. 29 28.75 Yes ∗∗ 0.0055
123 vs. 47 6.483 No ns >0.9999
123 vs. 29 10.13 No ns >0.9999
47 vs. 29 3.65 No ns >0.9999
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
0 vs. 2714 7.8 18.2 -10.4 5 5
0 vs. 540 7.8 28 -20.2 5 5
0 vs. 123 7.8 14.83 -7.033 5 6
0 vs. 47 7.8 12.4 -4.6 5 5
0 vs. 29 7.8 15 -7.2 5 5
2714 vs. 540 18.2 28 -9.8 5 5
2714 vs. 123 18.2 14.83 3.367 5 6
2714 vs. 47 18.2 12.4 5.8 5 5
2714 vs. 29 18.2 15 3.2 5 5
540 vs. 123 28 14.83 13.17 5 6
540 vs. 47 28 12.4 15.6 5 5
540 vs. 29 28 15 13 5 5
123 vs. 47 14.83 12.4 2.433 6 5
123 vs. 29 14.83 15 -0.1667 6 5
47 vs. 29 12.4 15 -2.6 5 5
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Results of the relative metabolic activity for immobilised HA -
Controls
Table E.43.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0018
Exact or approximate P value? Exact
P value summary ∗∗
Do the medians vary signif. (P < 0.05)? Yes
Number of groups 4
Kruskal-Wallis statistic 10.54
Number of treatments (columns) 4
Number of values (total) 15
Dunn’s comparisons Mean rank diff. Significant Summary
A vs. B 0.5833 No ns
A vs. C 7.917 No ns
A vs. D 7.65 No ns
B vs. C 7.333 No ns
B vs. D 7.067 No ns
C vs. D -0.2667 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
A vs. B 12.25 11.67 0.5833 4 3
A vs. C 12.25 4.333 7.917 4 3
A vs. D 12.25 4.6 7.65 4 5
B vs. C 11.67 4.333 7.333 3 3
B vs. D 11.67 4.6 7.067 3 5
C vs. D 4.333 4.6 -0.2667 3 5
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E.4. Toxicity Assays of Photocleavabel Ligand
Toxicity Assay of UV-light
Comparison of Irradiation Time after One Hour
Table E.44.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.1606
Exact or approximate P value? Exact
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 4
Kruskal-Wallis statistic 5.205
Number of treatments (columns) 4
Number of values (total) 12
Dunn’s comparisons Mean rank diff. Significant Summary Padj
positiv control vs. 60 s -4 No ns 0.5227
positiv control vs. 30 s -3.333 No ns 0.7726
positiv control vs. 15 s -6.667 No ns 0.0706
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
positiv control vs. 60 s 3 7 -4 3 3
positiv control vs. 30 s 3 6.333 -3.333 3 3
positiv control vs. 15 s 3 9.667 -6.667 3 3
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Comparison of Irradiation Time after Two Hours
Table E.45.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.1748
Exact or approximate P value? Exct
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 4
Kruskal-Wallis statistic 5.051
Number of treatments (columns) 4
Number of values (total) 12
Dunn’s comparisons Mean rank diff. Significant Summary P
positiv control vs. 60 s -4.667 No ns 0.3388
positiv control vs. 30 s -3 No ns 0.9245
positiv control vs. 15 s -6.333 No ns 0.0944
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
positiv control vs. 60 s 3 7.667 -4.667 3 3
positiv control vs. 30 s 3 6 -3 3 3
positiv control vs. 15 s 3 9.333 -6.333 3 3
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Comparison of Irradiation Time after Three Hours
Table E.46.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.3040
Exact or approximate P value? Exact
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 4
Kruskal-Wallis statistic 3.923
Number of treatments (columns) 4
Number of values (total) 12
Dunn’s comparisons Mean rank diff. Significant Summary P
positiv control vs. 60 s -1.667 No ns >0.9999
positiv control vs. 30 s -2.667 No ns >0.9999
positiv control vs. 15 s -5.667 No ns 0.1627
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
positiv control vs. 60 s 4 5.667 -1.667 3 3
positiv control vs. 30 s 4 6.667 -2.667 3 3
positiv control vs. 15 s 4 9.667 -5.667 3 3
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Comparison of Irradiation Time of 60 Seconds
Table E.47.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.2483
Exact or approximate P value? Exact
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 4
Kruskal-Wallis statistic 4.267
Number of treatments (columns) 4
Number of values (total) 18
Dunn’s comparisons Mean rank diff. Significant Summary P
positiv control vs. 60 s_1h -6.778 No ns 0.1706
positiv control vs. 60 s_2h -2.444 No ns >0.9999
positiv control vs. 60 s_3h -4.444 No ns 0.6352
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
positiv control vs. 60 s_1h 7.222 14 -6.778 9 3
positiv control vs. 60 s_2h 7.222 9.667 -2.444 9 3
positiv control vs. 60 s_3h 7.222 11.67 -4.444 9 3
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Comparison of Irradiation Time of 30 Seconds
Table E.48.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0394
Exact or approximate P value? Exact
P value summary ∗
Do the medians vary signif. (P < 0.05)? Yes
Number of groups 4
Kruskal-Wallis statistic 7.425
Number of treatments (columns) 4
Number of values (total) 18
Dunn’s comparisons Mean rank diff. Significant Summary P
positiv control vs. 30 s_1h -7.444 No ns 0.1094
positiv control vs. 30 s_2h -0.7778 No ns >0.9999
positiv control vs. 30 s_3h -7.444 No ns 0.1094
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
positiv control vs. 30 s_1h 6.889 14.33 -7.444 9 3
positiv control vs. 30 s_2h 6.889 7.667 -0.7778 9 3
positiv control vs. 30 s_3h 6.889 14.33 -7.444 9 3
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Comparison of Irradiation Time of 15 Seconds
Table E.49.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0006
Exact or approximate P value? Exact
P value summary ∗ ∗ ∗
Do the medians vary signif. (P < 0.05)? Yes
Number of groups 4
Kruskal-Wallis statistic 11.73
Number of treatments (columns) 4
Number of values (total) 18
Dunn’s comparisons Mean rank diff. Significant Summary P
positiv control vs. 15 s_1h -9.889 Yes ∗ 0.0164
positiv control vs. 15 s_2h -5.222 No ns 0.4269
positiv control vs. 15 s_3h -9.222 Yes ∗ 0.0287
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
positiv control vs. 15 s_1h 5.444 15.33 -9.889 9 3
positiv control vs. 15 s_2h 5.444 10.67 -5.222 9 3
positiv control vs. 15 s_3h 5.444 14.67 -9.222 9 3
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Toxicity Assay of DMNPE in DMSO
Table E.50.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.1591
Exact or approximate P value? Approximate
P value summary ns
Do the medians vary signif. (P < 0.05)? No
Number of groups 9
Kruskal-Wallis statistic 11.83
Number of treatments (columns) 9
Number of values (total) 27
Dunn’s comparisons Mean rank diff. Significant Summary
Positive control vs. DMSO control 7.667 No ns
Positive control vs. 5µm 143 -12 No ns
Positive control vs. 50µm 143 -16.83 No ns
Positive control vs. 500µm 143 -17.83 No ns
Positive control vs. 5µm 133 -11.33 No ns
Positive control vs. 50µm 133 -13.33 No ns
Positive control vs. 500µm 133 -15.33 No ns
Positive control vs. DMSO without cells 2 No ns
Mean
Test details rank 1 rank 2 rank diff n1 n2
Pos. con. vs. DMSO control 2.667 10.33 -7.667 3 3
Pos. con. vs. 5µm 143 2.667 14.67 -12 3 3
Pos. con. vs. 50µm 143 2.667 19.5 -16.83 3 3
Pos. con. vs. 500µm 143 2.667 20.5 -17.83 3 3
Pos. con. vs. 5µm 133 2.667 14 -11.33 3 3
Pos. con. vs. 50µm 133 2.667 16 -13.33 3 3
Pos. con. vs. 500µm 133 2.667 18 -15.33 3 3
Pos. con. vs. DMSO w/o cells 2.667 10.33 -7.667 3 3
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Toxicity assay of DMNPE in EtOH
Table E.51.: Kruskal-Wallis-Test with Dunn’s multiple comparison
P value 0.0074
Exact or approximate P value? Approximate
P value summary ∗∗
Do the medians vary signif. (P < 0.05)? Yes
Number of groups 8
Kruskal-Wallis statistic 19.28
Number of treatments (columns) 8
Number of values (total) 33
Dunn’s comparisons Mean rank diff. Significant Summary
Positive control vs. EtOH control 2 No ns
Positive control vs. 5µm 127 -7.167 No ns
Positive control vs. 50µm 127 1.083 No ns
Positive control vs. 500µm 127 -7.917 No ns
Positive control vs. 5µm 132 -12.17 No ns
Positive control vs. 50µm 132 -18.17 No ns
Positive control vs. 500µm 132 -20.67 No ns
Test details Mean rank 1 Mean rank 2 Mean rank diff. n1 n2
Pos. con. vs. EtOH control 10 8 2 3 3
Pos. con. vs. 5µm 127 10 17.17 -7.167 3 6
Pos. con. vs. 50µm 127 10 8.917 1.083 3 6
Pos. con. vs. 500µm 127 10 17.92 -7.917 3 6
Pos. con. vs. 5µm 132 10 22.17 -12.17 3 3
Pos. con. vs. 50µm 132 10 28.17 -18.17 3 3
Pos. con. vs. 500µm 132 10 30.67 -20.67 3 3

Appendix F.
NMR Spectra
Figure F.1.: 1H-NMR of the alkyne-functionalised HA within the chain (6)
in D2O (600MHz)
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Figure F.2.: 1H-NMR of PEG2000 silane (8) in CDCl3 (600MHz)
Figure F.3.: 1H-NMR of PEG3000 alkyne (9) in CDCl3 (600MHz)
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Figure F.4.: 1H-NMR of 4,5-Dimethoxy-2-nitroacetophenone (10) in CDCl3
(600MHz)
Figure F.5.: 13C-NMR of 4,5-Dimethoxy-2-nitroacetophenone (10) in CDCl3
(150MHz)
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Figure F.6.: 1H-NMR of 4,5-dimethoxy-2-nitrophenyl ethanol (2) in CDCl3
(600MHz)
Figure F.7.: 13C-NMR of 4,5-dimethoxy-2-nitrophenyl ethanol (2) in CDCl3
(150MHz)
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Figure F.8.: 1H-NMR of 11-(tritylthio)undecanoic acid (11) in CDCl3
(600MHz)
Figure F.9.: 13C-NMR of 11-(tritylthio)undecanoic acid (11) in CDCl3
(150MHz)
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Figure F.10.: 1H-NMR of 1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11--
(tritylthio)undecanoate (12) in CDCl3 (600MHz)
Figure F.11.: 13C-NMR of 1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11--
(tritylthio)undecanoate (12) in CDCl3 (150MHz)
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Figure F.12.: 1H-NMR of 1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercap-
toundecanoate (1) in CDCl3 (600MHz)
Figure F.13.: 13C-NMR of 1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercap-
toundecanoate (1) in CDCl3 (150MHz)
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Figure F.14.: 1H-NMR of 1-(4,5-dimethoxy-2-nitrophenyl)ethyl (3(S))-3-(4-
(3-(6-(3-mercaptopropanamido)hexanamido)propoxy)benzamido)-4-(4-(3--
((4-methoxypyridin-2-yl)amino)propoxy)phenyl)butanoate (14) in CDCl3
(600MHz)
Appendix G.
Kinetic Analysis of the Adsorption and
Cleavage Process of DMNPE-thiol in
the QCM-D
G.1. Adsorption of DMNPE-thiol at Different
Temperatures
To develop the effect of temperature to the adsorption of DMNPE-thiol (1) to
a gold surface, the curve of the adsorption process observed via QCM-D is fit-
ted with equation G.1 using OriginPro (2017G, version b9.4.0.220, OriginLab
Corporation).
y = y0 +A1exp
[
−
x
t1
]
+A2exp
[
−
x
t2
]
(G.1)
The results for the amplitude (A) and time (t) as well as the ratio of A1 of
the adsorption at 21 ◦C are summarised in table G.1 and for 37 ◦C in table
G.2. For the adsorption at 37 ◦C the equation can be simplified in two cases
because A2 is zero.
Table G.1.: Results of the fit to the adsorption curve of DMNPE-thiol (1) at
21 ◦C
sample A1 t1 A2 t2 ratio
A1 [%]
20160711 S3 120.70688 190.82759 78.60308 1353.69153 60.6
20161026 S2 44.04875 181.01587 149.96145 2330.31123 22.7
20161026 S3 21.17302 38.8034 140.28505 783.26099 13.1
20160711 S4 49.09925 138.12911 267.69231 1884.56792 15.5
20170306 S2 14.87394 42.37014 189.04852 1701.68984 7.3
20170306 S3 14.60207 72.69469 108.18859 3094.05399 11.9
20170309 S2 18.93493 25.39529 113.66793 2870.44861 14.3
20170309 S3 10.68453 24.05499 40.40023 2000.59515 20.9
20170309 S4 17.89268 33.96057 75.56981 1079.55234 19.1
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Table G.2.: Results of the fit to the adsorption curve of DMNPE-thiol (1) at
37 ◦C
sample A1 t1 A2 t2 ratio
A1 [%]
CA143b 1 309.17678 285.80784 100.0
CA143b 2 279.79702 288.58841 12.65282 2439.81225 95.7
CA143b 3 312.80638 388.24584 100.0
G.2. Cleavage of DMNPE-thiol in the QCM-D
To analyse the kinetic of the cleavage of DMNPE-thiol on a gold surface, the
curve of the cleavage process observed via QCM-D is fitted with equation G.2
using OriginPro (2017G, version b9.4.0.220, OriginLab Corporation).
y = y0 +A1exp
[
−
x− x0
t1
]
+A2exp
[
−
x− x0
t2
]
(G.2)
The results for the amplitude (A) and time (t) as well as the ratio of A1 are
summarised in table G.3.
Table G.3.: Results of the fit to the cleavgae curve of DMNPE-thiol (1) at
21 ◦C
sample A1 t1 A2 t2 ratio
A1 [%]
20160711 S3 -65.58113 3.04432 -20.28466 27.30017 76.4
20160711 S4 -86.31253 1.90945 -20.13366 24.39251 81.1
20160818 S2 -34.10663 2.45226 -8.89505 18.82567 79.3
20160818 S3 -14.81195 3.29734 -4.95054 14.87633 74.9
20161026 S2 -37.87714 2.88499 -12.54958 31.91942 75.1
20161026 S3 -49.11138 3.03432 -15.2357 31.47667 76.3
20170306 S2 -40.56384 1.99573 -12.86521 27.17474 75.9
20170306 S3 -25.16336 1.56184 -9.63555 12.45457 72.3
Appendix H.
Selection of the Solvent for the
Toxicity Assay of
1-(4,5-dimethoxy-2-nitrophenyl)ethyl
11-mercaptoundecanoate
To analyse the toxic effect of 1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-mercap-
toundecanoate (1) and 4,5-dimethoxy-2-nitrophenyl ethanol (2) on MDCK II
cells a solvent is necessary, because these compounds are not soluble in water
respectively media. In the beginning DMSO is tested, which is also used for the
application of drugs in cell experiments. [79] The toxicity is determined with
the AlamarBlue® assay. The results for the reduction of resazurin is shown in
figure H.1 a). The comparison of the controls (A-C) shows a large effect due
to mixing DMSO with the AlamarBlue® kit and media (A) even without cells.
The comparison of the positive control (B) and the control with DMSO and
cells shows more reduction when DMSO is added. Because of this, it stays un-
clear which effect in the following samples is due to the applied compounds and
which due to the DMSO. Nevertheless an increase in the reduction potential
with increasing concentration of the chemicals is found. This is significant in
case of the applied 500µm solution of 1-(4,5-dimethoxy-2-nitrophenyl)ethyl 11-
mercaptoundecanoate. But possibly here the crystallisation of the linker takes
place as described for the experiment in ethanol (section 4.5.3). So addition-
ally ethanol is tested as solvent, which is also used in the QCM-D experiments.
Here the determined reduction of resazurin of the positive control (A), con-
trol with ethanol without (B) and with (C) cells is shown in figure H.1 b).
In this case no effect on the toxicity due to the solvent is found. Because of
this ethanol seems to be the more appropriate solvent for using in the toxicity
assay.
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Figure H.1.: a) For the toxicity assay 1-(4,5-dimethoxy-2-nitrophenyl)ethyl
11-mercaptoundecanoate or 4,5-dimethoxy-2-nitrophenyl ethanol are added
in different concentration to MDCK II cells in DMSO and media. This sam-
ples are compared with the positive control (B) without additives, a mixture
of kit, media and DMSO (A) and a positiv control with DMSO(C). b) shows
the control surfaces for ethanol as solvent in A the positive control, B kit
with media and solvent and C the positive control with adding solvent. For
the statistical analysis a Kruskal-Wallis test with Dunn’s comparison is per-
formed.
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